Particle beam scanning

Information

  • Patent Grant
  • 10258810
  • Patent Number
    10,258,810
  • Date Filed
    Friday, September 26, 2014
    9 years ago
  • Date Issued
    Tuesday, April 16, 2019
    5 years ago
Abstract
An example particle therapy system includes: a synchrocyclotron to output a particle beam; a magnet to affect a direction of the particle beam to scan the particle beam across at least part of an irradiation target; scattering material that is configurable to change a spot size of the particle beam, where the scattering material is down-beam of the magnet relative to the synchrocyclotron; and a degrader to change an energy of the beam prior to output of the particle beam to the irradiation target, where the degrader is down-beam of the scattering material relative to the synchrocyclotron.
Description
TECHNICAL FIELD

This disclosure relates generally to features for use in a particle beam scanning system.


BACKGROUND

Particle therapy systems use an accelerator to generate a particle beam for treating afflictions, such as tumors. In operation, particles are accelerated in orbits inside a cavity in the presence of a magnetic field, and removed from the cavity through an extraction channel. A magnetic field regenerator generates a magnetic field bump near the outside of the cavity to distort the pitch and angle of some orbits so that they precess towards, and eventually into, the extraction channel. A beam, comprised of the particles, exits the extraction channel.


A scanning system is down-beam of the extraction channel. In this context, “down-beam” means closer to an irradiation target (here, relative to the extraction channel). The scanning system moves the beam across at least part of the irradiation target to expose various parts of the irradiation target to the beam. For example, to treat a tumor, the particle beam may be “scanned” over different cross-sections of the tumor.


SUMMARY

An example proton therapy system may comprise a particle accelerator, a scanning system, and a gantry on which the particle accelerator and at least part of the scanning system are mounted. The gantry is rotatable relative to a patient position. Protons are output essentially directly from the particle accelerator and through the scanning system to the position of an irradiation target, such as a patient. The particle accelerator may be a synchrocyclotron.


An example particle therapy system comprises a synchrocyclotron to output a particle beam; a magnet to affect a direction of the particle beam to scan the particle beam across at least part of an irradiation target; and scattering material that is configurable to change a spot size of the particle beam prior to output of the particle beam to the irradiation target. The example particle therapy system may include one or more of the following features, either alone or in combination.


The example particle therapy system may include a degrader to change an energy of the beam prior to output of the particle beam to the irradiation target. The degrader may be down-beam of the scattering material relative to the synchrocyclotron, and may be computer-controlled.


The synchrocyclotron may comprise: a voltage source to provide a radio frequency (RF) voltage to a cavity to accelerate particles from a plasma column, where the cavity has a magnetic field causing particles accelerated from the plasma column to move orbitally within the cavity; an extraction channel to receive the particles accelerated from the plasma column and to output the received particles from the cavity; and a regenerator to provide a magnetic field bump within the cavity to thereby change successive orbits of the particles accelerated from the plasma column so that, eventually, particles are output to the extraction channel. The magnetic field may be between 4 Tesla (T) and 20 T and the magnetic field bump may be at most 2 Tesla.


The scattering material may comprise multiple scatterers, each of which may be movable into, or out of, a path of the particle beam. In some examples, only one of the multiple scatterers at a time may be movable into the path of the particle beam. The scattering material may include piezoelectric material that is responsive to an applied voltage to increase or decrease in thickness. The scattering material may be configurable to change a spot size of the particle beam during a course of treatment of the irradiation target or in between times of treatment of the irradiation target (e.g., not during the course of treatment).


The scanning performed by the particle therapy system may be spot scanning. The spot size may be changeable from scan-location to scan-location. The spot size may be changeable on a time scale on the order of tenths of a second, on the order of tens of milliseconds, or on the order of some other time scale.


An example particle therapy system may comprise: a synchrocyclotron to output a particle beam; a scanning system to receive the particle beam from the synchrocyclotron and to perform spot scanning of at least part of an irradiation target with the particle beam, where the scanning system is controllable to change a spot size of the particle beam; and a gantry on which the synchrocyclotron and at least part of the scanning system are mounted, where the gantry is configured to move the synchrocyclotron and at least part of the scanning system around the irradiation target. The example particle therapy system may include one or more of the following features, either alone or in combination.


The scanning system may comprise: structures to move the particle beam output from the synchrocyclotron in three-dimensions relative to the irradiation target; and scattering material, among the structures, that is configurable to change the spot size of the particle beam. The scattering material may comprise multiple scatterers, each of which may be movable into, or out of, a path of the particle beam. In some examples, only one of the multiple scatterers at a time is movable into the path of the particle beam. The scattering material may comprise piezoelectric material that is responsive to an applied voltage to increase or decrease in thickness. The scattering material may be configurable to change a spot size of the particle beam during a course of treatment of the irradiation target. The scattering material may be configurable to change a spot size of the particle beam in between times of treatment of the irradiation target (e.g., not during the course of treatment).


The scanning performed by the scanning system may be spot scanning. The spot size may be changeable from scan-location to scan-location. The spot size may be changeable on a time scale on the order of tenths of a second, on the order of tens of milliseconds, or on some other time scale.


An example particle therapy system may comprise: a synchrocyclotron to output a particle beam; a scanning system to receive the particle beam from the synchrocyclotron and to perform spot scanning of at least part of an irradiation target with the particle beam; and one or more processing devices to control the scanning system to scan a cross-section of the irradiation target according to an irregular grid pattern. The example particle therapy system may include one or more of the following features, either alone or in combination.


In an example, in the irregular grid pattern, spacing between spots to be scanned varies. The irregular grid pattern may have a perimeter that corresponds to a perimeter of the cross-section of the irradiation target. A scanning speed of the particle beam between different spots on the cross-section of the irradiation target may be substantially the same or it may be different. For example, a scanning speed of the particle beam may be different between at least two different pairs of spots on the cross-section of the irradiation target.


The example particle therapy system may include memory to store a treatment plan. The treatment plan may comprise information to define the irregular grid pattern for the cross-section of the irradiation target, and also to define irregular grid patterns for other cross-sections of the irradiation target. Different irregular grid patterns for different cross sections of the irradiation target may have at least one of: different numbers of spots to be irradiated, different locations of spots to be irradiated, different spacing between spots to be irradiated, or different pattern perimeters.


The scanning system may comprise: a magnet to affect a direction of the particle beam to scan the particle beam across at least part of an irradiation target; and scattering material that is configurable to change a spot size of the particle beam prior to output of the particle beam to the irradiation target. The scattering material may be down-beam of the magnet relative to the synchrocyclotron. The scanning system may also comprise a degrader to change an energy of the beam prior to output of the particle beam to the irradiation target. The degrader may be down-beam of the scattering material relative to the synchrocyclotron.


The synchrocyclotron may comprise: a voltage source to provide a radio frequency (RF) voltage to a cavity to accelerate particles from a plasma column, where the cavity has a magnetic field causing particles accelerated from the plasma column to move orbitally within the cavity; an extraction channel to receive the particles accelerated from the plasma column and to output the received particles from the cavity as part of the particle beam; and a regenerator to provide a magnetic field bump within the cavity to thereby change successive orbits of the particles accelerated from the plasma column so that, eventually, particles output to the extraction channel. The magnetic field may be between 4 Tesla (T) and 20 T and the magnetic field bump may be at most 2 Tesla.


The particle therapy system may comprise a gantry on which the synchrocyclotron and the scanning system are mounted. The gantry may be configured to move the synchrocyclotron and at least part of the scanning system around the irradiation target. The one or more processing devices may be programmed to effect control to interrupt the particle beam between scanning of different cross-sections of the irradiation target.


An example particle therapy system may comprise: a synchrocyclotron to output a particle beam; a magnet to affect a direction of the particle beam to scan the particle beam across a cross-section of an irradiation target; and one or more processing devices to control the magnet to scan the cross-section of the irradiation target according to an irregular grid pattern, and to control an energy of the particle beam between scanning of different cross-sections of the irradiation target. The example particle therapy system may include one or more of the following features, either alone or in combination.


The example particle therapy system may comprise a degrader to change an energy of the particle beam prior to scanning the cross-section of the irradiation target. The degrader may be down-beam of the magnet relative to the synchrocyclotron. The one or more processing devices may be configured to control movement of one or more parts of the degrader to control the energy of the particle beam between scanning of different cross-sections of the irradiation target.


In an example, in the irregular grid pattern, spacing between spots to be scanned varies. The irregular grid pattern may have a perimeter that corresponds to a perimeter of the cross-section of the irradiation target. A scanning speed of the particle beam between different spots on the cross-section of the irradiation target may be substantially the same or different.


The example particle therapy system may comprise memory to store a treatment plan. The treatment plan may comprise information to define the irregular grid pattern for the cross-section of the irradiation target, and also to define irregular grid patterns for different cross-sections of the irradiation target. Different irregular grid patterns for different cross sections of the irradiation target may have at least one of: different numbers of spots to be irradiated, different locations of spots to be irradiated, different spacing between spots to be irradiated, or different pattern perimeters.


The synchrocyclotron may comprise: a voltage source to provide a radio frequency (RF) voltage to a cavity to accelerate particles from a plasma column, where the cavity has a magnetic field causing particles accelerated from the plasma column to move orbitally within the cavity; an extraction channel to receive the particles accelerated from the plasma column and to output the received particles from the cavity as part of the particle beam; and a regenerator to provide a magnetic field bump within the cavity to thereby change successive orbits of the particles accelerated from the plasma column so that, eventually, particles output to the extraction channel. The magnetic field may be between 4 Tesla (T) and 20 T and the magnetic field bump may be at most 2 Tesla. The example particle therapy system may comprise a gantry on which the synchrocyclotron and the scanning system are mounted. The gantry may be configured to move the synchrocyclotron and at least part of the scanning system around the irradiation target.


The one or more processing devices may be programmed to effect control to interrupt the particle beam between scanning of different cross-sections of the irradiation target. The scanning may be raster scanning, spot scanning, or a combination thereof. The synchrocyclotron may be a variable-energy machine. The one or more processing devices may be programmed to control the energy of the particle beam produced by the variable-energy synchrocyclotron between scanning of different cross-sections of the irradiation target by controlling the synchrocyclotron to output the particle beam at a specified energy level.


Two or more of the features described in this disclosure, including those described in this summary section, may be combined to form implementations not specifically described herein.


Control of the various systems described herein, or portions thereof, may be implemented via a computer program product that includes instructions that are stored on one or more non-transitory machine-readable storage media, and that are executable on one or more processing devices. The systems described herein, or portions thereof, may be implemented as an apparatus, method, or electronic system that may include one or more processing devices and memory to store executable instructions to implement control of the stated functions.


The details of one or more implementations are set forth in the accompanying drawings and the description below. Other features, objects, and advantages will be apparent from the description and drawings, and from the claims.





DESCRIPTION OF THE DRAWINGS


FIGS. 1 and 2 are a cross-sectional views of an example synchrocyclotron for use in a particle therapy system.



FIG. 3 is a side view of an example scanning system.



FIG. 4 is a perspective view of components of an example scanning system, excluding scattering material for spot size variation.



FIG. 5 is a front view of an example magnet for use in a scanning system of the type shown in FIGS. 3 and 4.



FIG. 6 is a perspective view of an example magnet for use in a scanning system of the type shown in FIGS. 3 and 4.



FIG. 7 is a perspective view of an example range modulator for use in a scanning system of the type shown in FIGS. 3 and 4.



FIG. 8 is a perspective view of an example energy degrader for use in a scanning system of the type shown in FIGS. 3 and 4.



FIG. 9 is a perspective side view of a scanning system of the type shown in FIGS. 3 and 4, showing example positions at which scatterers can be placed.



FIG. 10 is a perspective view of an example scatterer for use in a scanning system of the type shown in FIGS. 3 and 4.



FIG. 11 is a side view of an example scatterer for use in a scanning system of the type shown in FIGS. 3 and 4.



FIG. 12 is a top view of an example aperture.



FIG. 13 is a top view of an example non-uniform grid perimeter.



FIG. 14 is a top view of an example non-uniform grid perimeter having an irregular shape, regular scan spot intervals, and regular scan spot locations.



FIG. 15 is a top view of an example non-uniform grid perimeter having an irregular shape, regular scan spot intervals, and irregular scan spot locations.



FIG. 16 is a top view of an example non-uniform grid perimeter having an irregular shape, irregular scan spot intervals, and regular scan spot locations.



FIG. 17 is a top view of an example non-uniform grid perimeter having a regular shape, regular scan spot intervals, and irregular scan spot locations.



FIG. 18 is a top view of an example non-uniform grid perimeter having a regular shape, irregular scan spot intervals, and regular scan spot locations.



FIG. 19 is a top view of an example non-uniform grid perimeter having an irregular shape and variable scan spot sizes.



FIG. 20 is a perspective view of an example therapy system.



FIG. 21 is an exploded perspective view of components of an example synchrocyclotron for use in the particle therapy system.



FIG. 22 is a cross-sectional view of the example synchrocyclotron.



FIG. 23 is a perspective view of the example synchrocyclotron.



FIG. 24 is a cross-sectional view of a portion of an example reverse bobbin and superconducting coil windings for the synchrocyclotron.



FIG. 25 is a cross sectional view of an example cable-in-channel composite conductor for use in the superconducting coil windings.



FIG. 26 is a cross-sectional view of an example ion source for use in the synchrocyclotron.



FIG. 27 is a perspective view of an example dee plate and an example dummy dee for use in the synchrocyclotron.



FIGS. 28, 29 and 30 are perspective views of an example vault for use in the particle therapy system.



FIG. 31 shows a patient positioned within an example inner gantry of the example particle therapy system in a treatment room.



FIG. 32 is a conceptual view of an example particle therapy system that may use a variable-energy particle accelerator.



FIG. 33 is an example graph showing energy and current for variations in magnetic field and distance in a particle accelerator.



FIG. 34 is a side view of an example structure for sweeping voltage on a dee plate over a frequency range for each energy level of a particle beam, and for varying the frequency range when the particle beam energy is varied.



FIG. 35 is a perspective, exploded view of an example magnet system that may be used in a variable-energy particle accelerator.





Like reference symbols in the various drawings indicate like elements.


DETAILED DESCRIPTION

Described herein is an example of a particle accelerator for use in an example system, such as a proton or ion therapy system. The example system includes a particle accelerator—in this example, a synchrocyclotron—mounted on a gantry. The gantry enables the accelerator to be rotated around a patient position, as explained in more detail below. In some implementations, the gantry is steel and has two legs mounted for rotation on two respective bearings that lie on opposite sides of a patient. The particle accelerator is supported by a steel truss that is long enough to span a treatment area in which the patient lies and that is attached at both ends to the rotating legs of the gantry. As a result of rotation of the gantry around the patient, the particle accelerator also rotates.


In an example implementation, the particle accelerator (e.g., the synchrocyclotron) includes a cryostat that holds a superconducting coil for conducting a current that generates a magnetic field (B). In this example, the cryostat uses liquid helium (He) to maintain the coil at superconducting temperatures, e.g., 4° Kelvin (K). Magnetic pole pieces or yokes are located inside the cryostat, and define a cavity in which particles are accelerated.


In an example implementation, the particle accelerator includes a particle source (e.g., a Penning Ion Gauge—PIG source) to provide a plasma column to the cavity. Hydrogen gas is ionized to produce the plasma column. A voltage source provides a radio frequency (RF) voltage to the cavity to accelerate particles from the plasma column. As noted, in this example, the particle accelerator is a synchrocyclotron. Accordingly, the RF voltage is swept across a range of frequencies to account for relativistic effects on the particles (e.g., increasing particle mass) when accelerating particles from the column. The magnetic field produced by running current through the superconducting coil causes particles accelerated from the plasma column to accelerate orbitally within the cavity.


A magnetic field regenerator (“regenerator”) is positioned near the outside of the cavity (e.g., at an interior edge thereof) to adjust the existing magnetic field inside the cavity to thereby change locations (e.g., the pitch and angle) of successive orbits of the particles accelerated from the plasma column so that, eventually, the particles output to an extraction channel that passes through the cryostat. The regenerator may increase the magnetic field at a point in the cavity (e.g., it may produce a magnetic field “bump” at an area of the cavity), thereby causing each successive orbit of particles at that point to precess outwardly toward the entry point of the extraction channel until it reaches the extraction channel. The extraction channel receives particles accelerated from the plasma column and outputs the received particles from the cavity as a particle beam.


The superconducting (“main”) coils can produce relatively high magnetic fields. The magnetic field generated by a main coil may be within a range of 4 T to 20 T or more. For example, a main coil may be used to generate magnetic fields at, or that exceed, one or more of the following magnitudes: 4.0 T, 4.1 T, 4.2 T, 4.3 T, 4.4 T, 4.5 T, 4.6 T, 4.7 T, 4.8 T, 4.9 T, 5.0 T, 5.1 T, 5.2 T, 5.3 T, 5.4 T, 5.5 T, 5.6 T, 5.7 T, 5.8 T, 5.9 T, 6.0 T, 6.1 T, 6.2 T, 6.3 T, 6.4 T, 6.5 T, 6.6 T, 6.7 T, 6.8 T, 6.9 T, 7.0 T, 7.1 T, 7.2 T, 7.3 T, 7.4 T, 7.5 T, 7.6 T, 7.7 T, 7.8 T, 7.9 T, 8.0 T, 8.1 T, 8.2 T, 8.3 T, 8.4 T, 8.5 T, 8.6 T, 8.7 T, 8.8 T, 8.9 T, 9.0 T, 9.1 T, 9.2 T, 9.3 T, 9.4 T, 9.5 T, 9.6 T, 9.7 T, 9.8 T, 9.9 T, 10.0 T, 10.1 T, 10.2 T, 10.3 T, 10.4 T, 10.5 T, 10.6 T, 10.7 T, 10.8 T, 10.9 T, 11.0 T, 11.1 T, 11.2 T, 11.3 T, 11.4 T, 11.5 T, 11.6 T, 11.7 T, 11.8 T, 11.9 T, 12.0 T, 12.1 T, 12.2 T, 12.3 T, 12.4 T, 12.5 T, 12.6 T, 12.7 T, 12.8 T, 12.9 T, 13.0 T, 13.1 T, 13.2 T, 13.3 T, 13.4 T, 13.5 T, 13.6 T, 13.7 T, 13.8 T, 13.9 T, 14.0 T, 14.1 T, 14.2 T, 14.3 T, 14.4 T, 14.5 T, 14.6 T, 14.7 T, 14.8 T, 14.9 T, 15.0 T, 15.1 T, 15.2 T, 15.3 T, 15.4 T, 15.5 T, 15.6 T, 15.7 T, 15.8 T, 15.9 T, 16.0 T, 16.1 T, 16.2 T, 16.3 T, 16.4 T, 16.5 T, 16.6 T, 16.7 T, 16.8 T, 16.9 T, 17.0 T, 17.1 T, 17.2 T, 17.3 T, 17.4 T, 17.5 T, 17.6 T, 17.7 T, 17.8 T, 17.9 T, 18.0 T, 18.1 T, 18.2 T, 18.3 T, 18.4 T, 18.5 T, 18.6 T, 18.7 T, 18.8 T, 18.9 T, 19.0 T, 19.1 T, 19.2 T, 19.3 T, 19.4 T, 19.5 T, 19.6 T, 19.7 T, 19.8 T, 19.9 T, 20.0 T, 20.1 T, 20.2 T, 20.3 T, 20.4 T, 20.5 T, 20.6 T, 20.7 T, 20.8 T, 20.9 T, or more. Furthermore, a main coil may be used to generate magnetic fields that are within the range of 4 T to 20 T (or more) that are not specifically listed above.


In some implementations, such as the implementation shown in FIGS. 1 and 2, large ferromagnetic magnetic yokes act as a return for stray magnetic field produced by the superconducting coils. For example, in some implementations, the superconducting magnet can generate a relatively high magnetic field of, e.g., 4 T or more, resulting in considerable stray magnetic fields. In some systems, such as that shown in FIGS. 1 and 2, a relatively large ferromagnetic return yoke 82 is used as a return for the magnetic field generated by superconducting coils. A magnetic shield surrounds the yoke. The return yoke and the shield together dissipated stray magnetic field, thereby reducing the possibility that stray magnetic fields will adversely affect the operation of the accelerator.


In some implementations, the return yoke and shield may be replaced by, or augmented by, an active return system. An example active return system includes one or more active return coils that conduct current in a direction opposite to current through the main superconducting coils. In some example implementations, there is an active return coil for each superconducting coil, e.g., two active return coils—one for each superconducting coil (referred to as a “main” coil). Each active return coil may also be a superconducting coil that surrounds the outside of a corresponding main superconducting coil.


Current passes through the active return coils in a direction that is opposite to the direction of current passing through the main coils. The current passing through the active return coils thus generates a magnetic field that is opposite in polarity to the magnetic field generated by the main coils. As a result, the magnetic field generated by an active return coil is able to dissipate at least some of the relatively strong stray magnetic field resulting from the corresponding main coil. In some implementations, each active return may be used to generate a magnetic field of between 2.5 T and 12 T or more. An example of an active return system that may be used is described in U.S. patent application Ser. No. 13/907,601, filed on May 31, 2013, the contents of which are incorporated herein by reference.


Referring to FIG. 3, at the output of extraction channel 102 of particle accelerator 105 (which may have the configuration shown in FIGS. 1 and 2) is an example scanning system 106 that may be used to scan the particle beam across at least part of an irradiation target. FIG. 4 shows examples of the components of the scanning system include a scanning magnet 108, an ion chamber 109, and an energy degrader 110. Other components of the scanning system are not shown in FIG. 4, including scatterers for changing beam spot size. These components are shown in other figures and described below.


In an example operation, scanning magnet 108 is controllable in two dimensions (e.g., Cartesian XY dimensions) to direct the particle beam across a part (e.g., a cross-section) of an irradiation target. Ion chamber 109 detects the dosage of the beam and feeds-back that information to a control system. Energy degrader 110 is controllable (e.g., by one or more computer programs executable on one or more processing devices) to move material into, and out of, the path of the particle beam to change the energy of the particle beam and therefore the depth to which the particle beam will penetrate the irradiation target.



FIGS. 5 and 6 show views of an example scanning magnet 108. Scanning magnet 108 includes two coils 111, which control particle beam movement in the X direction, and two coils 112, which control particle beam movement in the Y direction. Control is achieved, in some implementations, by varying current through one or both sets of coils to thereby vary the magnetic field(s) produced thereby. By varying the magnetic field(s) appropriately, the particle beam can be moved in the X and/or Y direction across the irradiation target. In some implementations, the scanning magnet is not movable physically relative to the particle accelerator. In other implementations, the scanning magnet may be movable relative to the accelerator (e.g., in addition to the movement provided by the gantry).


In this example, ion chamber 109 detects dosage applied by the particle beam by detecting the numbers of ion pairs created within a gas caused by incident radiation. The numbers of ion pairs correspond to the dosage provided by the particle beam. That information is fed-back to a computer system that controls operation of the particle therapy system. The computer system (not shown), which may include memory and one or more processing devices, determines if the dosage detected by ion chamber is the intended dose. If the dosage is not as intended, the computer system may control the accelerator to interrupt production and/or output of the particle beam, and/or control the scanning magnet to prevent output of the particle beam to the irradiation target.



FIG. 7 shows a range modulator 115, which is an example implementation of energy degrader 110. In some implementations, such as that shown in FIG. 7, range modulator includes a series of plates 116. The plates may be made of one or more of the following example materials: carbon, beryllium or other material of low atomic number. Other materials, however, may be used in place of, or in addition to, these example materials.


One or more of the plates is movable into, or out of, the beam path to thereby affect the energy of the particle beam and, thus, the depth of penetration of the particle beam within the irradiation target. For example, the more plates that are moved into the path of the particle beam, the more energy that will be absorbed by the plates, and the less energy the particle beam will have. Conversely, the fewer plates that are moved into the path of the particle beam, the less energy that will be absorbed by the plates, and the more energy the particle beam will have. Higher energy particle beams penetrate deeper into the irradiation target than do lower energy particle beams. In this context, “higher” and “lower” are meant as relative terms, and do not have any specific numeric connotations.


Plates are moved physically into, and out of, the path of the particle beam. For example, as shown in FIG. 8, a plate 116a moves along the direction of arrow 117 between positions in the path of the particle beam and outside the path of the particle beam. The plates are computer-controlled. Generally, the number of plates that are moved into the path of the particle beam corresponds to the depth at which scanning of an irradiation target is to take place. For example, the irradiation target can be divided into cross-sections, each of which corresponds to an irradiation depth. One or more plates of the range modulator can be moved into, or out of, the beam path to the irradiation target in order to achieve the appropriate energy to irradiate each of these cross-sections of the irradiation target. In some implementations, the range modulator does not rotate with the accelerator, but rather remains in place and move plates into, and out of, the beam path.


In some implementations, a treatment plan is established prior to treating the irradiation target. The treatment plan may specify how scanning is to be performed for a particular irradiation target. In some implementations, the treatment plan specifies the following information: a type of scanning (e.g., spot scanning or raster scanning); scan locations (e.g., locations of spots to be scanned); magnet current per scan location; dosage-per-spot, spot size; locations (e.g., depths) of irradiation target cross-sections; particle beam energy per cross-section; plates to move into the beam path for each particle beam energy; and so forth. Generally, spot scanning involves applying irradiation at discrete spots on an irradiation target and raster scanning involves moving a radiation spot across the radiation target. The concept of spot size therefore applies for both raster and spot scanning.


In some implementations, the overall treatment plan of an irradiation target includes different treatment plans for different cross-sections of the irradiation target. The treatment plans for different cross-sections may contain the same information or different information, such as that provided above.


One or more scatterers may be inserted at one or more points in the particle beam path to change the size of the scanning spot prior to output to the irradiation target. For example, in some implementations, one or more scatterers may be movable into, or out of, the beam path down-beam of the scanning magnet but before (up-beam of) the energy degrader. Referring to FIG. 9, for example, a scatterer 120 may be moved into, or out of the beam path at location 122 or at location 123. In other implementations, scatterers may be positioned at different or multiple locations between magnet 108 and energy degrader 110. For example, there may be one or more scatterers placed immediately down-beam of the magnet and one or more scatterers placed immediately up-beam of the energy degrader. In still other implementations, one or more scatterers may be placed in the beam path either up-beam of the magnet or down-beam of the degrader. The one or more scatterers placed in the beam path up-beam of the magnet or down-beam of the degrader may be alone, in combination, or in combination with one or more scatterers in the beam path between the magnet and the energy degrader.


Example scatterers may be made of one or more of the following example scattering materials: lead, brass or similar materials. Other materials, however, may be used in place of, or in addition to, these example scattering materials.


In some implementations, the scatterers may be plates having the same or varying thickness, and may be similar in construction the plates of the energy degrader shown in FIG. 7. Each such plate may introduce an amount of scattering into the particle beam, thereby increasing the spot size of the particle beam relative to the spots size of the beam that emerged from the extraction channel. In some implementations, the more plates that are introduced into the particle beam, the larger the spot of the particle beam will be.


In some implementations, such as the plate-based implementations described above, the scatterers may supplant the energy degraders. For example, in addition to performing scattering, the scatterers may also absorb beam energy, thereby affecting the eventual energy output of the beam without use of energy degraders down-beam of, or up-beam of, the scatterers. In such example implementations, the scatterers may be computer-controlled in the same manner as the energy degraders described above to provide both an appropriate level of beam scattering and an appropriate amount of beam energy degradation. Accordingly, in some implementations, separate energy degraders are not used.


In some implementations, both the scatterers and one or more energy degraders are used to affect the output energy of the particle beam. For example, in an implementation, the scatterers may be used to reduce the energy of the beam to a certain level, and the energy degrader may be used to provide further beam energy reduction, or vice versa. Such implementations may enable reduction in the size of the energy degrader. In some implementations, the scatterers may provide a finer level of energy degradation than the energy degrader, or vice versa, thereby enabling either one or the other of the scatterers or the energy degrader to provide fine beam level energy adjustment and the other of the scatterers or the energy degrader to provide coarse beam level energy adjustment (where coarse and fine are relative terms, and do not have any particular numerical connotations).


In some implementations, each scatterer may be a wheel or other rotatable structure, which is either disposed within the beam path or moveable into, or out of, the beam path. The structure may have variable thickness ranging from a maximum thickness to a minimum thickness, which produce different amounts of scattering and, thus, different beam spot sizes. The structure may be movable relative to the beam to place one of the multiple thicknesses in the beam path. Typically, if a wheel, the structure is offset, so that edges of the wheel, having different thicknesses, impact the particle beam during rotation. Such example scatterers may be made of one or more of the following example materials: lead, brass or similar materials. Other materials, however, may be used in place of, or in addition to, these example scattering materials.


In an example implementation, the structure may be a rotatable variable-thickness wedge having a wheel-like shape. The structure scatters the particle beam, thereby varying the spot size of the beam during scanning. The thicker portions of the structure provide more scattering (and thus increase the spots size more) than the thinner portions of the structure. In some implementations, the structure may contain no material at a point where the particle beam is meant to pass without any scattering (e.g., spot size increase). In some implementations, the structure may be movable out of the beam path. Referring to FIG. 10, in some implementations, structure 124 may have continuously varying thickness to thereby enable scattering along a variable continuum and thereby enabling a continuous range of spots sizes. In the example of FIG. 10, the thickness varies continuously from a minimum thickness 126 to a maximum thickness 125. Referring to FIG. 11, in some implementations, the thicknesses of the structure may vary step-wise, to enable discrete amounts of scattering. In the example of FIG. 11, the thickness varies in steps from a minimum thickness 129 to a maximum thickness 128.


Any of the example scatterers described herein including, but not limited to, the example wheel-based implementations described above, may also be used to affect beam energy, thereby reducing the need for, or eliminating the need for, a separate energy degrader. As was also the case above, any scatterer may be used in conjunction with the energy degrader to provide different energy level reductions and/or coarse/fine energy reduction.


In some implementations, example spot sizes may range between 4 mm and 30 mm sigma or between 6 mm and 15 mm sigma. Other spot sizes, however, may be implemented in place of, or in addition to, these example spot sizes.


In some implementations, a single one or more scatterers of the type shown in FIG. 9, of the type shown in FIG. 10, or of the type shown in FIG. 11 may be positioned up-beam of the magnet, down-beam of the magnet and up-beam of the energy degrader, and/or down-beam of the energy degrader. In some implementations, any combinations of scatterers of the type shown in FIG. 9, of the type shown in FIG. 10, and of the type shown in FIG. 11 may be positioned up-beam of the magnet, down-beam of the magnet and up-beam of the energy degrader, and/or down-beam of the energy degrader.


Generally, mechanical scatterers, which move scattering material into, or out of, the path of the particle beam, have a response time on the order of tenths of a second (s), e.g., 0.1 s, 0.2 s, 0.3 s, 0.4 s, 0.5 s, 0.6 s, 0.7 s, 0.8 s, 0.9 s or longer. That is, such scatterers may be computer-controlled, and the amount of time to physically move scattering material into, or out of the particle beam, may be on the time scale of tenths of a second, and sometimes longer. In some implementations, the example scatterers of FIGS. 9, 10 and 11 have a response time on the order of tenths of a second, e.g., 0.1 s, 0.2 s, 0.3 s, 0.4 s, 0.5 s, 0.6 s, 0.7 s, 0.8 s, 0.9 s or longer. Notably, however, in some implementations, the examples scatterers of FIGS. 9, 10 and 11 may have a response time of less than 0.1 s.


In some implementations, piezoelectric scatterers may be used instead of, or in addition to, the mechanical scatterers described above. A piezoelectric scatterer may be made of a piezoelectric scattering material, which is disposed in the beam path such that application of applied voltage to the piezoelectric scatterer causes the piezoelectric scatterer to increase in thickness in the longitudinal direction of the particle beam. Conversely, application of a different voltage causes the piezoelectric scatterer to decrease in thickness in the longitudinal direction of the particle beam. In this way, the thickness of the scattering material, and thus the amount of scattering produced thereby, can be varied. As above, variations in the amount of scattering result in variations in the scan spot size (e.g., the more scattering, the bigger the spot). As was also the case above, a piezoelectric scatterer may be computer controlled. In some implementations, a piezoelectric scatterer may have a response time on the order of tens of milliseconds, e.g., 10 ms, 20 ms, 30 ms, 40 ms, 50 ms, 60 ms, 70 ms, 80 ms, 90 ms or longer in some implementations.


In some implementations, one or more piezoelectric scatterers may be positioned either up-beam of the magnet, down-beam of the magnet and up-beam of the energy degrader, and/or down-beam of the energy degrader. In some implementations, combinations of one or more piezoelectric scatterers may be used with one or more scatterers of the type shown in FIG. 9, of the type shown in FIG. 10, and/or of the type shown in FIG. 11 positioned either up-beam of the magnet, down-beam of the magnet and up-beam of the energy degrader, and/or down-beam of the energy degrader. Accordingly, in some implementations, one or more piezoelectric scatterers may be located, either alone, or with one or more scatterers of the type shown in FIG. 9, of the type shown in FIG. 10, and/or of the type shown in FIG. 11 up-beam of the magnet, down-beam of the magnet and up-beam of the energy degrader, and/or down-beam of the energy degrader.


In some implementations, spot size may be changed during treatment of an irradiation target cross-section, or in between treatment of different irradiation target cross-sections. For example, in some implementations, spot size may be changed between irradiation of different areas on the same cross-section of an irradiation target, e.g., the spot size may be changed between adjacent spots. Thus, in some implementations, changes in spot size may be made from spot-to-spot. In some implementations, spot size remains constant for a cross-section of the irradiation target, and is changed in between different cross-sections. In some implementations, spot size remains constant for a cross-section of the irradiation target, and is changed only in between different cross-sections. In some implementations, spot size may differ in different areas of the same cross-section. Generally, changes in spot size may be specified in the treatment plan for the irradiation target and/or the treatment plans for cross-sections of the irradiation target.


In some implementations, the scanning system may include a collimator 127 (FIG. 3) to collimate the particle bean, and an aperture (not shown) that is placeable relative to the irradiation target to limit the extent of the particle beam and thereby the shape of the spot applied to the irradiation target. In some implementations, spot size is controllable based on whether the particle therapy system includes one or more of those features. For example, an aperture may be placed in the beam path down-beam of the energy degrader and before the particle beam hits the irradiation target. The aperture, such as aperture 129 of FIG. 12, may contain an area (e.g., a hole 130) through which the particle beam passes and other material 131 defining the hole that prevents passage of the particle beam. In some implementations, therefore, the aperture defines the spot size. In such implementations, in the presence of an aperture and depending on the size and type of the aperture, the computer that implements the treatment plan may determine not to control spot size, at least part of the time (e.g., when the spot from the particle accelerator—the native spot size—is larger than the aperture hole).


In some implementations, the treatment plan for an irradiation target may be non-uniform (e.g., irregular). In this regard, traditionally and particularly in spot scanning systems, treatment plans define regular (e.g., rectangular) grids for an irradiation target. The regular grid includes a regular pattern of evenly-spaced target locations to which spots of irradiation are to be applied. In most cases, however, the portion (e.g., cross-section) of the irradiation target to be treated does not have a shape that corresponds to that of the regular grid. Accordingly, at locations of the regular grid that are off of the irradiation target, the particle beam is interrupted or directed so that the particle beam is not applied at those locations.


In the example particle therapy system described herein, a treatment plan may specify scanning according to a non-uniform grid. Various features of the particle therapy system may be controlled by computer (e.g., one or more processing devices) to implement scanning along a non-uniform grid. A non-uniform grid may have an irregular grid pattern that corresponds to (e.g., substantially tracks) the perimeter of an irradiation target. For example, the non-uniform grid may have spots arranged within a perimeter that substantially tracks the perimeter of a cross-section of the target to be irradiated using a particular treatment plan. An example of an irregular perimeter 132 for a non-uniform grid is shown in FIG. 13. The perimeter is typically of an irregular (e.g., non-polygonal, non-circular, non-oval, and so forth) shape to track the typically irregular shape of the cross-section of the irradiation target. However, in some instances, the non-uniform grid may have a regular (e.g., polygonal, circular, oval, and so forth) perimeter, e.g., if that perimeter corresponds to the perimeter of the irradiation target.


The non-uniform grid may include spot locations (e.g., locations to be irradiated) that are at regular intervals or locations within the perimeter or that are at irregular intervals or locations within the perimeter. In this context, an “interval” refers to a space between spots and a “location” refers to a place on the target where a spot is applied. So, for example, spots may be scanned in lines, which are regular locations, but at irregular intervals. Also, for example, spots may be scanned so that they have the same spacing, which are regular intervals, but that are at irregular locations. Examples are shown in the figures.


For example, FIG. 14 shows an example non-uniform grid having an irregular perimeter 133 and having spot locations 134 that are at regular intervals and regular locations. FIG. 15 shows an example non-uniform grid 135 having an irregular perimeter and having spot locations 136 that are at regular intervals and irregular locations. FIG. 16 shows an example non-uniform grid 137 having an irregular perimeter and having spot locations 138 that are at irregular intervals and regular locations. FIG. 17 shows an example non-uniform grid having a regular perimeter 139 (e.g., a rectangle) and having spot locations 140 that are at regular intervals and irregular locations. FIG. 18 shows an example non-uniform grid having a regular perimeter 141 and having spot locations 142 that are at irregular intervals and regular locations. A computer system that controls the particle therapy system may also control scanning magnet 108 or other elements of the scanning system according to the treatment plan to produce non-uniform grid scanning. Other types of non-uniform grids may also be used for scanning.


By implementing non-uniform grid scanning, the example particle therapy system described herein reduces the need to interrupt or redirect the particle beam during scanning. For example, in some implementations, the particle beam is interrupted between scanning different depth cross-sections of an irradiation target. In some in some implementations, the particle beam is only interrupted between scanning different depth cross-sections of an irradiation target. So, for example, during irradiation of a particular depth cross-section of the irradiation target, the particle beam need not be interrupted or redirected so as not to hit the target.


A treatment plan may specify, for an irradiation target or cross-section thereof, a non-uniform grid to be scanned and spot sizes at each scan location of the non-uniform grid. Elements of the particle therapy system, including the scanning system, may then be computer-controlled to scan the cross-section according to the non-uniform grid and variable spot size. For example, as shown in FIG. 19, scanning may be performed so, at a perimeter 144 of an irregular cross-section, smaller spots 145 are deposited at a relatively high density. In an interior region of the irregular cross-section, larger spots 146 may be deposited at a density that is lower than the density of spots deposited at the perimeter. As a result, the cross-section of the irradiation target may be more accurately scanned with or without the use of apertures and without interrupting or redirecting the particle beam.


In some implementations, the scanning is performed at a same speed from spot-to-spot. In some implementations, raster scanning may be performed using a variable spot size and non-uniform scanning grid. Control over the various components of the particle therapy system are similar to the control performed to implement spot scanning using these features.


Different cross-sections of the irradiation target may be scanned according to different treatment plans. As described above, in some examples, the energy degrader is used to control the scanning depth. In some implementations, the particle beam may be interrupted or redirected during configuration of the energy degrader. In other implementations, this need not be the case.


Described herein are examples of treating cross-sections of an irradiation target. These are generally cross-sections that are perpendicular to the direction of the particle beam. However, the concepts described herein are equally applicable to treating other portions of an irradiation target that are not cross-sections perpendicular to the direction of the particle beam. For example, an irradiation target may be segmented into spherical, cubical or other shaped volumes, and those volumes treated according to the concepts described herein.


The processes described herein may be used with a single particle accelerator, and any two or more of the features thereof described herein may be used with the single particle accelerator. The particle accelerator may be used in any type of medical or non-medical application. An example of a particle therapy system that may be used is provided below. Notably, the concepts described herein may be used in other systems not specifically described.


Referring to FIG. 20, an example implementation of a charged particle radiation therapy system 500 includes a beam-producing particle accelerator 502 having a weight and size small enough to permit it to be mounted on a rotating gantry 504 with its output directed straight (that is, essentially directly) from the accelerator housing toward a patient 506. Particle accelerator 502 also includes a scanning system of a type described herein (e.g., FIGS. 3 to 19).


In some implementations, the steel gantry has two legs 508, 510 mounted for rotation on two respective bearings 512, 514 that lie on opposite sides of the patient. The accelerator is supported by a steel truss 516 that is long enough to span a treatment area 518 in which the patient lies (e.g., twice as long as a tall person, to permit the person to be rotated fully within the space with any desired target area of the patient remaining in the line of the beam) and is attached stably at both ends to the rotating legs of the gantry.


In some examples, the rotation of the gantry is limited to a range 520 of less than 360 degrees, e.g., about 180 degrees, to permit a floor 522 to extend from a wall of the vault 524 that houses the therapy system into the patient treatment area. The limited rotation range of the gantry also reduces the required thickness of some of the walls (which are not directly aligned with the beam, e.g., wall 530), which provide radiation shielding of people outside the treatment area. A range of 180 degrees of gantry rotation is enough to cover all treatment approach angles, but providing a larger range of travel can be useful. For example the range of rotation may be between 180 and 330 degrees and still provide clearance for the therapy floor space.


The horizontal rotational axis 532 of the gantry is located nominally one meter above the floor where the patient and therapist interact with the therapy system. This floor is positioned about 3 meters above the bottom floor of the therapy system shielded vault. The accelerator can swing under the raised floor for delivery of treatment beams from below the rotational axis. The patient couch moves and rotates in a substantially horizontal plane parallel to the rotational axis of the gantry. The couch can rotate through a range 534 of about 270 degrees in the horizontal plane with this configuration. This combination of gantry and patient rotational ranges and degrees of freedom allow the therapist to select virtually any approach angle for the beam. If needed, the patient can be placed on the couch in the opposite orientation and then all possible angles can be used.


In some implementations, the accelerator uses a synchrocyclotron configuration having a very high magnetic field superconducting electromagnetic structure. Because the bend radius of a charged particle of a given kinetic energy is reduced in direct proportion to an increase in the magnetic field applied to it, the very high magnetic field superconducting magnetic structure permits the accelerator to be made smaller and lighter. The synchrocyclotron uses a magnetic field that is uniform in rotation angle and falls off in strength with increasing radius. Such a field shape can be achieved regardless of the magnitude of the magnetic field, so in theory there is no upper limit to the magnetic field strength (and therefore the resulting particle energy at a fixed radius) that can be used in a synchrocyclotron.


The synchrocyclotron is supported on the gantry so that the beam is generated directly in line with the patient. The gantry permits rotation of the cyclotron about a horizontal rotational axis that contains a point (isocenter 540) within, or near, the patient. The split truss that is parallel to the rotational axis, supports the cyclotron on both sides.


Because the rotational range of the gantry is limited, a patient support area can be accommodated in a wide area around the isocenter. Because the floor can be extended broadly around the isocenter, a patient support table can be positioned to move relative to and to rotate about a vertical axis 542 through the isocenter so that, by a combination of gantry rotation and table motion and rotation, any angle of beam direction into any part of the patient can be achieved. The two gantry arms are separated by more than twice the height of a tall patient, allowing the couch with patient to rotate and translate in a horizontal plane above the raised floor.


Limiting the gantry rotation angle allows for a reduction in the thickness of at least one of the walls surrounding the treatment room. Thick walls, typically constructed of concrete, provide radiation protection to individuals outside the treatment room. A wall downstream of a stopping proton beam may be about twice as thick as a wall at the opposite end of the room to provide an equivalent level of protection. Limiting the range of gantry rotation enables the treatment room to be sited below earth grade on three sides, while allowing an occupied area adjacent to the thinnest wall reducing the cost of constructing the treatment room.


In the example implementation shown in FIG. 20, the superconducting synchrocyclotron 502 operates with a peak magnetic field in a pole gap of the synchrocyclotron of 8.8 Tesla. The synchrocyclotron produces a beam of protons having an energy of 250 MeV. In other implementations the field strength could be in the range of 4 T to 20 T and the proton energy could be in the range of 150 to 300 MeV; however, field strength and energy are not limited to these ranges.


The radiation therapy system described in this example is used for proton radiation therapy, but the same principles and details can be applied in analogous systems for use in heavy ion (ion) treatment systems.


As shown in FIGS. 1, 2, 21, 22, and 23, an example synchrocyclotron 10 (e.g., 502 in FIG. 1) includes a magnet system 12 that contains an particle source 90, a radiofrequency drive system 91, and a beam extraction system 38. The magnetic field established by the magnet system has a shape appropriate to maintain focus of a contained proton beam using a combination of a split pair of annular superconducting coils 40, 42 and a pair of shaped ferromagnetic (e.g., low carbon steel) pole faces 44, 46.


The two superconducting magnet coils are centered on a common axis 47 and are spaced apart along the axis. As shown in FIGS. 24 and 25, the coils are formed by of Nb3Sn-based superconducting 0.8 mm diameter strands 48 (that initially comprise a niobium-tin core surrounded by a copper sheath) deployed in a twisted cable-in-channel conductor geometry. After seven individual strands are cabled together, they are heated to cause a reaction that forms the final (brittle) superconducting material of the wire. After the material has been reacted, the wires are soldered into the copper channel (outer dimensions 3.18×2.54 mm and inner dimensions 2.08×2.08 mm) and covered with insulation 52 (in this example, a woven fiberglass material). The copper channel containing the wires 53 is then wound in a coil having a rectangular cross-section. The wound coil is then vacuum impregnated with an epoxy compound. The finished coils are mounted on an annular stainless steel reverse bobbin 56. Heater blankets 55 are placed at intervals in the layers of the windings to protect the assembly in the event of a magnet quench.


The entire coil can then be covered with copper sheets to provide thermal conductivity and mechanical stability and then contained in an additional layer of epoxy. The precompression of the coil can be provided by heating the stainless steel reverse bobbin and fitting the coils within the reverse bobbin. The reverse bobbin inner diameter is chosen so that when the entire mass is cooled to 4 K, the reverse bobbin stays in contact with the coil and provides some compression. Heating the stainless steel reverse bobbin to approximately 50 degrees C. and fitting coils at a temperature of 100 degrees Kelvin can achieve this.


The geometry of the coil is maintained by mounting the coils in a reverse rectangular bobbin 56 to exert a restorative force 60 that works against the distorting force produced when the coils are energized. As shown in FIG. 22, the coil position is maintained relative to the magnet yoke and cryostat using a set of warm-to-cold support straps 402, 404, 406. Supporting the cold mass with thin straps reduces the heat leakage imparted to the cold mass by the rigid support system. The straps are arranged to withstand the varying gravitational force on the coil as the magnet rotates on board the gantry. They withstand the combined effects of gravity and the large de-centering force realized by the coil when it is perturbed from a perfectly symmetric position relative to the magnet yoke. Additionally the links act to reduce dynamic forces imparted on the coil as the gantry accelerates and decelerates when its position is changed. Each warm-to-cold support includes one S2 fiberglass link and one carbon fiber link. The carbon fiber link is supported across pins between the warm yoke and an intermediate temperature (50-70 K), and the S2 fiberglass link 408 is supported across the intermediate temperature pin and a pin attached to the cold mass. Each pin may be made of high strength stainless steel.


Referring to FIG. 1, the field strength profile as a function of radius is determined largely by choice of coil geometry and pole face shape; the pole faces 44, 46 of the permeable yoke material can be contoured to fine tune the shape of the magnetic field to ensure that the particle beam remains focused during acceleration.


The superconducting coils are maintained at temperatures near absolute zero (e.g., about 4 degrees Kelvin) by enclosing the coil assembly (the coils and the bobbin) inside an evacuated annular aluminum or stainless steel cryostatic chamber 70 that provides a free space around the coil structure, except at a limited set of support points 71, 73. In an alternate version (e.g., FIG. 2) the outer wall of the cryostat may be made of low carbon steel to provide an additional return flux path for the magnetic field.


In some implementations, the temperature near absolute zero is achieved and maintained using one single-stage Gifford-McMahon cryo-cooler and three two-stage Gifford McMahon cryo-coolers. Each two stage cryo-cooler has a second stage cold end attached to a condenser that recondenses Helium vapor into liquid Helium. In some implementations, the temperature near absolute zero is achieved and maintained using a cooling channel (not shown) containing the liquid helium, which is formed inside a superconducting coil support structure (e.g., the reverse bobbin), and which contains a thermal connection between the liquid helium in the channel and the corresponding superconducting coil. An example of a liquid helium cooling system of the type described above, and that may be used is described in U.S. patent application Ser. No. 13/148,000 (Begg et al.).


The coil assembly and cryostatic chambers are mounted within and fully enclosed by two halves 81, 83 of a pillbox-shaped magnet yoke 82. The iron yoke 82 provides a path for the return magnetic field flux 84 and magnetically shields the volume 86 between the pole faces 44, 46 to prevent external magnetic influences from perturbing the shape of the magnetic field within that volume. The yoke also serves to decrease the stray magnetic field in the vicinity of the accelerator.


As shown in FIGS. 1 and 26, the synchrocyclotron includes a particle source 90 of a Penning ion gauge geometry located near the geometric center 92 of the magnet structure 82. The particle source may be as described below, or the particle source may be of the type described in U.S. patent application Ser. No. 11/948,662 incorporated herein by reference.


Particle source 90 is fed from a supply 99 of hydrogen through a gas line 201 and tube 194 that delivers gaseous hydrogen. Electric cables 94 carry an electric current from a current source 95 to stimulate electron discharge from cathodes 192, 190 that are aligned with the magnetic field 199.


In some implementations, the gas in gas tube 101 may include a mixture of hydrogen and one or more other gases. For example, the mixture may contain hydrogen and one or more of the noble gases, e.g., helium, neon, argon, krypton, xenon and/or radon (although the mixture is not limited to use with the noble gases). In some implementations, the mixture may be a mixture of hydrogen and helium. For example, the mixture may contain about 75% or more of hydrogen and about 25% or less of helium (with possible trace gases included). In another example, the mixture may contain about 90% or more of hydrogen and about 10% or less of helium (with possible trace gases included). In examples, the hydrogen/helium mixture may be any of the following: >95%/<5%, >90%/<10%, >85%/<15%, >80%/<20%, >75%/<20%, and so forth.


Possible advantages of using a noble (or other) gas in combination with hydrogen in the particle source may include: increased beam intensity, increased cathode longevity, and increased consistency of beam output.


In this example, the discharged electrons ionize the gas exiting through a small hole from tube 194 to create a supply of positive ions (protons) for acceleration by one semicircular (dee-shaped) radio-frequency plate that spans half of the space enclosed by the magnet structure and one dummy dee plate 102. In the case of an interrupted particle source (an example of which is described in U.S. patent application Ser. No. 11/948,662), all (or a substantial part) of the tube containing plasma is removed at the acceleration region.


As shown in FIG. 27, the dee plate 200 is a hollow metal structure that has two semicircular surfaces 203, 205 that enclose a space 207 in which the protons are accelerated during half of their rotation around the space enclosed by the magnet structure. A duct 209 opening into the space 207 extends through the yoke to an external location from which a vacuum pump can be attached to evacuate the space 207 and the rest of the space within a vacuum chamber 219 in which the acceleration takes place. The dummy dee 202 comprises a rectangular metal ring that is spaced near to the exposed rim of the dee plate. The dummy dee is grounded to the vacuum chamber and magnet yoke. The dee plate 200 is driven by a radio-frequency signal that is applied at the end of a radio-frequency transmission line to impart an electric field in the space 207. The radio frequency electric field is made to vary in time as the accelerated particle beam increases in distance from the geometric center. The radio frequency electric field may be controlled in the manner described in U.S. patent application Ser. No. 11/948,359, entitled “Matching A Resonant Frequency Of A Resonant Cavity To A Frequency Of An Input Voltage”, the contents of which are incorporated herein by reference.


For the beam emerging from the centrally located particle source to clear the particle source structure as it begins to spiral outward, a large voltage difference is required across the radio frequency plates. 20,000 Volts is applied across the radio frequency plates. In some versions from 8,000 to 20,000 Volts may be applied across the radio frequency plates. To reduce the power required to drive this large voltage, the magnet structure is arranged to reduce the capacitance between the radio frequency plates and ground. This is done by forming holes with sufficient clearance from the radio frequency structures through the outer yoke and the cryostat housing and making sufficient space between the magnet pole faces.


The high voltage alternating potential that drives the dee plate has a frequency that is swept downward during the accelerating cycle to account for the increasing relativistic mass of the protons and the decreasing magnetic field. The dummy dee does not require a hollow semi-cylindrical structure as it is at ground potential along with the vacuum chamber walls. Other plate arrangements could be used such as more than one pair of accelerating electrodes driven with different electrical phases or multiples of the fundamental frequency. The RF structure can be tuned to keep the Q high during the required frequency sweep by using, for example, a rotating capacitor having intermeshing rotating and stationary blades. During each meshing of the blades, the capacitance increases, thus lowering the resonant frequency of the RF structure. The blades can be shaped to create a precise frequency sweep required. A drive motor for the rotating condenser can be phase locked to the RF generator for precise control. One bunch of particles is accelerated during each meshing of the blades of the rotating condenser.


The vacuum chamber in which the acceleration occurs is a generally cylindrical container that is thinner in the center and thicker at the rim. The vacuum chamber encloses the RF plates and the particle source and is evacuated by the vacuum pump 211. Maintaining a high vacuum insures that accelerating ions are not lost to collisions with gas molecules and enables the RF voltage to be kept at a higher level without arcing to ground.


Protons traverse a generally spiral orbital path beginning at the particle source. In half of each loop of the spiral path, the protons gain energy as they pass through the RF electric field in space 107. As the ions gain energy, the radius of the central orbit of each successive loop of their spiral path is larger than the prior loop until the loop radius reaches the maximum radius of the pole face. At that location a magnetic and electric field perturbation directs ions into an area where the magnetic field rapidly decreases, and the ions depart the area of the high magnetic field and are directed through an evacuated tube 38, referred to herein as the extraction channel, to exit the yoke of the cyclotron. A magnetic regenerator may be used to change the magnetic field perturbation to direct the ions. The ions exiting the cyclotron will tend to disperse as they enter the area of markedly decreased magnetic field that exists in the room around the cyclotron. Beam shaping elements 407, 409 in the extraction channel 38 redirect the ions so that they stay in a straight beam of limited spatial extent.


As the beam exits the extraction channel it is passed through a beam formation system 225 (FIG. 22) comprised of a scanning system of the type described herein. Beam formation system 125 may be used in conjunction with an inner gantry that controls application of the beam.


Stray magnetic fields exiting from the cyclotron may be limited by both the pillbox magnet yoke (which also serves as a shield) and a separate magnetic shield 214. The separate magnetic shield includes of a layer 217 of ferromagnetic material (e.g., steel or iron) that encloses the pillbox yoke, separated by a space 216. This configuration that includes a sandwich of a yoke, a space, and a shield achieves adequate shielding for a given leakage magnetic field at lower weight. As described above, in some implementations, an active return system may be used in place of, or to augment, the operation of the magnetic yoke and shield.


As mentioned, the gantry allows the synchrocyclotron to be rotated about the horizontal rotational axis 532. The truss structure 516 has two generally parallel spans 580, 582. The synchrocyclotron is cradled between the spans about midway between the legs. The gantry is balanced for rotation about the bearings using counterweights 222, 224 mounted on ends of the legs opposite the truss.


The gantry is driven to rotate by an electric motor mounted to one or both of the gantry legs and connected to the bearing housings by drive gears. The rotational position of the gantry is derived from signals provided by shaft angle encoders incorporated into the gantry drive motors and the drive gears.


At the location at which the ion beam exits the cyclotron, the beam formation system 225 acts on the ion beam to give it properties suitable for patient treatment. For example, the beam may be spread and its depth of penetration varied to provide uniform radiation across a given target volume. The beam formation system includes active scanning elements as described herein.


All of the active systems of the synchrocyclotron (the current driven superconducting coils, the RF-driven plates, the vacuum pumps for the vacuum acceleration chamber and for the superconducting coil cooling chamber, the current driven particle source, the hydrogen gas source, and the RF plate coolers, for example), may be controlled by appropriate synchrocyclotron control electronics (not shown), which may include, e.g., one or more computers programmed with appropriate programs to effect control.


The control of the gantry, the patient support, the active beam shaping elements, and the synchrocyclotron to perform a therapy session is achieved by appropriate therapy control electronics (not shown).


As shown in FIGS. 20, 28, and 29, the gantry bearings are supported by the walls of a cyclotron vault 524. The gantry enables the cyclotron to be swung through a range 520 of 180 degrees (or more) including positions above, to the side of, and below the patient. The vault is tall enough to clear the gantry at the top and bottom extremes of its motion. A maze 246 sided by walls 248, 150 provides an entry and exit route for therapists and patients. Because at least one wall 152 is not in line with the proton beam directly from the cyclotron, it can be made relatively thin and still perform its shielding function. The other three side walls 154, 156, 150/248 of the room, which may need to be more heavily shielded, can be buried within an earthen hill (not shown). The required thickness of walls 154, 156, and 158 can be reduced, because the earth can itself provide some of the needed shielding.


Referring to FIGS. 28, 29 and 30, for safety and aesthetic reasons, a therapy room 160 may be constructed within the vault. The therapy room is cantilevered from walls 154, 156, 150 and the base 162 of the containing room into the space between the gantry legs in a manner that clears the swinging gantry and also maximizes the extent of the floor space 164 of the therapy room. Periodic servicing of the accelerator can be accomplished in the space below the raised floor. When the accelerator is rotated to the down position on the gantry, full access to the accelerator is possible in a space separate from the treatment area. Power supplies, cooling equipment, vacuum pumps and other support equipment can be located under the raised floor in this separate space. Within the treatment room, the patient support 170 can be mounted in a variety of ways that permit the support to be raised and lowered and the patient to be rotated and moved to a variety of positions and orientations.


In system 602 of FIG. 31, a beam-producing particle accelerator of the type described herein, in this case synchrocyclotron 604, is mounted on rotating gantry 605. Rotating gantry 605 is of the type described herein, and can angularly rotate around patient support 606. This feature enables synchrocyclotron 604 to provide a particle beam directly to the patient from various angles. For example, as in FIG. 31, if synchrocyclotron 604 is above patient support 606, the particle beam may be directed downwards toward the patient. Alternatively, if synchrocyclotron 604 is below patient support 606, the particle beam may be directed upwards toward the patient. The particle beam is applied directly to the patient in the sense that an intermediary beam routing mechanism is not required. A routing mechanism, in this context, is different from a shaping or sizing mechanism in that a shaping or sizing mechanism does not re-route the beam, but rather sizes and/or shapes the beam while maintaining the same general trajectory of the beam.


Further details regarding an example implementation of the foregoing system may be found in U.S. Pat. No. 7,728,311, filed on Nov. 16, 2006 and entitled “Charged Particle Radiation Therapy”, and in U.S. patent application Ser. No. 12/275,103, filed on Nov. 20, 2008 and entitled “Inner Gantry”. The contents of U.S. Pat. No. 7,728,311 and in U.S. patent application Ser. No. 12/275,103 are hereby incorporated by reference into this disclosure. In some implementations, the synchrocyclotron may be a variable-energy device, such as that described in U.S. patent application Ser. No. 13/916,401, filed on Jun. 12, 2013, the contents of which are incorporated herein by reference.


Variable-Energy Particle Accelerator

The particle accelerator used in the example particle therapy systems and example scanning systems described herein may be a variable-energy particle accelerator. Different spot-size scatterers may be configured for use with different energies produced by a variable-energy particle accelerator. Likewise, different energy degraders, if used (and, in some cases, they may not be), may be configured for use with different energies produced by a variable-energy particle accelerator.


The energy of the extracted particle beam (the particle beam output from the accelerator) can affect the use of the particle beam during treatment. In some machines, the energy of the particle beam (or particles in the particle beam) does not increase after extraction. However, the energy may be reduced based on treatment needs after the extraction and before the treatment. Referring to FIG. 32, an example treatment system 910 includes an accelerator 912, e.g., a synchrocyclotron, from which a particle (e.g., proton) beam 914 having a variable energy is extracted to irradiate a target volume 924 of a body 922. Optionally, one or more additional devices, such as a scanning unit 916 or a scattering unit 916, one or more monitoring units 918, and an energy degrader 920, are placed along the irradiation direction 928. The devices intercept the cross-section of the extracted beam 914 and alter one or more properties of the extracted beam for the treatment.


A target volume to be irradiated (an irradiation target) by a particle beam for treatment typically has a three-dimensional configuration. In some examples, to carry-out the treatment, the target volume is divided into layers along the irradiation direction of the particle beam so that the irradiation can be done on a layer-by-layer basis. For certain types of particles, such as protons, the penetration depth (or which layer the beam reaches) within the target volume is largely determined by the energy of the particle beam. A particle beam of a given energy does not reach substantially beyond a corresponding penetration depth for that energy. To move the beam irradiation from one layer to another layer of the target volume, the energy of the particle beam is changed.


In the example shown in FIG. 32, the target volume 924 is divided into nine layers 926a-926i along the irradiation direction 928. In an example process, the irradiation starts from the deepest layer 926i, one layer at a time, gradually to the shallower layers and finishes with the shallowest layer 926a. Before application to the body 922, the energy of the particle beam 914 is controlled to be at a level to allow the particle beam to stop at a desired layer, e.g., the layer 926d, without substantially penetrating further into the body or the target volume, e.g., the layers 926e-926i or deeper into the body. In some examples, the desired energy of the particle beam 914 decreases as the treatment layer becomes shallower relative to the particle acceleration. In some examples, the beam energy difference for treating adjacent layers of the target volume 924 is about 3 MeV to about 100 MeV, e.g., about 10 MeV to about 80 MeV, although other differences may also be possible, depending on, e.g., the thickness of the layers and the properties of the beam.


The energy variation for treating different layers of the target volume 924 can be performed at the accelerator 912 (e.g., the accelerator can vary the energy) so that, in some implementations, no additional energy variation is required after the particle beam is extracted from the accelerator 912. So, the optional energy degrader 920 in the treatment system 10 may be eliminated from the system. In some implementations, the accelerator 912 can output particle beams having an energy that varies between about 100 MeV and about 300 MeV, e.g., between about 115 MeV and about 250 MeV. The variation can be continuous or non-continuous, e.g., one step at a time. In some implementations, the variation, continuous or non-continuous, can take place at a relatively high rate, e.g., up to about 50 MeV per second or up to about 20 MeV per second. Non-continuous variation can take place one step at a time with a step size of about 10 MeV to about 90 MeV.


When irradiation is complete in one layer, the accelerator 912 can vary the energy of the particle beam for irradiating a next layer, e.g., within several seconds or within less than one second. In some implementations, the treatment of the target volume 924 can be continued without substantial interruption or even without any interruption. In some situations, the step size of the non-continuous energy variation is selected to correspond to the energy difference needed for irradiating two adjacent layers of the target volume 924. For example, the step size can be the same as, or a fraction of, the energy difference.


In some implementations, the accelerator 912 and the degrader 920 collectively vary the energy of the beam 914. For example, the accelerator 912 provides a coarse adjustment and the degrader 920 provides a fine adjustment or vice versa. In this example, the accelerator 912 can output the particle beam that varies energy with a variation step of about 10-80 MeV, and the degrader 920 adjusts (e.g., reduces) the energy of the beam at a variation step of about 2-10 MeV.


The reduced use (or absence) of the energy degrader, which can include range shifters, helps to maintain properties and quality of the output beam from the accelerator, e.g., beam intensity. The control of the particle beam can be performed at the accelerator. Side effects, e.g., from neutrons generated when the particle beam passes the degrader 920, can be reduced or eliminated.


The energy of the particle beam 914 may be adjusted to treat another target volume 930 in another body or body part 922′ after completing treatment in target volume 924. The target volumes 924, 930 may be in the same body (or patient), or may belong to different patients. It is possible that the depth D of the target volume 930 from a surface of body 922′ is different from that of the target volume 924. Although some energy adjustment may be performed by the degrader 920, the degrader 912 may only reduce the beam energy and not increase the beam energy.


In this regard, in some cases, the beam energy required for treating target volume 930 is greater than the beam energy required to treat target volume 924. In such cases, the accelerator 912 may increase the output beam energy after treating the target volume 924 and before treating the target volume 930. In other cases, the beam energy required for treating target volume 930 is less than the beam energy required to treat target volume 924. Although the degrader 920 can reduce the energy, the accelerator 912 can be adjusted to output a lower beam energy to reduce or eliminate the use of the degrader 920. The division of the target volumes 924, 930 into layers can be different or the same. And the target volume 930 can be treated similarly on a layer by layer basis to the treatment of the target volume 924.


The treatment of the different target volumes 924, 930 on the same patient may be substantially continuous, e.g., with the stop time between the two volumes being no longer than about 30 minutes or less, e.g., 25 minutes or less, 20 minutes or less, 15 minutes or less, 10 minutes or less, 5 minutes or less, or 1 minute or less. As is explained herein, the accelerator 912 can be mounted on a movable gantry and the movement of the gantry can move the accelerator to aim at different target volumes. In some situations, the accelerator 912 can complete the energy adjustment of the output beam 914 during the time the treatment system makes adjustment (such as moving the gantry) after completing the treatment of the target volume 924 and before starting treating the target volume 930. After the alignment of the accelerator and the target volume 930 is done, the treatment can begin with the adjusted, desired beam energy. Beam energy adjustment for different patients can also be completed relatively efficiently. In some examples, all adjustments, including increasing/reducing beam energy and/or moving the gantry are done within about 30 minutes, e.g., within about 25 minutes, within about 20 minutes, within about 15 minutes, within about 10 minutes or within about 5 minutes.


In the same layer of a target volume, an irradiation dose is applied by moving the beam across the two-dimensional surface of the layer (which is sometimes called scanning beam) using a scanning unit 916. Alternatively, the layer can be irradiated by passing the extracted beam through one or more scatterers of the scattering unit 16 (which is sometimes called scattering beam).


Beam properties, such as energy and intensity, can be selected before a treatment or can be adjusted during the treatment by controlling the accelerator 912 and/or other devices, such as the scanning unit/scatterer(s) 916, the degrader 920, and others not shown in the figures. In this example implementation, as in the example implementations described above, system 910 includes a controller 932, such as a computer, in communication with one or more devices in the system. Control can be based on results of the monitoring performed by the one or more monitors 918, e.g., monitoring of the beam intensity, dose, beam location in the target volume, etc. Although the monitors 918 are shown to be between the device 916 and the degrader 920, one or more monitors can be placed at other appropriate locations along the beam irradiation path. Controller 932 can also store a treatment plan for one or more target volumes (for the same patient and/or different patients). The treatment plan can be determined before the treatment starts and can include parameters, such as the shape of the target volume, the number of irradiation layers, the irradiation dose for each layer, the number of times each layer is irradiated, etc. The adjustment of a beam property within the system 910 can be performed based on the treatment plan. Additional adjustment can be made during the treatment, e.g., when deviation from the treatment plan is detected.


In some implementations, the accelerator 912 is configured to vary the energy of the output particle beam by varying the magnetic field in which the particle beam is accelerated. In an example implementation, one or more sets of coils receives variable electrical current to produce a variable magnetic field in the cavity. In some examples, one set of coils receives a fixed electrical current, while one or more other sets of coils receives a variable current so that the total current received by the coil sets varies. In some implementations, all sets of coils are superconducting. In other implementations, some sets of coils, such as the set for the fixed electrical current, are superconducting, while other sets of coils, such as the one or more sets for the variable current, are non-superconducting. In some examples, all sets of coils are non-superconducting.


Generally, the magnitude of the magnetic field is scalable with the magnitude of the electrical current. Adjusting the total electric current of the coils in a predetermined range can generate a magnetic field that varies in a corresponding, predetermined range. In some examples, a continuous adjustment of the electrical current can lead to a continuous variation of the magnetic field and a continuous variation of the output beam energy. Alternatively, when the electrical current applied to the coils is adjusted in a non-continuous, step-wise manner, the magnetic field and the output beam energy also varies accordingly in a non-continuous (step-wise) manner. The scaling of the magnetic field to the current can allow the variation of the beam energy to be carried out relatively precisely, although sometimes minor adjustment other than the input current may be performed.


In some implementations, to output particle beams having a variable energy, the accelerator 912 is configured to apply RF voltages that sweep over different ranges of frequencies, with each range corresponding to a different output beam energy. For example, if the accelerator 912 is configured to produce three different output beam energies, the RF voltage is capable of sweeping over three different ranges of frequencies. In another example, corresponding to continuous beam energy variations, the RF voltage sweeps over frequency ranges that continuously change. The different frequency ranges may have different lower frequency and/or upper frequency boundaries.


The extraction channel may be configured to accommodate the range of different energies produced by the variable-energy particle accelerator. Particle beams having different energies can be extracted from the accelerator 912 without altering the features of the regenerator that is used for extracting particle beams having a single energy. In other implementations, to accommodate the variable particle energy, the regenerator can be moved to disturb (e.g., change) different particle orbits in the manner described above and/or iron rods (magnetic shims) can be added or removed to change the magnetic field bump provided by the regenerator. More specifically, different particle energies will typically be at different particle orbits within the cavity. By moving the regenerator in the manner described herein, it is possible to intercept a particle orbit at a specified energy and thereby provide the correct perturbation of that orbit so that particles at the specified energy reach the extraction channel. In some implementations, movement of the regenerator (and/or addition/removal of magnetic shims) is performed in real-time to match real-time changes in the particle beam energy output by the accelerator. In other implementations, particle energy is adjusted on a per-treatment basis, and movement of the regenerator (and/or addition/removal of magnetic shims) is performed in advance of the treatment. In either case, movement of the regenerator (and/or addition/removal of magnetic shims) may be computer controlled. For example, a computer may control one or more motors that effect movement of the regenerator and/or magnetic shims. In some implementations, iron rods (magnetic shims) can be moved into and out of any appropriate part of magnetic yoke 82 to alter and control the magnetic field produced in the acceleration cavity.


In some implementations, the regenerator is implemented using one or more magnetic shims that are controllable to move to the appropriate location(s).


In some implementations, a structure (not shown) is at the entrance to the extraction channel is controlled to accommodate the different energies produced by the particle accelerator. For example, the structure may be rotated so that an appropriate thickness intercepts a particle beam having a particular energy. The structure thus absorbs at least some of the energy in the particle beam, enabling the particle beam to traverse the extraction channel, as described above.


As an example, table 1 shows three example energy levels at which example accelerator 912 can output particle beams. The corresponding parameters for producing the three energy levels are also listed. In this regard, the magnet current refers to the total electrical current applied to the one or more coil sets in the accelerator 912; the maximum and minimum frequencies define the ranges in which the RF voltage sweeps; and “r” is the radial distance of a location to a center of the cavity in which the particles are accelerated.









TABLE 1







Examples of beam energies and respective parameters.












Beam
Magnet
Maximum
Minimum
Magnetic Field
Magnetic Field


Energy
Current
Frequency
Frequency
at r = 0 mm
at r = 298 mm


(MeV)
(Amps)
(MHz)
(MHz)
(Tesla)
(Tesla)





250
1990
132
99
8.7
8.2


235
1920
128
97
8.4
8.0


211
1760
120
93
7.9
7.5









Details that may be included in an example particle accelerator that produces charged particles having variable energies are described below. The accelerator can be a synchrocyclotron and the particles may be protons. The particles may be output as pulsed beams. The energy of the beam output from the particle accelerator can be varied during the treatment of one target volume in a patient, or between treatments of different target volumes of the same patient or different patients. In some implementations, settings of the accelerator are changed to vary the beam energy when no beam (or particles) is output from the accelerator. The energy variation can be continuous or non-continuous over a desired range.


Referring to the example shown in FIG. 1, the particle accelerator (synchrocyclotron 502), which may be a variable-energy particle accelerator like accelerator 912 described above, may be configured to particle beams that have a variable energy. The range of the variable energy can have an upper boundary that is about 200 MeV to about 300 MeV or higher, e.g., 200 MeV, about 205 MeV, about 210 MeV, about 215 MeV, about 220 MeV, about 225 MeV, about 230 MeV, about 235 MeV, about 240 MeV, about 245 MeV, about 250 MeV, about 255 MeV, about 260 MeV, about 265 MeV, about 270 MeV, about 275 MeV, about 280 MeV, about 285 MeV, about 290 MeV, about 295 MeV, or about 300 MeV or higher. The range can also have a lower boundary that is about 100 MeV or lower to about 200 MeV, e.g., about 100 MeV or lower, about 105 MeV, about 110 MeV, about 115 MeV, about 120 MeV, about 125 MeV, about 130 MeV, about 135 MeV, about 140 MeV, about 145 MeV, about 150 MeV, about 155 MeV, about 160 MeV, about 165 MeV, about 170 MeV, about 175 MeV, about 180 MeV, about 185 MeV, about 190 MeV, about 195 MeV, about 200 MeV.


In some examples, the variation is non-continuous and the variation step can have a size of about 10 MeV or lower, about 15 MeV, about 20 MeV, about 25 MeV, about 30 MeV, about 35 MeV, about 40 MeV, about 45 MeV, about 50 MeV, about 55 MeV, about 60 MeV, about 65 MeV, about 70 MeV, about 75 MeV, or about 80 MeV or higher. Varying the energy by one step size can take no more than 30 minutes, e.g., about 25 minutes or less, about 20 minutes or less, about 15 minutes or less, about 10 minutes or less, about 5 minutes or less, about 1 minute or less, or about 30 seconds or less. In other examples, the variation is continuous and the accelerator can adjust the energy of the particle beam at a relatively high rate, e.g., up to about 50 MeV per second, up to about 45 MeV per second, up to about 40 MeV per second, up to about 35 MeV per second, up to about 30 MeV per second, up to about 25 MeV per second, up to about 20 MeV per second, up to about 15 MeV per second, or up to about 10 MeV per second. The accelerator can be configured to adjust the particle energy both continuously and non-continuously. For example, a combination of the continuous and non-continuous variation can be used in a treatment of one target volume or in treatments of different target volumes. Flexible treatment planning and flexible treatment can be achieved.


A particle accelerator that outputs a particle beam having a variable energy can provide accuracy in irradiation treatment and reduce the number of additional devices (other than the accelerator) used for the treatment. For example, the use of degraders for changing the energy of an output particle beam may be reduced or eliminated. The properties of the particle beam, such as intensity, focus, etc. can be controlled at the particle accelerator and the particle beam can reach the target volume without substantial disturbance from the additional devices. The relatively high variation rate of the beam energy can reduce treatment time and allow for efficient use of the treatment system.


In some implementations, the accelerator, such as the synchrocyclotron 502 of FIG. 1, accelerates particles or particle beams to variable energy levels by varying the magnetic field in the accelerator, which can be achieved by varying the electrical current applied to coils for generating the magnetic field. As shown in FIGS. 3, 4, 5, 6, and 7, example synchrocyclotron 10 (502 in FIG. 1) includes a magnet system that contains a particle source 90, a radiofrequency drive system 91, and a beam extraction system 38. FIG. 35 shows an example of a magnet system that may be used in a variable-energy accelerator. In this example implementation, the magnetic field established by the magnet system 1012 can vary by about 5% to about 35% of a maximum value of the magnetic field that two sets of coils 40a and 40b, and 42a and 42b are capable of generating. The magnetic field established by the magnet system has a shape appropriate to maintain focus of a contained proton beam using a combination of the two sets of coils and a pair of shaped ferromagnetic (e.g., low carbon steel) structures, examples of which are provided above.


Each set of coils may be a split pair of annular coils to receive electrical current. In some situations, both sets of coils are superconducting. In other situations, only one set of the coils is superconducting and the other set is non-superconducting or normal conducting (also discussed further below). It is also possible that both sets of coils are non-superconducting. Suitable superconducting materials for use in the coils include niobium-3 tin (Nb3Sn) and/or niobium-titanium. Other normal conducting materials can include copper. Examples of the coil set constructions are described further below.


The two sets of coils can be electrically connected serially or in parallel. In some implementations, the total electrical current received by the two sets of coils can include about 2 million ampere turns to about 10 million ampere turns, e.g., about 2.5 to about 7.5 million ampere turns or about 3.75 million ampere turns to about 5 million ampere turns. In some examples, one set of coils is configured to receive a fixed (or constant) portion of the total variable electrical current, while the other set of coils is configured to receive a variable portion of the total electrical current. The total electrical current of the two coil sets varies with the variation of the current in one coil set. In other situations, the electrical current applied to both sets of coils can vary. The variable total current in the two sets of coils can generate a magnetic field having a variable magnitude, which in turn varies the acceleration pathways of the particles and produces particles having variable energies.


Generally, the magnitude of the magnetic field generated by the coil(s) is scalable to the magnitude of the total electrical current applied to the coil(s). Based on the scalability, in some implementations, linear variation of the magnetic field strength can be achieved by linearly changing the total current of the coil sets. The total current can be adjusted at a relatively high rate that leads to a relatively high-rate adjustment of the magnetic field and the beam energy.


In the example reflected in Table 1 above, the ratio between values of the current and the magnetic field at the geometric center of the coil rings is: 1990:8.7 (approximately 228.7:1); 1920:8.4 (approximately 228.6:1); 1760:7.9 (approximately 222.8:1). Accordingly, adjusting the magnitude of the total current applied to a superconducting coil(s) can proportionally (based on the ratio) adjust the magnitude of the magnetic field.


The scalability of the magnetic field to the total electrical current in the example of Table 1 is also shown in the plot of FIG. 33, where BZ is the magnetic field along the Z direction; and R is the radial distance measured from a geometric center of the coil rings along a direction perpendicular to the Z direction. The magnetic field has the highest value at the geometric center, and decreases as the distance R increases. The curves 1035, 1037 represent the magnetic field generated by the same coil sets receiving different total electrical current: 1760 Amperes and 1990 Amperes, respectively. The corresponding energies of the extracted particles are 211 MeV and 250 MeV, respectively. The two curves 1035, 1037 have substantially the same shape and the different parts of the curves 1035, 1037 are substantially parallel. As a result, either the curve 1035 or the curve 1037 can be linearly shifted to substantially match the other curve, indicating that the magnetic field is scalable to the total electrical current applied to the coil sets.


In some implementations, the scalability of the magnetic field to the total electrical current may not be perfect. For example, the ratio between the magnetic field and the current calculated based on the example shown in table 1 is not constant. Also, as shown in FIG. 33, the linear shift of one curve may not perfectly match the other curve. In some implementations, the total current is applied to the coil sets under the assumption of perfect scalability. The target magnetic field (under the assumption of perfect scalability) can be generated by additionally altering the features, e.g., geometry, of the coils to counteract the imperfection in the scalability. As one example, ferromagnetic (e.g., iron) rods (magnetic shims) can be inserted or removed from one or both of the magnetic structures. The features of the coils can be altered at a relatively high rate so that the rate of the magnetic field adjustment is not substantially affected as compared to the situation in which the scalability is perfect and only the electrical current needs to be adjusted. In the example of iron rods, the rods can be added or removed at the time scale of seconds or minutes, e.g., within 5 minutes, within 1 minute, less than 30 seconds, or less than 1 second.


In some implementations, settings of the accelerator, such as the current applied to the coil sets, can be chosen based on the substantial scalability of the magnetic field to the total electrical current in the coil sets.


Generally, to produce the total current that varies within a desired range, any combination of current applied to the two coil sets can be used. In an example, the coil set 42a, 42b can be configured to receive a fixed electrical current corresponding to a lower boundary of a desired range of the magnetic field. In the example shown in table 1, the fixed electrical current is 1760 Amperes. In addition, the coil set 40a, 40b can be configured to receive a variable electrical current having an upper boundary corresponding to a difference between an upper boundary and a lower boundary of the desired range of the magnetic field. In the example shown in table 1, the coil set 40a, 40b is configured to receive electrical current that varies between 0 Ampere and 230 Amperes.


In another example, the coil set 42a, 42b can be configured to receive a fixed electrical current corresponding to an upper boundary of a desired range of the magnetic field. In the example shown in table 1, the fixed current is 1990 Amperes. In addition, the coil set 40a, 40b can be configured to receive a variable electrical current having an upper boundary corresponding to a difference between a lower boundary and an upper boundary of the desired range of the magnetic field. In the example shown in table 1, the coil set 40a, 40b is configured to receive electrical current that varies between −230 Ampere and 0 Ampere.


The total variable magnetic field generated by the variable total current for accelerating the particles can have a maximum magnitude greater than 4 Tesla, e.g., greater than 5 Tesla, greater than 6 Tesla, greater than 7 Tesla, greater than 8 Tesla, greater than 9 Tesla, or greater than 10 Tesla, and up to about 20 Tesla or higher, e.g., up to about 18 Tesla, up to about 15 Tesla, or up to about 12 Tesla. In some implementations, variation of the total current in the coil sets can vary the magnetic field by about 0.2 Tesla to about 4.2 Tesla or more, e.g., about 0.2 Tesla to about 1.4 Tesla or about 0.6 Tesla to about 4.2 Tesla. In some situations, the amount of variation of the magnetic field can be proportional to the maximum magnitude.



FIG. 34 shows an example RF structure for sweeping the voltage on the dee plate 100 over an RF frequency range for each energy level of the particle beam, and for varying the frequency range when the particle beam energy is varied. The semicircular surfaces 103, 105 of the dee plate 100 are connected to an inner conductor 1300 and housed in an outer conductor 1302. The high voltage is applied to the dee plate 100 from a power source (not shown, e.g., an oscillating voltage input) through a power coupling device 1304 that couples the power source to the inner conductor. In some implementations, the coupling device 1304 is positioned on the inner conductor 1300 to provide power transfer from the power source to the dee plate 100. In addition, the dee plate 100 is coupled to variable reactive elements 1306, 1308 to perform the RF frequency sweep for each particle energy level, and to change the RF frequency range for different particle energy levels.


The variable reactive element 1306 can be a rotating capacitor that has multiple blades 1310 rotatable by a motor (not shown). By meshing or unmeshing the blades 1310 during each cycle of RF sweeping, the capacitance of the RF structure changes, which in turn changes the resonant frequency of the RF structure. In some implementations, during each quarter cycle of the motor, the blades 1310 mesh with the each other. The capacitance of the RF structure increases and the resonant frequency decreases. The process reverses as the blades 1310 unmesh. As a result, the power required to generate the high voltage applied to the dee plate 103 and necessary to accelerate the beam can be reduced by a large factor. In some implementations, the shape of the blades 1310 is machined to form the required dependence of resonant frequency on time.


The RF frequency generation is synchronized with the blade rotation by sensing the phase of the RF voltage in the resonator, keeping the alternating voltage on the dee plates close to the resonant frequency of the RF cavity. (The dummy dee is grounded and is not shown in FIG. 34).


The variable reactive element 1308 can be a capacitor formed by a plate 1312 and a surface 1316 of the inner conductor 1300. The plate 1312 is movable along a direction 1314 towards or away from the surface 1316. The capacitance of the capacitor changes as the distance D between the plate 1312 and the surface 1316 changes. For each frequency range to be swept for one particle energy, the distance D is at a set value, and to change the frequency range, the plate 1312 is moved corresponding to the change in the energy of the output beam.


In some implementations, the inner and outer conductors 1300, 1302 are formed of a metallic material, such as copper, aluminum, or silver. The blades 1310 and the plate 1312 can also be formed of the same or different metallic materials as the conductors 1300, 1302. The coupling device 1304 can be an electrical conductor. The variable reactive elements 1306, 1308 can have other forms and can couple to the dee plate 100 in other ways to perform the RF frequency sweep and the frequency range alteration. In some implementations, a single variable reactive element can be configured to perform the functions of both the variable reactive elements 1306, 1308. In other implementations, more than two variable reactive elements can be used.


Control of the particle therapy system described herein and its various features may be implemented using hardware or a combination of hardware and software. For example, a system like the ones described herein may include various controllers and/or processing devices located at various points. A central computer may coordinate operation among the various controllers or processing devices. The central computer, controllers, and processing devices may execute various software routines to effect control and coordination of testing and calibration.


System operation can be controlled, at least in part, using one or more computer program products, e.g., one or more computer program tangibly embodied in one or more information carriers, such as one or more non-transitory machine-readable media, for execution by, or to control the operation of, one or more data processing apparatus, e.g., a programmable processor, a computer, multiple computers, and/or programmable logic components.


A computer program can be written in any form of programming language, including compiled or interpreted languages, and it can be deployed in any form, including as a stand-alone program or as a module, component, subroutine, or other unit suitable for use in a computing environment. A computer program can be deployed to be executed on one computer or on multiple computers at one site or distributed across multiple sites and interconnected by a network.


Actions associated with implementing all or part of the operations of the particle therapy system described herein can be performed by one or more programmable processors executing one or more computer programs to perform the functions described herein. All or part of the operations can be implemented using special purpose logic circuitry, e.g., an FPGA (field programmable gate array) and/or an ASIC (application-specific integrated circuit).


Processors suitable for the execution of a computer program include, by way of example, both general and special purpose microprocessors, and any one or more processors of any kind of digital computer. Generally, a processor will receive instructions and data from a read-only storage area or a random access storage area or both. Elements of a computer (including a server) include one or more processors for executing instructions and one or more storage area devices for storing instructions and data. Generally, a computer will also include, or be operatively coupled to receive data from, or transfer data to, or both, one or more machine-readable storage media, such as mass PCBs for storing data, e.g., magnetic, magneto-optical disks, or optical disks. Non-transitory machine-readable storage media suitable for embodying computer program instructions and data include all forms of non-volatile storage area, including by way of example, semiconductor storage area devices, e.g., EPROM, EEPROM, and flash storage area devices; magnetic disks, e.g., internal hard disks or removable disks; magneto-optical disks; and CD-ROM and DVD-ROM disks.


Any “electrical connection” as used herein may imply a direct physical connection or a connection that includes intervening components but that nevertheless allows electrical signals, including wireless signals, to flow between connected components. Any “connection” involving electrical circuitry mentioned herein, unless stated otherwise, is an electrical connection and not necessarily a direct physical connection regardless of whether the word “electrical” is used to modify “connection”.


Any two more of the foregoing implementations may be used in an appropriate combination in an appropriate particle accelerator (e.g., a synchrocyclotron). Likewise, individual features of any two more of the foregoing implementations may be used in an appropriate combination.


Elements of different implementations described herein may be combined to form other implementations not specifically set forth above. Elements may be left out of the processes, systems, apparatus, etc., described herein without adversely affecting their operation. Various separate elements may be combined into one or more individual elements to perform the functions described herein.


The example implementations described herein are not limited to use with a particle therapy system or to use with the example particle therapy systems described herein. Rather, the example implementations can be used in any appropriate system that directs accelerated particles to an output.


Additional information concerning the design of an example implementation of a particle accelerator that may be used in a system as described herein can be found in U.S. Provisional Application No. 60/760,788, entitled “High-Field Superconducting Synchrocyclotron” and filed Jan. 20, 2006; U.S. patent application Ser. No. 11/463,402, entitled “Magnet Structure For Particle Acceleration” and filed Aug. 9, 2006; and U.S. Provisional Application No. 60/850,565, entitled “Cryogenic Vacuum Break Pneumatic Thermal Coupler” and filed Oct. 10, 2006, all of which are incorporated herein by reference.


The following applications are incorporated by reference into the subject application: the U.S. Provisional Application entitled “CONTROLLING INTENSITY OF A PARTICLE BEAM” (Application No. 61/707,466), the U.S. Provisional Application entitled “ADJUSTING ENERGY OF A PARTICLE BEAM” (Application No. 61/707,515), the U.S. Provisional Application entitled “ADJUSTING COIL POSITION” (Application No. 61/707,548), the U.S. Provisional Application entitled “FOCUSING A PARTICLE BEAM USING MAGNETIC FIELD FLUTTER” (Application No. 61/707,572), the U.S. Provisional Application entitled “MAGNETIC FIELD REGENERATOR” (Application No. 61/707,590), the U.S. Provisional Application entitled “FOCUSING A PARTICLE BEAM” (Application No. 61/707,704), the U.S. Provisional Application entitled “CONTROLLING PARTICLE THERAPY (Application No. 61/707,624), and the U.S. Provisional Application entitled “CONTROL SYSTEM FOR A PARTICLE ACCELERATOR” (Application No. 61/707,645).


The following are also incorporated by reference into the subject application: U.S. Pat. No. 7,728,311 which issued on Jun. 1, 2010, U.S. patent application Ser. No. 11/948,359 which was filed on Nov. 30, 2007, U.S. patent application Ser. No. 12/275,103 which was filed on Nov. 20, 2008, U.S. patent application Ser. No. 11/948,662 which was filed on Nov. 30, 2007, U.S. Provisional Application No. 60/991,454 which was filed on Nov. 30, 2007, U.S. Pat. No. 8,003,964 which issued on Aug. 23, 2011, U.S. Pat. No. 7,208,748 which issued on Apr. 24, 2007, U.S. Pat. No. 7,402,963 which issued on Jul. 22, 2008, U.S. patent application Ser. No. 13/148,000 filed Feb. 9, 2010, U.S. patent application Ser. No. 11/937,573 filed on Nov. 9, 2007, U.S. patent application Ser. No. 11/187,633, titled “A Programmable Radio Frequency Waveform Generator for a Synchrocyclotron,” filed Jul. 21, 2005, U.S. Provisional Application No. 60/590,089, filed on Jul. 21, 2004, U.S. patent application Ser. No. 10/949,734, titled “A Programmable Particle Scatterer for Radiation Therapy Beam Formation”, filed Sep. 24, 2004, and U.S. Provisional Application No. 60/590,088, filed Jul. 21, 2005.


Any features of the subject application may be combined with one or more appropriate features of the following: the U.S. Provisional Application entitled “CONTROLLING INTENSITY OF A PARTICLE BEAM” (Application No. 61/707,466), the U.S. Provisional Application entitled “ADJUSTING ENERGY OF A PARTICLE BEAM” (Application No. 61/707,515), the U.S. Provisional Application entitled “ADJUSTING COIL POSITION” (Application No. 61/707,548), the U.S. Provisional Application entitled “FOCUSING A PARTICLE BEAM USING MAGNETIC FIELD FLUTTER” (Application No. 61/707,572), the U.S. Provisional Application entitled “MAGNETIC FIELD REGENERATOR” (Application No. 61/707,590), the U.S. Provisional Application entitled “FOCUSING A PARTICLE BEAM” (Application No. 61/707,704), the U.S. Provisional Application entitled “CONTROLLING PARTICLE THERAPY (Application No. 61/707,624), and the U.S. Provisional Application entitled “CONTROL SYSTEM FOR A PARTICLE ACCELERATOR” (Application No. 61/707,645), U.S. Pat. No. 7,728,311 which issued on Jun. 1, 2010, U.S. patent application Ser. No. 11/948,359 which was filed on Nov. 30, 2007, U.S. patent application Ser. No. 12/275,103 which was filed on Nov. 20, 2008, U.S. patent application Ser. No. 11/948,662 which was filed on Nov. 30, 2007, U.S. Provisional Application No. 60/991,454 which was filed on Nov. 30, 2007, U.S. patent application Ser. No. 13/907,601, which was filed on May 31, 2013, U.S. patent application Ser. No. 13/916,401, filed on Jun. 12, 2013, U.S. Pat. No. 8,003,964 which issued on Aug. 23, 2011, U.S. Pat. No. 7,208,748 which issued on Apr. 24, 2007, U.S. Pat. No. 7,402,963 which issued on Jul. 22, 2008, U.S. patent application Ser. No. 13/148,000 filed Feb. 9, 2010, U.S. patent application Ser. No. 11/937,573 filed on Nov. 9, 2007, U.S. patent application Ser. No. 11/187,633, titled “A Programmable Radio Frequency Waveform Generator for a Synchrocyclotron,” filed Jul. 21, 2005, U.S. Provisional Application No. 60/590,089, filed on Jul. 21, 2004, U.S. patent application Ser. No. 10/949,734, titled “A Programmable Particle Scatterer for Radiation Therapy Beam Formation”, filed Sep. 24, 2004, and U.S. Provisional Application No. 60/590,088, filed Jul. 21, 2005.


Other implementations not specifically described herein are also within the scope of the following claims.

Claims
  • 1. A particle therapy system comprising: a synchrocyclotron to output a particle beam;a magnet to affect a direction of the particle beam to scan the particle beam across at least part of an irradiation target; andscattering material that is configurable to change a spot size of the particle beam prior to the particle beam reaching the irradiation target;wherein scanning performed by the particle therapy system is spot scanning;wherein the spot size is changeable from scan-location to scan-location; andwherein the spot size is changeable on a time scale on the order of tenths of a second.
  • 2. The particle therapy system of claim 1, further comprising: a degrader to change an energy of the particle beam prior to the particle beam reaching the irradiation target, the degrader being down-beam of the scattering material relative to the synchrocyclotron.
  • 3. The particle therapy system of claim 1, wherein the synchrocyclotron comprises: a voltage source to provide a radio frequency (RF) voltage to a cavity to accelerate particles from a plasma column, the cavity having a magnetic field causing particles accelerated from the plasma column to move orbitally within the cavity;an extraction channel to receive the particles accelerated from the plasma column and to output the received particles from the cavity in the particle beam; anda regenerator to provide a magnetic field bump within the cavity to thereby change successive orbits of the particles accelerated from the plasma column so that, eventually, particles output to the extraction channel;wherein the magnetic field is between 4 Tesla (T) and 20 T.
  • 4. The particle therapy system of claim 1, wherein the scattering material comprises multiple scatterers, each of the multiple scatterers being movable into, or out of, a path of the particle beam.
  • 5. The particle therapy system of claim 4, wherein only one of the multiple scatterers at a time is movable into the path of the particle beam.
  • 6. A particle therapy system comprising: a synchrocyclotron to output a particle beam;a magnet to affect a direction of the particle beam to scan the particle beam across at least part of an irradiation target; andscattering material that is configurable to change a spot size of the particle beam prior to the particle beam reaching the irradiation target;wherein the scattering material comprises piezoelectric material that is responsive to an applied voltage to increase or to decrease in thickness.
  • 7. The particle therapy system of claim 1, wherein the scattering material is configurable to change a spot size of the particle beam during a course of treatment of the irradiation target.
  • 8. The particle therapy system of claim 1, wherein the scattering material is configurable to change a spot size of the particle beam in between times of treatment of the irradiation target.
  • 9. A particle therapy system comprising: a synchrocyclotron to output a particle beam;a magnet to affect a direction of the particle beam to scan the particle beam across at least part of an irradiation target; andscattering material that is configurable to change a spot size of the particle beam prior to the particle beam reaching the irradiation target;wherein the spot size is changeable on a time scale on the order of tens of milliseconds.
  • 10. A particle therapy system comprising: a synchrocyclotron to output a particle beam;a scanning system to receive the particle beam from the synchrocyclotron and to perform spot scanning of at least part of an irradiation target with the particle beam, the scanning system being controllable to change a spot size of the particle beam; anda gantry on which the synchrocyclotron and at least part of the scanning system are mounted, the gantry being configured to move the synchrocyclotron and at least part of the scanning system around the irradiation target;wherein the spot size is changeable on a time scale on the order of tenths of a second.
  • 11. The particle therapy system of claim 10, wherein the scanning system comprises: structures to move the particle beam output from the synchrocyclotron in three-dimensions relative to the irradiation target; andscattering material, among the structures, that is configurable to change the spot size of the particle beam.
  • 12. The particle therapy system of claim 11, wherein the scattering material comprises multiple scatterers, each of the multiple scatterers being movable into, or out of, a path of the particle beam.
  • 13. The particle therapy system of claim 12, wherein only one of the multiple scatterers at a time is movable into the path of the particle beam.
  • 14. A particle therapy system comprising: a synchrocyclotron to output a particle beam;a scanning system to receive the particle beam from the synchrocyclotron and to perform spot scanning of at least part of an irradiation target with the particle beam, the scanning system being controllable to change a spot size of the particle beam; anda gantry on which the synchrocyclotron and at least part of the scanning system are mounted, the gantry being configured to move the synchrocyclotron and at least part of the scanning system around the irradiation target;wherein the scanning system comprises: structures to move the particle beam output from the synchrocyclotron in three-dimensions relative to the irradiation target; andscattering material, among the structures, that is configurable to change the spot size of the particle beam; andwherein the scattering material comprises piezoelectric material that is responsive to an applied voltage or to increase or to decrease in thickness.
  • 15. The particle therapy system of claim 11, wherein the scattering material is configurable to change the spot size of the particle beam during a course of treatment of the irradiation target.
  • 16. The particle therapy system of claim 11, wherein the scattering material is configurable to change the spot size of the particle beam in between times of treatment of the irradiation target.
  • 17. The particle therapy system of claim 10, wherein the spot size is changeable from scan-location to scan-location.
  • 18. A particle therapy system comprising: a synchrocyclotron to output a particle beam;a scanning system to receive the particle beam from the synchrocyclotron and to perform spot scanning of at least part of an irradiation target with the particle beam, the scanning system being controllable to change a spot size of the particle beam; anda gantry on which the synchrocyclotron and at least part of the scanning system are mounted, the gantry being configured to move the synchrocyclotron and at least part of the scanning system around the irradiation target;wherein the spot size is changeable on a time scale on the order of tens of milliseconds.
  • 19. The particle therapy system of claim 6, further comprising: a degrader to change an energy of the particle beam prior to the particle beam reaching the irradiation target, the degrader being down-beam of the scattering material relative to the synchrocyclotron.
  • 20. The particle therapy system of claim 6, wherein the synchrocyclotron comprises: a voltage source to provide a radio frequency (RF) voltage to a cavity to accelerate particles from a plasma column, the cavity having a magnetic field causing particles accelerated from the plasma column to move orbitally within the cavity;an extraction channel to receive the particles accelerated from the plasma column and to output the received particles from the cavity in the particle beam; anda regenerator to provide a magnetic field bump within the cavity to thereby change successive orbits of the particles accelerated from the plasma column so that, eventually, particles output to the extraction channel;wherein the magnetic field is between 4 Tesla (T) and 20 T.
  • 21. The particle therapy system of claim 6, wherein the spot size is changeable from scan-location to scan-location.
  • 22. The particle therapy system of claim 9, further comprising: a degrader to change an energy of the particle beam prior to the particle beam reaching the irradiation target, the degrader being down-beam of the scattering material relative to the synchrocyclotron.
  • 23. The particle therapy system of claim 9, wherein the synchrocyclotron comprises: a voltage source to provide a radio frequency (RF) voltage to a cavity to accelerate particles from a plasma column, the cavity having a magnetic field causing particles accelerated from the plasma column to move orbitally within the cavity;an extraction channel to receive the particles accelerated from the plasma column and to output the received particles from the cavity in the particle beam; anda regenerator to provide a magnetic field bump within the cavity to thereby change successive orbits of the particles accelerated from the plasma column so that, eventually, particles output to the extraction channel;wherein the magnetic field is between 4 Tesla (T) and 20 T.
  • 24. The particle therapy system of claim 9, wherein the spot size is changeable from scan-location to scan-location.
  • 25. The particle therapy system of claim 10, further comprising: a degrader to change an energy of the particle beam prior to the particle beam reaching the irradiation target, the degrader being down-beam of scattering material relative to the synchrocyclotron.
  • 26. The particle therapy system of claim 10, wherein the synchrocyclotron comprises: a voltage source to provide a radio frequency (RF) voltage to a cavity to accelerate particles from a plasma column, the cavity having a magnetic field causing particles accelerated from the plasma column to move orbitally within the cavity;an extraction channel to receive the particles accelerated from the plasma column and to output the received particles from the cavity in the particle beam; anda regenerator to provide a magnetic field bump within the cavity to thereby change successive orbits of the particles accelerated from the plasma column so that, eventually, particles output to the extraction channel;wherein the magnetic field is between 4 Tesla (T) and 20 T.
  • 27. The particle therapy system of claim 10, wherein the spot size is changeable from scan-location to scan-location.
  • 28. The particle therapy system of claim 14, further comprising: a degrader to change an energy of the particle beam prior to the particle beam reaching the irradiation target, the degrader being down-beam of the scattering material relative to the synchrocyclotron.
  • 29. The particle therapy system of claim 14, wherein the synchrocyclotron comprises: a voltage source to provide a radio frequency (RF) voltage to a cavity to accelerate particles from a plasma column, the cavity having a magnetic field causing particles accelerated from the plasma column to move orbitally within the cavity;an extraction channel to receive the particles accelerated from the plasma column and to output the received particles from the cavity in the particle beam; anda regenerator to provide a magnetic field bump within the cavity to thereby change successive orbits of the particles accelerated from the plasma column so that, eventually, particles output to the extraction channel;wherein the magnetic field is between 4 Tesla (T) and 20 T.
  • 30. The particle therapy system of claim 14, wherein the spot size is changeable from scan-location to scan-location.
  • 31. The particle therapy system of claim 18, further comprising: a degrader to change an energy of the particle beam prior to the particle beam reaching the irradiation target, the degrader being down-beam of scattering material relative to the synchrocyclotron.
  • 32. The particle therapy system of claim 18, wherein the synchrocyclotron comprises: a voltage source to provide a radio frequency (RF) voltage to a cavity to accelerate particles from a plasma column, the cavity having a magnetic field causing particles accelerated from the plasma column to move orbitally within the cavity;an extraction channel to receive the particles accelerated from the plasma column and to output the received particles from the cavity in the particle beam; anda regenerator to provide a magnetic field bump within the cavity to thereby change successive orbits of the particles accelerated from the plasma column so that, eventually, particles output to the extraction channel;wherein the magnetic field is between 4 Tesla (T) and 20 T.
  • 33. The particle therapy system of claim 18, wherein the spot size is changeable from scan-location to scan-location.
  • 34. A particle therapy system comprising: a synchrocyclotron to output a particle beam;a magnet to affect a direction of the particle beam to scan the particle beam across at least part of an irradiation target;scattering material that is configurable to change a spot size of the particle beam prior to the particle beam reaching the irradiation target; anda degrader to change an energy of the particle beam prior to the particle beam reaching the irradiation target, the degrader being down-beam of the scattering material relative to the synchrocyclotron;wherein the spot size is changeable on a time scale on the order of tenths of a second or less.
  • 35. The particle therapy system of claim 34, wherein the synchrocyclotron comprises: a voltage source to provide a radio frequency (RF) voltage to a cavity to accelerate particles from a plasma column, the cavity having a magnetic field causing particles accelerated from the plasma column to move orbitally within the cavity;an extraction channel to receive the particles accelerated from the plasma column and to output the received particles from the cavity in the particle beam; anda regenerator to provide a magnetic field bump within the cavity to thereby change successive orbits of the particles accelerated from the plasma column so that, eventually, particles output to the extraction channel;wherein the magnetic field is between 4 Tesla (T) and 20T.
  • 36. The particle therapy system of claim 34, wherein the scattering material comprises multiple scatterers, each of the multiple scatterers being movable into, or out of, a path of the particle beam.
  • 37. The particle therapy system of claim 36, wherein only one of the multiple scatterers at a time is movable into the path of the particle beam.
  • 38. The particle therapy system of claim 34, wherein the scattering material is configurable to change a spot size of the particle beam during a course of treatment of the irradiation target.
  • 39. The particle therapy system of claim 34, wherein the scattering material is configurable to change a spot size of the particle beam in between times of treatment of the irradiation target.
  • 40. A particle therapy system comprising: a synchrocyclotron to output a particle beam;a scanning system to receive the particle beam from the synchrocyclotron and to perform spot scanning of at least part of an irradiation target with the particle beam, the scanning system being controllable to change a spot size of the particle beam; anda gantry on which the synchrocyclotron and at least part of the scanning system are mounted, the gantry being configured to move the synchrocyclotron and at least part of the scanning system around the irradiation target;a degrader to change an energy of the particle beam prior to the particle beam reaching the irradiation target;wherein the spot size is changeable on a time scale on the order of tenths of a second.
CROSS-REFERENCE TO RELATED APPLICATION

Priority is hereby claimed to U.S. Provisional Application No. 61/883,631, filed on Sep. 27, 2013. The contents of U.S. Provisional Application No. 61/883,631 are incorporated herein by reference.

US Referenced Citations (1041)
Number Name Date Kind
463291 Dodson Nov 1891 A
773508 Leblanc Oct 1904 A
2280606 Van et al. Apr 1942 A
2492324 Salisbury Dec 1949 A
2615129 McMillan Oct 1952 A
2616042 Weeks Oct 1952 A
2659000 Salisbury Nov 1953 A
2701304 Dickinson Feb 1955 A
2789222 Martin Apr 1957 A
3175131 Burleigh, et al. Mar 1965 A
3432721 Naydan et al. Mar 1969 A
3582650 Avery Jun 1971 A
3679899 Dimeff Jul 1972 A
3689847 Verster Sep 1972 A
3757118 Hodge et al. Sep 1973 A
3868522 Bigham et al. Feb 1975 A
3886367 Castle May 1975 A
3925676 Bigham et al. Dec 1975 A
2958327 Marancik et al. May 1976 A
3955089 McIntyre et al. May 1976 A
3958327 Marancik et al. May 1976 A
3992625 Schmidt et al. Nov 1976 A
4038622 Purcell Jul 1977 A
4047068 Ress et al. Sep 1977 A
4112306 Nunan Sep 1978 A
4129784 Tschunt et al. Dec 1978 A
4139777 Rautenbach Feb 1979 A
4197510 Szu Apr 1980 A
4220866 Symmons et al. Sep 1980 A
4230129 LeVeen Oct 1980 A
4256966 Heinz Mar 1981 A
4293772 Stieber Oct 1981 A
4336505 Meyer Jun 1982 A
4342060 Gibson Jul 1982 A
4345210 Tran Aug 1982 A
4353033 Karasawa Oct 1982 A
4425506 Brown et al. Jan 1984 A
4490616 Cipollina et al. Dec 1984 A
4507614 Prono et al. Mar 1985 A
4507616 Blosser et al. Mar 1985 A
4589126 Augustsson et al. May 1986 A
4598208 Brunelli et al. Jul 1986 A
4628523 Heflin Dec 1986 A
4633125 Blosser et al. Dec 1986 A
4641057 Blosser et al. Feb 1987 A
4641104 Blosser et al. Feb 1987 A
4651007 Perusek et al. Mar 1987 A
4680565 Jahnke Jul 1987 A
4705955 Mileikowsky Nov 1987 A
4710722 Jahnke Dec 1987 A
4726046 Nunan Feb 1988 A
4734653 Jahnke Mar 1988 A
4736106 Kashy et al. Apr 1988 A
4736173 Blosser et al. Apr 1988 A
4737727 Yamada et al. Apr 1988 A
4739173 Blosser et al. Apr 1988 A
4741012 Duinker et al. Apr 1988 A
4745367 Dustmann et al. May 1988 A
4754147 Maughan et al. Jun 1988 A
4763483 Olsen Aug 1988 A
4767930 Stieber et al. Aug 1988 A
4769623 Marsing et al. Sep 1988 A
4771208 Jongen et al. Sep 1988 A
4783634 Yamamoto et al. Nov 1988 A
4808941 Marsing Feb 1989 A
4812658 Koehler Mar 1989 A
4843333 Marsing et al. Jun 1989 A
4845371 Stieber Jul 1989 A
4865284 Gosis et al. Sep 1989 A
4868843 Nunan Sep 1989 A
4868844 Nunan Sep 1989 A
4870287 Cole et al. Sep 1989 A
4880985 Jones Nov 1989 A
4894541 Ono Jan 1990 A
4896206 Denham Jan 1990 A
4902993 Krevent Feb 1990 A
4904949 Wilson Feb 1990 A
4905267 Miller et al. Feb 1990 A
4917344 Prechter et al. Apr 1990 A
4943781 Wilson et al. Jul 1990 A
4945478 Merickel et al. Jul 1990 A
4968915 Wilson et al. Nov 1990 A
4987309 Klasen et al. Jan 1991 A
4992744 Fujita et al. Feb 1991 A
4996496 Kitamura et al. Feb 1991 A
5006759 Krispel Apr 1991 A
5010562 Hernandez et al. Apr 1991 A
5012111 Ueda Apr 1991 A
5017789 Young et al. May 1991 A
5017882 Finlan May 1991 A
5036290 Sonobe et al. Jul 1991 A
5039057 Prechter et al. Aug 1991 A
5039867 Nishihara et al. Aug 1991 A
5046078 Hernandez et al. Sep 1991 A
5072123 Johnsen Dec 1991 A
5111042 Sullivan et al. May 1992 A
5111173 Matsuda et al. May 1992 A
5117194 Nakanishi et al. May 1992 A
5117212 Yamamoto et al. May 1992 A
5117829 Miller et al. Jun 1992 A
5148032 Hernandez Sep 1992 A
5166531 Huntzinger Nov 1992 A
5189687 Bova et al. Feb 1993 A
5191706 Cosden Mar 1993 A
5240218 Dye Aug 1993 A
5260579 Yasuda et al. Nov 1993 A
5260581 Lesyna et al. Nov 1993 A
5278533 Kawaguchi Jan 1994 A
5285166 Hiramoto et al. Feb 1994 A
5317164 Kurokawa May 1994 A
5336891 Crewe Aug 1994 A
5341104 Anton et al. Aug 1994 A
5349198 Takanaka Sep 1994 A
5365742 Boffito et al. Nov 1994 A
5374913 Pissantezky et al. Dec 1994 A
5382914 Hamm et al. Jan 1995 A
5401973 McKeown et al. Mar 1995 A
5405235 Lebre et al. Apr 1995 A
5434420 McKeown et al. Jul 1995 A
5440133 Moyers et al. Aug 1995 A
5451794 McKeown et al. Sep 1995 A
5461773 Kawaguchi Oct 1995 A
5463291 Carroll et al. Oct 1995 A
5464411 Schulte et al. Nov 1995 A
5492922 Palkowitz Feb 1996 A
5511549 Legg et al. Apr 1996 A
5521469 Laisne May 1996 A
5538942 Koyama et al. Jul 1996 A
5549616 Schulte et al. Aug 1996 A
5561697 Takafuji et al. Oct 1996 A
5585642 Britton et al. Dec 1996 A
5633747 Nikoonahad May 1997 A
5635721 Bardi et al. Jun 1997 A
5668371 Deasy et al. Sep 1997 A
5672878 Yao Sep 1997 A
5691679 Ackermann et al. Nov 1997 A
5726448 Smith et al. Mar 1998 A
5727554 Kalend et al. Mar 1998 A
5730745 Schulte et al. Mar 1998 A
5751781 Brown et al. May 1998 A
5778047 Mansfield et al. Jul 1998 A
5783914 Hiramoto et al. Jul 1998 A
5784431 Kalend et al. Jul 1998 A
5797924 Schulte et al. Aug 1998 A
5811944 Sampayan et al. Sep 1998 A
5818058 Nakanishi et al. Oct 1998 A
5821705 Caporasco et al. Oct 1998 A
5825845 Blair et al. Oct 1998 A
5841237 Alton Nov 1998 A
5846043 Spath Dec 1998 A
5851182 Sahadevan Dec 1998 A
5866912 Slater et al. Feb 1999 A
5874811 Finlan et al. Feb 1999 A
5895926 Britton et al. Apr 1999 A
5920601 Nigg et al. Jul 1999 A
5929458 Nemezawa et al. Jul 1999 A
5963615 Egley et al. Oct 1999 A
5993373 Nonaka et al. Nov 1999 A
6008499 Hiramoto et al. Dec 1999 A
6034377 Pu Mar 2000 A
6057655 Jongen May 2000 A
6061426 Linders et al. May 2000 A
6064807 Arai et al. May 2000 A
6066851 Madono et al. May 2000 A
6080992 Nonaka et al. Jun 2000 A
6087670 Hiramoto et al. Jul 2000 A
6094760 Nonaka et al. Aug 2000 A
6118848 Reiffel Sep 2000 A
6140021 Nakasuji et al. Oct 2000 A
6144875 Sachweikard et al. Nov 2000 A
6158708 Egley et al. Dec 2000 A
6207952 Kan et al. Mar 2001 B1
6219403 Nishihara Apr 2001 B1
6222905 Yoda et al. Apr 2001 B1
6241671 Ritter et al. Jun 2001 B1
6246066 Yuehu Jun 2001 B1
6256591 Yoda et al. Jul 2001 B1
6265837 Akiyama et al. Jul 2001 B1
6268610 Pu Jul 2001 B1
6278239 Caporasco et al. Aug 2001 B1
6279579 Riaziat et al. Aug 2001 B1
6307914 Kunieda et al. Oct 2001 B1
6316776 Hiramoto et al. Nov 2001 B1
6366021 Meddaugh et al. Apr 2002 B1
6369585 Yao Apr 2002 B2
6380545 Yan Apr 2002 B1
6407505 Bertsche Jun 2002 B1
6417634 Bergstrom Jul 2002 B1
6433336 Jongen et al. Aug 2002 B1
6433349 Akiyama et al. Aug 2002 B2
6433494 Kulish et al. Aug 2002 B1
6441569 Janzow Aug 2002 B1
6443349 Van Der Burg Sep 2002 B1
6465957 Whitham et al. Oct 2002 B1
6472834 Hiramoto et al. Oct 2002 B2
6476403 Dolinskii et al. Nov 2002 B1
6492922 New Dec 2002 B1
6493424 Whitham Dec 2002 B2
6498444 Hanna et al. Dec 2002 B1
6501981 Schweikard et al. Dec 2002 B1
6519316 Collins Feb 2003 B1
6593696 Ding et al. Jul 2003 B2
6594336 Nishizawa et al. Jul 2003 B2
6600164 Badura et al. Jul 2003 B1
6617598 Matsuda Sep 2003 B1
6621889 Mostafavi Sep 2003 B1
6639234 Badura et al. Oct 2003 B1
6646383 Bertsche et al. Nov 2003 B2
6670618 Hartmann et al. Dec 2003 B1
6683162 Scheinberg et al. Jan 2004 B2
6683318 Haberer et al. Jan 2004 B1
6683426 Kleeven Jan 2004 B1
6693283 Eickhoff et al. Feb 2004 B2
6710362 Kraft et al. Mar 2004 B2
6713773 Lyons et al. Mar 2004 B1
6713976 Zumoto et al. Mar 2004 B1
6717162 Jongen Apr 2004 B1
6736831 Hartmann et al. May 2004 B1
6745072 Badura et al. Jun 2004 B1
6769806 Moyers Aug 2004 B2
6774383 Norimine et al. Aug 2004 B2
6777689 Nelson Aug 2004 B2
6777700 Yanagisawa et al. Aug 2004 B2
6780149 Schulte Aug 2004 B1
6799068 Hartmann et al. Sep 2004 B1
6800866 Amemiya et al. Oct 2004 B2
6803591 Muramatsu et al. Oct 2004 B2
6814694 Pedroni Nov 2004 B1
6822244 Beloussov et al. Nov 2004 B2
6853142 Chistyakov Feb 2005 B2
6853703 Svatos et al. Feb 2005 B2
6864770 Nemoto et al. Mar 2005 B2
6865254 Nafstadius Mar 2005 B2
6873123 Marchand et al. Mar 2005 B2
6891177 Kraft et al. May 2005 B1
6891924 Yoda et al. May 2005 B1
6894300 Reimoser et al. May 2005 B2
6897451 Kaercher et al. May 2005 B2
6914396 Symons et al. Jul 2005 B1
6936832 Norimine et al. Aug 2005 B2
6953943 Yanagisawa et al. Oct 2005 B2
6965116 Wagner et al. Nov 2005 B1
6969194 Nafstadius Nov 2005 B1
6979832 Yanagisawa et al. Dec 2005 B2
6984835 Harada Jan 2006 B2
6992312 Yanagisawa et al. Jan 2006 B2
6993112 Hesse Jan 2006 B2
7008105 Amann et al. Mar 2006 B2
7011447 Moyers Mar 2006 B2
7012267 Moriyama et al. Mar 2006 B2
7014361 Ein-Gal Mar 2006 B1
7026636 Yanagisawa et al. Apr 2006 B2
7038403 Mastrangeli et al. May 2006 B2
7041479 Swartz et al. May 2006 B2
7045781 Adamec et al. May 2006 B2
7049613 Yanagisawa et al. May 2006 B2
7053389 Yanagisawa et al. May 2006 B2
7054801 Sakamoto et al. May 2006 B2
7060997 Norimine et al. Jun 2006 B2
7071479 Yanagisawa et al. Jul 2006 B2
7073508 Moyers Jul 2006 B2
7081619 Bashkirov et al. Jul 2006 B2
7084410 Beloussov et al. Aug 2006 B2
7091478 Haberer Aug 2006 B2
7102144 Matsuda et al. Sep 2006 B2
7122811 Matsuda et al. Oct 2006 B2
7122966 Norling et al. Oct 2006 B2
7122978 Nakanishi et al. Oct 2006 B2
7135678 Wang et al. Nov 2006 B2
7138771 Bechthold et al. Nov 2006 B2
7154107 Yanagisawa et al. Dec 2006 B2
7154108 Tadokoro et al. Dec 2006 B2
7154991 Earnst et al. Dec 2006 B2
7162005 Bjorkholm Jan 2007 B2
7173264 Moriyama et al. Feb 2007 B2
7173265 Miller et al. Feb 2007 B2
7173385 Caporasco et al. Feb 2007 B2
7186991 Kato et al. Mar 2007 B2
7193227 Hiramoto et al. Mar 2007 B2
7199382 Rigney et al. Apr 2007 B2
7208748 Sliski et al. Apr 2007 B2
7212608 Nagamine et al. May 2007 B2
7212609 Nagamine et al. May 2007 B2
7221733 Takai et al. May 2007 B1
7227161 Matsuda et al. Jun 2007 B2
7247869 Tadokoro et al. Jul 2007 B2
7257191 Sommer Aug 2007 B2
7259529 Tanaka Aug 2007 B2
7262424 Moriyama et al. Aug 2007 B2
7262565 Fujisawa Aug 2007 B2
7268358 Ma et al. Sep 2007 B2
7274018 Adamec et al. Sep 2007 B2
7280633 Cheng et al. Oct 2007 B2
7295649 Johnsen Nov 2007 B2
7297967 Yanagisawa Nov 2007 B2
7301162 Matsuda et al. Nov 2007 B2
7307264 Brusasco et al. Dec 2007 B2
7318805 Schweikard et al. Jan 2008 B2
7319231 Moriyama et al. Jan 2008 B2
7319336 Bauer et al. Jan 2008 B2
7331713 Moyers Feb 2008 B2
7332880 Ina et al. Feb 2008 B2
7345291 Kats Mar 2008 B2
7345292 Moriyama et al. Mar 2008 B2
7348557 Armit Mar 2008 B2
7348579 Pedroni Mar 2008 B2
7351988 Naumann et al. Apr 2008 B2
7355189 Yanagisawa et al. Apr 2008 B2
7368740 Beloussov et al. May 2008 B2
7372053 Yamashita et al. May 2008 B2
7378672 Harada May 2008 B2
7381979 Yamashita et al. Jun 2008 B2
7397054 Natori et al. Jul 2008 B2
7397901 Johnsen Jul 2008 B1
7398309 Baumann et al. Jul 2008 B2
7402822 Guertin et al. Jul 2008 B2
7402823 Guertin et al. Jul 2008 B2
7402824 Guertin et al. Jul 2008 B2
7402963 Sliski Jul 2008 B2
7405407 Hiramoto et al. Jul 2008 B2
7425717 Matsuda et al. Sep 2008 B2
7432516 Peggs et al. Oct 2008 B2
7439528 Nishiuchi et al. Oct 2008 B2
7446328 Rigney et al. Nov 2008 B2
7446490 Jongen et al. Nov 2008 B2
7449701 Fujimaki et al. Nov 2008 B2
7453076 Welch et al. Nov 2008 B2
7465944 Ueno et al. Dec 2008 B2
7466085 Nutt Dec 2008 B2
7468506 Rogers et al. Dec 2008 B2
7469035 Keall et al. Dec 2008 B2
7473913 Hermann et al. Jan 2009 B2
7476867 Fritsch et al. Jan 2009 B2
7476883 Nutt Jan 2009 B2
7482606 Groezinger et al. Jan 2009 B2
7492556 Atkins et al. Feb 2009 B2
7507975 Mohr Mar 2009 B2
7525104 Harada Apr 2009 B2
7541905 Antaya Jun 2009 B2
7547901 Guertin et al. Jun 2009 B2
7554096 Ward et al. Jun 2009 B2
7554097 Ward et al. Jun 2009 B2
7554275 Amaldi Jun 2009 B2
7555103 Johnsen Jun 2009 B2
7557358 Ward et al. Jul 2009 B2
7557359 Ward et al. Jul 2009 B2
7557360 Ward et al. Jul 2009 B2
7557361 Ward et al. Jul 2009 B2
7560698 Rietzel Jul 2009 B2
7560712 Kim et al. Jul 2009 B2
7560715 Pedroni Jul 2009 B2
7560717 Matsuda et al. Jul 2009 B2
7567694 Lu et al. Jul 2009 B2
7574251 Lu et al. Aug 2009 B2
7576499 Caporaso et al. Aug 2009 B2
7579603 Birgy et al. Aug 2009 B2
7579610 Grozinger et al. Aug 2009 B2
7582866 Furuhashi et al. Sep 2009 B2
7582885 Katagiri et al. Sep 2009 B2
7582886 Trbojevic Sep 2009 B2
7586112 Chiba et al. Sep 2009 B2
7598497 Yamamoto et al. Oct 2009 B2
7609009 Tanaka et al. Oct 2009 B2
7609809 Kapatoes et al. Oct 2009 B2
7609811 Siljamaki et al. Oct 2009 B1
7615942 Sanders et al. Nov 2009 B2
7626347 Sliski Dec 2009 B2
7629598 Harada Dec 2009 B2
7639853 Olivera et al. Dec 2009 B2
7639854 Schnarr et al. Dec 2009 B2
7643661 Ruchala et al. Jan 2010 B2
7656258 Antaya et al. Feb 2010 B1
7659521 Pedroni Feb 2010 B2
7659528 Uematsu Feb 2010 B2
7668291 Nord et al. Feb 2010 B2
7672429 Urano et al. Mar 2010 B2
7679049 Rietzel Mar 2010 B2
7679073 Urano et al. Mar 2010 B2
7682078 Rietzel Mar 2010 B2
7692166 Muraki et al. Apr 2010 B2
7692168 Moriyama et al. Apr 2010 B2
7696499 Miller et al. Apr 2010 B2
7696847 Antaya Apr 2010 B2
7701677 Schultz et al. Apr 2010 B2
7709818 Matsuda et al. May 2010 B2
7710051 Caporaso et al. May 2010 B2
7718982 Sliski May 2010 B2
7728311 Gall Jun 2010 B2
7746978 Cheng et al. Jun 2010 B2
7755068 Ma et al. Jul 2010 B2
7755305 Umezawa et al. Jul 2010 B2
7759642 Nir Jul 2010 B2
7763867 Birgy et al. Jul 2010 B2
7767988 Kaiser et al. Aug 2010 B2
7770231 Prater et al. Aug 2010 B2
7772577 Saito et al. Aug 2010 B2
7773723 Nord et al. Aug 2010 B2
7773788 Lu et al. Aug 2010 B2
7778488 Nord et al. Aug 2010 B2
7783010 Clayton Aug 2010 B2
7784124 Long et al. Aug 2010 B2
7784127 Kuro et al. Aug 2010 B2
7786433 Gunzert-Marx et al. Aug 2010 B2
7786451 Ward et al. Aug 2010 B2
7786452 Ward et al. Aug 2010 B2
7789560 Moyers Sep 2010 B2
7791051 Beloussov et al. Sep 2010 B2
7796731 Nord et al. Sep 2010 B2
7801269 Cravens et al. Sep 2010 B2
7801270 Nord et al. Sep 2010 B2
7801988 Baumann et al. Sep 2010 B2
7807982 Nishiuchi et al. Oct 2010 B2
7809107 Nord et al. Oct 2010 B2
7812319 Diehl et al. Oct 2010 B2
7812326 Grozinger et al. Oct 2010 B2
7816657 Hansmann et al. Oct 2010 B2
7817778 Nord et al. Oct 2010 B2
7817836 Chao et al. Oct 2010 B2
7818045 Rietzel Oct 2010 B2
7834334 Grozinger et al. Nov 2010 B2
7834336 Boeh et al. Nov 2010 B2
7835494 Nord et al. Nov 2010 B2
7835502 Spence et al. Nov 2010 B2
7839972 Ruchala et al. Nov 2010 B2
7839973 Nord et al. Nov 2010 B2
7842606 Lee et al. Nov 2010 B2
7848488 Mansfield Dec 2010 B2
7857756 Warren et al. Dec 2010 B2
7860216 Jongen et al. Dec 2010 B2
7860550 Saracen et al. Dec 2010 B2
7868301 Diehl Jan 2011 B2
7875846 Gunzert-Marx et al. Jan 2011 B2
7875861 Huttenberger et al. Jan 2011 B2
7875868 Moriyama et al. Jan 2011 B2
7881431 Aoi et al. Feb 2011 B2
7894574 Nord et al. Feb 2011 B1
7903781 Foland et al. Mar 2011 B2
7906769 Blasche et al. Mar 2011 B2
7914734 Livingston Mar 2011 B2
7919765 Timmer Apr 2011 B2
7920040 Antaya et al. Apr 2011 B2
7920675 Lomax et al. Apr 2011 B2
7928415 Bert et al. Apr 2011 B2
7934869 Ivanov et al. May 2011 B2
7940881 Jongen et al. May 2011 B2
7943913 Balakin May 2011 B2
7947969 Pu May 2011 B2
7949096 Cheng et al. May 2011 B2
7950587 Henson et al. May 2011 B2
7953205 Balakin May 2011 B2
7960710 Kruip et al. Jun 2011 B2
7961844 Takeda et al. Jun 2011 B2
7977648 Westerly et al. Jul 2011 B2
7977656 Fujimaki et al. Jul 2011 B2
7982198 Nishiuchi et al. Jul 2011 B2
7982416 Tanaka et al. Jul 2011 B2
7984715 Moyers Jul 2011 B2
7986768 Nord et al. Jul 2011 B2
7987053 Schaffner Jul 2011 B2
7989785 Emhofer et al. Aug 2011 B2
7990524 Jureller et al. Aug 2011 B2
7997553 Sloan et al. Aug 2011 B2
8002466 Von Neubeck et al. Aug 2011 B2
8003964 Stark et al. Aug 2011 B2
8009803 Nord et al. Aug 2011 B2
8009804 Siljamaki et al. Aug 2011 B2
8016336 Messinger et al. Sep 2011 B2
8039822 Rietzel Oct 2011 B2
8041006 Boyden et al. Oct 2011 B2
8044364 Yamamoto Oct 2011 B2
8049187 Tachikawa Nov 2011 B2
8053508 Korkut et al. Nov 2011 B2
8053739 Rietzel Nov 2011 B2
8053745 Moore Nov 2011 B2
8053746 Timmer et al. Nov 2011 B2
8063381 Tsoupas et al. Nov 2011 B2
8067748 Balakin Nov 2011 B2
8069675 Radovinsky et al. Dec 2011 B2
8071966 Kaiser et al. Dec 2011 B2
8080801 Safai Dec 2011 B2
8085899 Nord et al. Dec 2011 B2
8089054 Balakin Jan 2012 B2
8093564 Balakin Jan 2012 B2
8093568 Mackie et al. Jan 2012 B2
8111125 Antaya et al. Feb 2012 B2
8129694 Balakin Mar 2012 B2
8129699 Balakin Mar 2012 B2
8144832 Balakin Mar 2012 B2
8153989 Tachikawa et al. Apr 2012 B2
8173981 Trbojevic May 2012 B2
8183541 Wilkens et al. May 2012 B2
8188688 Balakin May 2012 B2
8189889 Pearlstein et al. May 2012 B2
8198607 Balakin Jun 2012 B2
8207656 Baumgartner et al. Jun 2012 B2
8222613 Tajiri et al. Jul 2012 B2
8227768 Smick et al. Jul 2012 B2
8232536 Harada Jul 2012 B2
8253121 Gnutzmann et al. Aug 2012 B2
8283645 Guneysel Oct 2012 B2
8288742 Balakin Oct 2012 B2
8291717 Radovinsky et al. Oct 2012 B2
8294127 Tachibana Oct 2012 B2
8304725 Komuro et al. Nov 2012 B2
8304750 Preikszas et al. Nov 2012 B2
8309941 Balakin Nov 2012 B2
8330132 Guertin et al. Dec 2012 B2
8334520 Otaka et al. Dec 2012 B2
8335397 Takane et al. Dec 2012 B2
8344340 Gall Jan 2013 B2
8350214 Otaki et al. Jan 2013 B2
8354656 Beloussov et al. Jan 2013 B2
8368038 Balakin Feb 2013 B2
8368043 Havelange et al. Feb 2013 B2
8373143 Balakin Feb 2013 B2
8373145 Balakin Feb 2013 B2
8373146 Balakin Feb 2013 B2
8374314 Balakin Feb 2013 B2
8378299 Frosien Feb 2013 B2
8378311 Balakin Feb 2013 B2
8378312 Gordon et al. Feb 2013 B1
8378321 Balakin Feb 2013 B2
8382943 Clark Feb 2013 B2
8389949 Harada et al. Mar 2013 B2
8399866 Balakin Mar 2013 B2
8405042 Honda et al. Mar 2013 B2
8405056 Amaldi et al. Mar 2013 B2
8415643 Balakin Apr 2013 B2
8416918 Nord et al. Apr 2013 B2
8421041 Balakin Apr 2013 B2
8426833 Trbojevic Apr 2013 B2
8436323 Iseki et al. May 2013 B2
8436325 Noda et al. May 2013 B2
8436327 Balakin May 2013 B2
8440987 Stephani et al. May 2013 B2
8445872 Behrens et al. May 2013 B2
8459714 Pomper et al. Jun 2013 B2
8461559 Lomax Jun 2013 B2
8462912 O'Connor et al. Jun 2013 B2
8466441 Iwata et al. Jun 2013 B2
8472583 Star-Lack et al. Jun 2013 B2
8481951 Jongen et al. Jul 2013 B2
8483357 Siljamaki et al. Jul 2013 B2
8487278 Balakin Jul 2013 B2
8519365 Balakin Aug 2013 B2
8525419 Smith et al. Sep 2013 B2
8525447 Antaya Sep 2013 B2
8525448 Tanaka et al. Sep 2013 B2
8546769 Uno Oct 2013 B2
8552406 Phaneuf et al. Oct 2013 B2
8552408 Hanawa et al. Oct 2013 B2
8558461 Poehlmann-Martins et al. Oct 2013 B2
8558485 Antaya Oct 2013 B2
8569717 Balakin Oct 2013 B2
8575563 Cameron et al. Nov 2013 B2
8575579 Moskvin et al. Nov 2013 B2
8581215 Balakin Nov 2013 B2
8581218 Fujimoto et al. Nov 2013 B2
8581523 Gall et al. Nov 2013 B2
8581525 Antaya et al. Nov 2013 B2
8598543 Balakin Dec 2013 B2
8601116 Baumann et al. Dec 2013 B2
8613694 Walsh Dec 2013 B2
8614554 Balakin Dec 2013 B2
8614612 Antaya et al. Dec 2013 B2
8618519 Ueda Dec 2013 B2
8619242 Suzuki Dec 2013 B2
8624528 Balakin Jan 2014 B2
8627822 Balakin Jan 2014 B2
8632448 Schulte et al. Jan 2014 B1
8637818 Balakin Jan 2014 B2
8637839 Brauer Jan 2014 B2
8642978 Balakin Feb 2014 B2
8643314 Touchi Feb 2014 B2
8644571 Schulte et al. Feb 2014 B1
8653314 Pelati et al. Feb 2014 B2
8653473 Yajima Feb 2014 B2
8657354 Pomper et al. Feb 2014 B2
8657743 Rietzel et al. Feb 2014 B2
8688197 Balakin Apr 2014 B2
8702578 Fahrig et al. Apr 2014 B2
8710462 Balakin Apr 2014 B2
8716663 Brusasco et al. May 2014 B2
8718231 Balakin May 2014 B2
8748852 Jongen Jun 2014 B2
8750453 Cheng et al. Jun 2014 B2
8766217 Balakin Jul 2014 B2
8766218 Jongen Jul 2014 B2
8791435 Balakin Jul 2014 B2
8791656 Zwart et al. Jul 2014 B1
8796648 Fujimoto et al. Aug 2014 B2
8835885 Ogasawara Sep 2014 B2
8847179 Fujitaka et al. Sep 2014 B2
8859264 Bert et al. Oct 2014 B2
8866109 Sasai Oct 2014 B2
8896239 Balakin Nov 2014 B2
8897857 Tome et al. Nov 2014 B2
8901509 Balakin Dec 2014 B2
8901520 Tachibana et al. Dec 2014 B2
8907309 Spotts Dec 2014 B2
8907311 Gall et al. Dec 2014 B2
8907594 Begg et al. Dec 2014 B2
8916838 Claereboudt et al. Dec 2014 B2
8916841 Totake et al. Dec 2014 B2
8916843 Gall et al. Dec 2014 B2
8927946 Behrens et al. Jan 2015 B2
8927950 Gall et al. Jan 2015 B2
8933650 O'Neal, III et al. Jan 2015 B2
8941084 Balakin Jan 2015 B2
8941086 Yajima Jan 2015 B2
8947021 Tsutsui Feb 2015 B2
8948341 Beckman Feb 2015 B2
8952343 Stephani et al. Feb 2015 B2
8952634 Sliski et al. Feb 2015 B2
8957396 Balakin Feb 2015 B2
8963112 Balakin Feb 2015 B1
8969834 Balakin Mar 2015 B2
8970137 Gall et al. Mar 2015 B2
8971363 Levecq et al. Mar 2015 B2
8975600 Balakin Mar 2015 B2
8975602 Huber et al. Mar 2015 B2
8975836 Bromberg et al. Mar 2015 B2
8986186 Zhang et al. Mar 2015 B2
8993522 Vidyasagar et al. Mar 2015 B2
9006693 Sasai Apr 2015 B2
9007740 Touchi Apr 2015 B2
9012832 Bert et al. Apr 2015 B2
9012866 Benna et al. Apr 2015 B2
9012873 Fujimoto et al. Apr 2015 B2
9018601 Balakin Apr 2015 B2
9024256 Ruan et al. May 2015 B2
9029760 Beddar et al. May 2015 B2
9044600 Balakin Jun 2015 B2
9056199 Balakin Jun 2015 B2
9058910 Balakin Jun 2015 B2
9060998 Stockfleth Jun 2015 B2
9061143 Sasai et al. Jun 2015 B2
9084887 Schulte et al. Jul 2015 B2
9093209 Jongen Jul 2015 B2
9095040 Balakin Jul 2015 B2
9108050 Bula et al. Aug 2015 B2
9142385 Iwanaga Sep 2015 B1
9155186 Zwart et al. Oct 2015 B2
9155908 Meltsner et al. Oct 2015 B2
9185789 Zwart et al. Nov 2015 B2
9186525 Prieels et al. Nov 2015 B2
9188685 Takayanagi et al. Nov 2015 B2
9196082 Pearlstein et al. Nov 2015 B2
9220920 Schulte et al. Dec 2015 B2
9220923 Yajima et al. Dec 2015 B2
9237640 Abs et al. Jan 2016 B2
9237642 Kleeven Jan 2016 B2
9245336 Mallya et al. Jan 2016 B2
9254396 Mihaylov Feb 2016 B2
9259155 Bharat et al. Feb 2016 B2
9271385 Verbruggen et al. Feb 2016 B2
9283406 Prieels Mar 2016 B2
9283407 Benna et al. Mar 2016 B2
9289140 Ross et al. Mar 2016 B2
9289624 Jongen Mar 2016 B2
9297912 Campbell et al. Mar 2016 B2
9301384 Zwart et al. Mar 2016 B2
9302121 Totake et al. Apr 2016 B2
9305742 Aptaker et al. Apr 2016 B2
9355784 Abs May 2016 B2
9364688 Pausch et al. Jun 2016 B2
9370089 Ungaro et al. Jun 2016 B2
9381379 Beckman Jul 2016 B2
9393443 Fujimoto et al. Jul 2016 B2
9417302 Kuhn Aug 2016 B2
9451688 Jongen Sep 2016 B2
9451689 Tsutsui Sep 2016 B2
9452300 Anferov Sep 2016 B2
9452301 Gall et al. Sep 2016 B2
9468608 Lin et al. Oct 2016 B2
9492684 Takayanagi et al. Nov 2016 B2
9661736 O'Neal, III et al. May 2017 B2
20020058007 Scheinberg et al. May 2002 A1
20020172317 Maksimchuk et al. Nov 2002 A1
20030048080 Amemiya et al. Mar 2003 A1
20030125622 Schweikard et al. Jul 2003 A1
20030136924 Kraft et al. Jul 2003 A1
20030152197 Moyers Aug 2003 A1
20030163015 Yanagisawa et al. Aug 2003 A1
20030183779 Norimine et al. Oct 2003 A1
20030234369 Glukhoy Dec 2003 A1
20040000650 Yanagisawa et al. Jan 2004 A1
20040017888 Seppi et al. Jan 2004 A1
20040056212 Yanagisawa et al. Mar 2004 A1
20040061077 Muramatsu et al. Apr 2004 A1
20040061078 Muramatsu et al. Apr 2004 A1
20040085023 Chistyakov May 2004 A1
20040098445 Baumann et al. May 2004 A1
20040104354 Haberer et al. Jun 2004 A1
20040111134 Muramatsu et al. Jun 2004 A1
20040118081 Reimoser et al. Jun 2004 A1
20040149934 Yanagisawa et al. Aug 2004 A1
20040155206 Marchand et al. Aug 2004 A1
20040159795 Kaercher et al. Aug 2004 A1
20040164254 Beloussov et al. Aug 2004 A1
20040173763 Moriyama et al. Sep 2004 A1
20040174958 Moriyama et al. Sep 2004 A1
20040183033 Moriyama et al. Sep 2004 A1
20040183035 Yanagisawa et al. Sep 2004 A1
20040200982 Moriyama et al. Oct 2004 A1
20040200983 Fujimaki et al. Oct 2004 A1
20040213381 Harada Oct 2004 A1
20040227104 Matsuda et al. Nov 2004 A1
20040232356 Norimine et al. Nov 2004 A1
20040240626 Moyers Dec 2004 A1
20050029472 Ueno et al. Feb 2005 A1
20050051740 Yanagisawa et al. Mar 2005 A1
20050058245 Ein-Gal Mar 2005 A1
20050072940 Beloussov et al. Apr 2005 A1
20050079235 Stockfleth Apr 2005 A1
20050087700 Tadokoro et al. Apr 2005 A1
20050089141 Brown Apr 2005 A1
20050099145 Nishiuchi et al. May 2005 A1
20050113327 Roiz et al. May 2005 A1
20050127306 Yanagisawa et al. Jun 2005 A1
20050139787 Chiba et al. Jun 2005 A1
20050161618 Pedroni Jul 2005 A1
20050167616 Yanagisawa et al. Aug 2005 A1
20050184686 Caporasco et al. Aug 2005 A1
20050186179 Harats et al. Aug 2005 A1
20050205806 Tadokoro et al. Sep 2005 A1
20050228255 Saracen et al. Oct 2005 A1
20050234327 Saracen et al. Oct 2005 A1
20050247890 Norimine et al. Nov 2005 A1
20050259779 Abraham-Fuchs et al. Nov 2005 A1
20060017015 Sliski et al. Jan 2006 A1
20060067468 Rietzel Mar 2006 A1
20060126792 Li Jun 2006 A1
20060127879 Fuccione Jun 2006 A1
20060145088 Ma Jul 2006 A1
20060175991 Fujisawa Aug 2006 A1
20060192146 Yanagisawa et al. Aug 2006 A1
20060203967 Nilsson Sep 2006 A1
20060204478 Harats et al. Sep 2006 A1
20060219948 Ueno et al. Oct 2006 A1
20060284562 Hruby et al. Dec 2006 A1
20070001128 Sliski et al. Jan 2007 A1
20070013273 Albert et al. Jan 2007 A1
20070014654 Haverfield et al. Jan 2007 A1
20070018120 Beloussov et al. Jan 2007 A1
20070023699 Yamashita et al. Feb 2007 A1
20070029510 Hermann et al. Feb 2007 A1
20070031337 Schulte Feb 2007 A1
20070034812 Ma et al. Feb 2007 A1
20070051904 Kaiser et al. Mar 2007 A1
20070053484 Chiba et al. Mar 2007 A1
20070059387 Stockfleth Mar 2007 A1
20070075273 Birgy et al. Apr 2007 A1
20070083101 Rietzel Apr 2007 A1
20070092812 Caporasco et al. Apr 2007 A1
20070108922 Amaldi May 2007 A1
20070114464 Birgy et al. May 2007 A1
20070114471 Birgy et al. May 2007 A1
20070114945 Mattaboni et al. May 2007 A1
20070145916 Caporasco et al. Jun 2007 A1
20070171015 Antaya Jul 2007 A1
20070181519 Khoshnevis Aug 2007 A1
20070217575 Kaiser et al. Sep 2007 A1
20070262269 Trbojevic Nov 2007 A1
20070284548 Kaiser et al. Dec 2007 A1
20080023644 Pedroni Jan 2008 A1
20080029706 Kaiser et al. Feb 2008 A1
20080031414 Coppens Feb 2008 A1
20080061241 Rietzel Mar 2008 A1
20080078942 Rietzel Apr 2008 A1
20080093567 Gall Apr 2008 A1
20080131419 Roiz et al. Jun 2008 A1
20080179544 Kaiser et al. Jul 2008 A1
20080191142 Pedroni Aug 2008 A1
20080191152 Grozinger et al. Aug 2008 A1
20080218102 Sliski Sep 2008 A1
20080219407 Kaiser et al. Sep 2008 A1
20080219410 Gunzert-Marx et al. Sep 2008 A1
20080219411 Gunzert-Marx et al. Sep 2008 A1
20080237494 Beloussov et al. Oct 2008 A1
20080237495 Grozinger et al. Oct 2008 A1
20080267349 Rietzel Oct 2008 A1
20080270517 Baumann et al. Oct 2008 A1
20080272284 Rietzel Nov 2008 A1
20080290299 Hansmann et al. Nov 2008 A1
20080301872 Fahrig et al. Dec 2008 A1
20080315111 Sommer Dec 2008 A1
20090032742 Kaiser et al. Feb 2009 A1
20090050819 Ma et al. Feb 2009 A1
20090060130 Wilkens et al. Mar 2009 A1
20090065717 Kaiser et al. Mar 2009 A1
20090069640 Rietzel et al. Mar 2009 A1
20090077209 Schneider Mar 2009 A1
20090096179 Stark et al. Apr 2009 A1
20090098145 Mata et al. Apr 2009 A1
20090101833 Emhofer et al. Apr 2009 A1
20090114847 Grozinger et al. May 2009 A1
20090140671 O'Neal et al. Jun 2009 A1
20090140672 Gall et al. Jun 2009 A1
20090175414 Messinger et al. Jul 2009 A1
20090200483 Gall et al. Aug 2009 A1
20090230327 Rietzel Sep 2009 A1
20090234237 Ross et al. Sep 2009 A1
20090236545 Timmer Sep 2009 A1
20090261275 Rietzel Oct 2009 A1
20090274269 Foland et al. Nov 2009 A1
20090296885 Boeh et al. Dec 2009 A1
20090309046 Balakin Dec 2009 A1
20090309047 Gunzert-Marx et al. Dec 2009 A1
20090309520 Balakin Dec 2009 A1
20090314960 Balakin Dec 2009 A1
20090314961 Balakin Dec 2009 A1
20090321656 Rietzel et al. Dec 2009 A1
20090321665 Timmer et al. Dec 2009 A1
20100006106 Balakin Jan 2010 A1
20100006770 Balakin Jan 2010 A1
20100008466 Balakin Jan 2010 A1
20100014639 Balakin Jan 2010 A1
20100014640 Balakin Jan 2010 A1
20100027745 Balakin Feb 2010 A1
20100038552 Trbojevic Feb 2010 A1
20100045213 Sliski et al. Feb 2010 A1
20100046697 Balakin Feb 2010 A1
20100060209 Balakin Mar 2010 A1
20100090122 Balakin Apr 2010 A1
20100091948 Balakin Apr 2010 A1
20100126964 Smith et al. May 2010 A1
20100127184 Balakin May 2010 A1
20100128846 Balakin May 2010 A1
20100133444 Balakin Jun 2010 A1
20100133446 Balakin Jun 2010 A1
20100141183 Balakin Jun 2010 A1
20100171045 Guneysel Jul 2010 A1
20100171447 Balakin Jul 2010 A1
20100207552 Balakin Aug 2010 A1
20100230617 Gall Sep 2010 A1
20100230620 Tsoupas et al. Sep 2010 A1
20100264327 Bonig et al. Oct 2010 A1
20100266100 Balakin Oct 2010 A1
20100288945 Gnutzmann et al. Nov 2010 A1
20100296534 Levecq et al. Nov 2010 A1
20100308235 Sliski Dec 2010 A1
20100320404 Tanke Dec 2010 A1
20100327187 Beloussov et al. Dec 2010 A1
20110006214 Bonig Jan 2011 A1
20110009736 Maltz et al. Jan 2011 A1
20110011729 Poehlmann-Martins et al. Jan 2011 A1
20110027853 Bert et al. Feb 2011 A1
20110047469 Baumann et al. Feb 2011 A1
20110051891 O'Connor et al. Mar 2011 A1
20110101236 Cameron et al. May 2011 A1
20110108737 Pu May 2011 A1
20110118529 Balakin May 2011 A1
20110118531 Balakin May 2011 A1
20110124976 Sabczynski et al. May 2011 A1
20110127443 Comer et al. Jun 2011 A1
20110147608 Balakin Jun 2011 A1
20110150180 Balakin Jun 2011 A1
20110166219 Stockfleth Jul 2011 A1
20110180720 Balakin Jul 2011 A1
20110180731 Welsh Jul 2011 A1
20110182410 Balakin Jul 2011 A1
20110186720 Jongen et al. Aug 2011 A1
20110196223 Balakin Aug 2011 A1
20110214588 Grubling et al. Sep 2011 A1
20110218430 Balakin Sep 2011 A1
20110220794 Censor et al. Sep 2011 A1
20110220798 Baurichter et al. Sep 2011 A1
20110233423 Balakin Sep 2011 A1
20110238440 Leuschner Sep 2011 A1
20110248188 Brusasco et al. Oct 2011 A1
20110266981 Umezawa et al. Nov 2011 A1
20110278477 Balakin Nov 2011 A1
20110284757 Butuceanu et al. Nov 2011 A1
20110284760 Balakin Nov 2011 A1
20110285327 Begg et al. Nov 2011 A1
20110297850 Claereboudt et al. Dec 2011 A1
20110299657 Havelange et al. Dec 2011 A1
20110299919 Stark Dec 2011 A1
20110306870 Kuhn Dec 2011 A1
20110313232 Balakin Dec 2011 A1
20120001085 Fujimoto et al. Jan 2012 A1
20120056098 Harada Mar 2012 A1
20120056099 Behrens et al. Mar 2012 A1
20120056109 Lomax Mar 2012 A1
20120061582 Iwata Mar 2012 A1
20120069961 Pomper et al. Mar 2012 A1
20120077748 Vidyasagar et al. Mar 2012 A1
20120112092 Pomper et al. May 2012 A1
20120119114 Brauer May 2012 A1
20120119115 Iwata May 2012 A1
20120136194 Zhang et al. May 2012 A1
20120143051 Balakin Jun 2012 A1
20120160996 Jongen Jun 2012 A1
20120199757 Pu Aug 2012 A1
20120205551 Balakin Aug 2012 A1
20120207276 Pomper et al. Aug 2012 A1
20120209109 Balakin Aug 2012 A1
20120223246 Stephani et al. Sep 2012 A1
20120223247 Honda Sep 2012 A1
20120224667 Cheng et al. Sep 2012 A1
20120242257 Balakin Sep 2012 A1
20120248325 Balakin Oct 2012 A1
20120264998 Fujitaka et al. Oct 2012 A1
20120267543 Noda et al. Oct 2012 A1
20120273666 Bert et al. Nov 2012 A1
20120280150 Jongen Nov 2012 A1
20120303384 Stepaniak et al. Nov 2012 A1
20120313003 Trbojevic Dec 2012 A1
20120326722 Weinberg et al. Dec 2012 A1
20130001432 Jongen Jan 2013 A1
20130043403 Gordon et al. Feb 2013 A1
20130053616 Gall Feb 2013 A1
20130068938 Heese Mar 2013 A1
20130072743 Fieres et al. Mar 2013 A1
20130072744 Moskvin et al. Mar 2013 A1
20130086500 Kane et al. Apr 2013 A1
20130090549 Meltsner et al. Apr 2013 A1
20130108014 Tome et al. May 2013 A1
20130127375 Sliski May 2013 A1
20130131424 Sliski May 2013 A1
20130131433 Katscher et al. May 2013 A1
20130150647 Chen et al. Jun 2013 A1
20130187060 Jongen Jul 2013 A1
20130193353 Ikeda et al. Aug 2013 A1
20130208867 Beckman Aug 2013 A1
20130209450 Cohen et al. Aug 2013 A1
20130211482 Piipponen Aug 2013 A1
20130217946 Balakin Aug 2013 A1
20130217948 Mihaylov Aug 2013 A1
20130217950 Partanen et al. Aug 2013 A1
20130218009 Balakin Aug 2013 A1
20130221213 Takayanagi et al. Aug 2013 A1
20130237425 Leigh et al. Sep 2013 A1
20130237822 Gross et al. Sep 2013 A1
20130243722 Basile et al. Sep 2013 A1
20130245113 Stockfleth Sep 2013 A1
20130259335 Mallya et al. Oct 2013 A1
20130267756 Totake et al. Oct 2013 A1
20130277569 Behrens et al. Oct 2013 A1
20130303824 Stephani et al. Nov 2013 A1
20130324479 Zhang et al. Dec 2013 A1
20130345489 Beloussov et al. Dec 2013 A1
20140005463 Jongen Jan 2014 A1
20140005464 Bharat et al. Jan 2014 A1
20140021375 Nishiuchi et al. Jan 2014 A1
20140028220 Bromberg et al. Jan 2014 A1
20140042934 Tsutsui Feb 2014 A1
20140046113 Fujimoto et al. Feb 2014 A1
20140061493 Prieels et al. Mar 2014 A1
20140066755 Matteo et al. Mar 2014 A1
20140077699 Boswell et al. Mar 2014 A1
20140091734 Gall et al. Apr 2014 A1
20140094371 Zwart et al. Apr 2014 A1
20140094637 Zwart et al. Apr 2014 A1
20140094638 Gall et al. Apr 2014 A1
20140094639 Zwart et al. Apr 2014 A1
20140094640 Gall et al. Apr 2014 A1
20140094641 Gall et al. Apr 2014 A1
20140094643 Gall et al. Apr 2014 A1
20140097920 Goldie et al. Apr 2014 A1
20140107390 Brown et al. Apr 2014 A1
20140113388 Bitter et al. Apr 2014 A1
20140121441 Huber et al. May 2014 A1
20140128719 Longfield May 2014 A1
20140145090 Jongen May 2014 A9
20140193058 Bharat et al. Jul 2014 A1
20140200448 Schulte et al. Jul 2014 A1
20140221816 Franke et al. Aug 2014 A1
20140252227 Sasai et al. Sep 2014 A1
20140257011 Spotts Sep 2014 A1
20140257099 Balakin Sep 2014 A1
20140275699 Benna et al. Sep 2014 A1
20140308202 Matusik et al. Oct 2014 A1
20140316184 Fujimoto et al. Oct 2014 A1
20140330063 Balakin Nov 2014 A1
20140332691 Campbell et al. Nov 2014 A1
20140336438 Bharat et al. Nov 2014 A1
20140350322 Schulte et al. Nov 2014 A1
20140369958 Basile Dec 2014 A1
20140371076 Jongen Dec 2014 A1
20140371511 Zwart et al. Dec 2014 A1
20150015167 Ungaro et al. Jan 2015 A1
20150030223 Pearlstein et al. Jan 2015 A1
20150041665 Hollebeek et al. Feb 2015 A1
20150060703 Ogasawara et al. Mar 2015 A1
20150076370 Totake et al. Mar 2015 A1
20150080633 Anferov Mar 2015 A1
20150080634 Huber et al. Mar 2015 A1
20150087883 Boudreau et al. Mar 2015 A1
20150087885 Boisseau et al. Mar 2015 A1
20150087960 Treffert Mar 2015 A1
20150090894 Zwart et al. Apr 2015 A1
20150099917 Bula et al. Apr 2015 A1
20150126797 Aptaker et al. May 2015 A1
20150146856 Beckman May 2015 A1
20150174429 Zwart et al. Jun 2015 A1
20150196534 Vidyasagar et al. Jul 2015 A1
20150196779 Tonner Jul 2015 A1
20150209601 Benna et al. Jul 2015 A1
20150217138 Fujimoto et al. Aug 2015 A1
20150217139 Bert et al. Aug 2015 A1
20150217140 Balakin Aug 2015 A1
20150231411 O'Neal, III et al. Aug 2015 A1
20150321025 Freud et al. Nov 2015 A1
20150328483 Odawara et al. Nov 2015 A1
20150335463 De Gruytere Nov 2015 A1
20150335919 Behar et al. Nov 2015 A1
20150337393 Keller et al. Nov 2015 A1
20150343238 Balakin Dec 2015 A1
20150352372 Takayanagi et al. Dec 2015 A1
20150352374 Gattiker et al. Dec 2015 A1
20150374324 Nishimura et al. Dec 2015 A1
20160000387 Buchsbaum et al. Jan 2016 A1
20160008631 Harada et al. Jan 2016 A1
20160016010 Schulte et al. Jan 2016 A1
20160048981 Pearlstein et al. Feb 2016 A1
20160059039 Liu Mar 2016 A1
20160067316 Sunavala-Dossabhoy Mar 2016 A1
20160074675 Moskvin et al. Mar 2016 A1
20160113884 Lin et al. Apr 2016 A1
20160136457 Jung et al. May 2016 A1
20160144201 Schulte May 2016 A1
20160172066 Claereboudt Jun 2016 A1
20160172067 Claereboudt et al. Jun 2016 A1
20160175052 Kumar et al. Jun 2016 A1
20160175617 Spatola et al. Jun 2016 A1
20160199671 Jongen Jul 2016 A1
20160220846 Matteo et al. Aug 2016 A1
20160220847 Benna et al. Aug 2016 A1
20160243232 Pickett Aug 2016 A1
20160250501 Balakin Sep 2016 A1
20160250503 Balakin et al. Sep 2016 A1
20160256712 Vahala et al. Sep 2016 A1
20160263404 Mougenot Sep 2016 A1
20160270203 Ungaro et al. Sep 2016 A1
20160271424 Lee et al. Sep 2016 A1
20160287899 Park et al. Oct 2016 A1
20160296766 El Fakhri et al. Oct 2016 A1
20160303399 Balakin Oct 2016 A1
20160331999 Hartman et al. Nov 2016 A1
Foreign Referenced Citations (159)
Number Date Country
2629333 May 2007 CA
86101248 Aug 1986 CN
1377521 Oct 2002 CN
1537657 Oct 2004 CN
1816243 Aug 2006 CN
101361156 Feb 2009 CN
101932361 Dec 2010 CN
101933405 Dec 2010 CN
101933406 Dec 2010 CN
101061759 May 2011 CN
2753397 Jun 1978 DE
31 48 100 Jun 1983 DE
35 30 446 Aug 1984 DE
41 01 094 May 1992 DE
4411171 Oct 1995 DE
0190789 Aug 1986 EP
0 194 728 Sep 1986 EP
0 277 521 Aug 1988 EP
0 208 163 Jan 1989 EP
0 222 786 Jul 1990 EP
0 221 987 Jan 1991 EP
0 499 253 Aug 1992 EP
0 306 966 Apr 1995 EP
0 388 123 May 1995 EP
0 465 597 May 1997 EP
0 911 064 Jun 1998 EP
0 864 337 Sep 1998 EP
0 776 595 Dec 1998 EP
1 069 809 Jan 2001 EP
1 153 398 Apr 2001 EP
1 294 445 Mar 2003 EP
1 348 465 Oct 2003 EP
1 358 908 Nov 2003 EP
1 371 390 Dec 2003 EP
1 402 923 Mar 2004 EP
1 430 932 Jun 2004 EP
1 454 653 Sep 2004 EP
1 454 654 Sep 2004 EP
1 454 655 Sep 2004 EP
1 454 656 Sep 2004 EP
1 454 657 Sep 2004 EP
1 477 206 Nov 2004 EP
1684313 Jul 2006 EP
1 738 798 Jan 2007 EP
1 826 778 Aug 2007 EP
1 949 404 Jul 2008 EP
2183753 Jul 2008 EP
2394498 Feb 2010 EP
2232961 Sep 2010 EP
2232962 Sep 2010 EP
2227295 May 2011 EP
1 605 742 Jun 2011 EP
2363170 Sep 2011 EP
2363171 Sep 2011 EP
2910278 Aug 2015 EP
2 560 421 Aug 1985 FR
2911843 Aug 2008 FR
0 957 342 May 1964 GB
2 015 821 Sep 1979 GB
2 361 523 Oct 2001 GB
43-23267 Oct 1968 JP
U48-108098 Dec 1973 JP
57-162527 Oct 1982 JP
58-141000 Aug 1983 JP
61-80800 Apr 1986 JP
61-225798 Oct 1986 JP
62-150804 Jul 1987 JP
62-186500 Aug 1987 JP
10-071213 Mar 1988 JP
63-149344 Jun 1988 JP
63-218200 Sep 1988 JP
63-226899 Sep 1988 JP
64-89621 Apr 1989 JP
01-276797 Nov 1989 JP
01-302700 Dec 1989 JP
4-94198 Mar 1992 JP
04-128717 Apr 1992 JP
04-129768 Apr 1992 JP
04-273409 Sep 1992 JP
04-337300 Nov 1992 JP
05-341352 Dec 1993 JP
06-233831 Aug 1994 JP
06-036893 Oct 1994 JP
07-260939 Oct 1995 JP
07-263196 Oct 1995 JP
08-173890 Jul 1996 JP
08-264298 Oct 1996 JP
09-162585 Jun 1997 JP
H11408 Jan 1999 JP
11-47287 Feb 1999 JP
11-102800 Apr 1999 JP
11-243295 Sep 1999 JP
2000-243309 Sep 2000 JP
2000-294399 Oct 2000 JP
2001-6900 Jan 2001 JP
2001-009050 Jan 2001 JP
2001-129103 May 2001 JP
2001-212253 Aug 2001 JP
2001212253 Aug 2001 JP
2001-346893 Dec 2001 JP
2002-164686 Jun 2002 JP
A2003-504628 Feb 2003 JP
2003-517755 May 2003 JP
2004-031115 Jan 2004 JP
2005-516634 Jun 2005 JP
2005-526578 Sep 2005 JP
2006-032282 Feb 2006 JP
05-046928 Mar 2008 JP
2008-507826 Mar 2008 JP
2009045229 Mar 2009 JP
2009-515671 Apr 2009 JP
2009-515671 Apr 2009 JP
2009-516905 Apr 2009 JP
2010-536130 Nov 2010 JP
2011-505191 Feb 2011 JP
2011-505670 Feb 2011 JP
2011-507151 Mar 2011 JP
300137 Nov 1969 SU
569 635 Aug 1977 SU
200930160 Jul 2009 TW
200934682 Aug 2009 TW
200939908 Sep 2009 TW
200940120 Oct 2009 TW
WO 198607229 Dec 1986 WO
WO 1990012413 Oct 1990 WO
WO 199203028 Feb 1992 WO
WO 199302536 Feb 1993 WO
WO 199817342 Apr 1998 WO
WO 199939385 Aug 1999 WO
WO 200040064 Jul 2000 WO
WO 200049624 Aug 2000 WO
WO 2001026230 Apr 2001 WO
WO 2001026569 Apr 2001 WO
WO 2002007817 Jan 2002 WO
WO 2003039212 May 2003 WO
WO 2003092812 Nov 2003 WO
WO 2004026401 Apr 2004 WO
WO 2004101070 Nov 2004 WO
WO-2004103145 Dec 2004 WO
WO 2006-012467 Feb 2006 WO
WO 2007061937 May 2007 WO
WO-2007061937 May 2007 WO
WO 2007084701 Jul 2007 WO
WO 2007130164 Nov 2007 WO
WO 2007145906 Dec 2007 WO
WO 2008030911 Mar 2008 WO
WO 2008081480 Oct 2008 WO
WO 2009048745 Apr 2009 WO
WO 2009070173 Jun 2009 WO
WO 2009070588 Jun 2009 WO
WO 2009073480 Jun 2009 WO
WO 2010149740 Dec 2010 WO
WO-2011148486 Dec 2011 WO
WO-2012117538 Sep 2012 WO
WO-2013054788 Apr 2013 WO
WO 2013098089 Jul 2013 WO
WO2014018706 Jan 2014 WO
WO2014018876 Jan 2014 WO
WO2015048468 Apr 2015 WO
Non-Patent Literature Citations (263)
Entry
International Search Report and Written Opinion in PCT application No. PCT/US2014/057750 dated Dec. 3, 2014 (9 pages).
First Office Action for JP2016-517466 (English translation), 5 pages (dated Mar. 23, 2017).
First Office Action for JP2016-517466 (Japanese version), 5 pages (dated Mar. 23, 2017).
Communication pursuant to Article 94(3) EPC for EP14781423.0, 4 pages (dated Apr. 26, 2017).
Blosser, Progress on the Coupled Superconducting Cyclotron Project, Bulletin of the American Physical Society, 1993 (p. 3).
Communication pursuant to Article 94(3) EPC for EP15155935.8, 3 pages (dated May 22, 2017).
Communication pursuant to Article 94(3) EPC for EP15155935.8, 4 pages (dated Jul. 7, 2016).
Communication pursuant to Rules 161(1) and 162 EPC for EP14781423.0, 2 pages (dated May 4, 2016).
Communication under Rule 71(3) EPC for EP15155935.8, 100 pages (dated Mar. 24, 2017).
Extended European Search Report in European counterpart application 15155935.8 dated Jun. 10, 2015 (5 pages).
Lorin, Stefan, et al., Development of a compact proton scanning system in Uppsala with a moveable second magnet, Phys. Med. Biol. 45, pp. 1151-1163, 2000 (13 pages).
The Journal of Practical Pharmacy, 1995, 46(1):97-103 [English Abstract included].
“Beam Delivery and Properties,” Journal of the ICRU, 2007, 7(2):20 pages.
“510(k) Summary: Ion Beam Applications S.A.”, FDA, Jul. 12, 2001, 5 pages.
“510(k) Summary: Optivus Proton Beam Therapy System”, Jul. 21, 2000, 5 pages.
“An Accelerated Collaboration Meets with Beaming Success,” Lawrence Livermore National Laboratory, Apr. 12, 2006, S&TR, Livermore, California, pp. 1-3, http://www.llnl.gov/str/April06/Caporaso.html.
“CPAC Highlights Its Proton Therapy Program at ESTRO Annual Meeting”, TomoTherapy Incorporated, Sep. 18, 2008, Madison, Wisconsin, pp. 1-2.
“Indiana's mega-million proton therapy cancer center welcomes its first patients” [online] Press release, Health & Medicine Week, 2004, retrieved from NewsRx.com, Mar. 1, 2004, pp. 119-120.
“LLNL, UC Davis Team Up to Fight Cancer,” Lawrence Livermore National Laboratory, Apr. 28, 2006, SF-06-04-02, Livermore, California, pp. 1-4.
“Patent Assignee Search Paul Scherrer Institute,” Library Services at Fish & Richardson P.C., Mar. 20, 2007, 40 pages.
“Patent Prior Art Search for ‘Proton Therapy System’,” Library Services at Fish & Richardson P.C., Mar. 20, 2007, 46 pages.
“Superconducting Cyclotron Contract” awarded by Paul Scherrer Institute (PSI), Villigen, Switzerland, http://www.accel.de/News/superconducting_cyclotron_contract.htm, Jan. 2009, 1 page.
“The Davis 76-Inch Isochronous Cyclotron”, Beam On: Crocker Nuclear Laboratory, University of California, 2009, 1 page.
“The K100 Neutron-therapy Cyclotron,” National Superconducting Cyclotron Laboratory at Michigan State University (NSCL), retrieved from: http://www.nscl.msu.edu/tech/accelerators/k100, Feb. 2005, 1 page.
“The K250 Proton therapy Cyclotron,” National Superconducting Cyclotron Laboratory at Michigan State University (NSCL), retrieved from: http://www.nscl.msu.edu/tech/accelerators/k250.html , Feb. 2005, 2 pages.
“The K250 Proton-therapy Cyclotron Photo Illustration,” National Superconducting Cyclotron Laboratory at Michigan State University (NSCL), retrieved from: http://www.nscl.msu.edu/media/image/experimental-equipment-technology/250.html, Feb. 2005, 1 page.
18th Japan Conference on Radiation and Radioisotopes [Japanese], Nov. 25-27, 1987, 9 pages.
Abrosimov et al., “1000MeV Proton Beam Therapy facility at Petersburg Nuclear Physics Institute Synchrocyclotron,” Medical Radiology (Moscow) 32, 10 (1987) revised in Journal of Physics, Conference Series 41, 2006, pp. 424-432, Institute of Physics Publishing Limited.
Abrosimov et al., “Neutron Time-of-flight Spectrometer Gneis at the Gatchina 1 GeV Protron Syncrhocyclotron”, Mar. 9, 1985 and revised form Jul. 31, 1985, Lemingrad Nuclear Physics Institute, Gatchina, 188350, USSR (15 pages).
Adachi et al., “A 150MeV FFAG Synchrotron with “Return-Yoke Free” Magent,” Proceedings of the 2001 Particle Accelerator Conference, Chicago, 2001, 3 pages.
Ageyev et al., “The IHEP Accelerating and Storage Complex (UNK) Status Report,” 11th International Conference on High-Energy Accelerators, 1980, pp. 60-70.
Agosteo et al., “Maze Design of a gantry room for proton therapy,” Nuclear Instruments & Methods in Physics Research, 1996, Section A, 382, pp. 573-582.
Alexeev et al., “R4 Design of Superconducting Magents for Proton Synchrotrons,” Proceedings of the Fifth International Cryogenic Engineering Conference, 1974, pp. 531-533.
Allardyce et al., “Performance and Prospects of the Reconstructed CERN 600 MeV Synchrocyclotron,” IEEE Transactions on Nuclear Science USA, Jun. 1977, ns-24:(3)1631-1633.
Alonso, “Magnetically Scanned Ion Beams for Radiation Therapy,” Accelerator & Fusion Research Division, Lawrence Berkeley Laboratory, Berkeley, CA, Oct. 1988, 13 pages.
Amaldi et al., “The Italian project for a hadrontherapy centre” Nuclear Instruments and Methods in Physics Research A, 1995, 360, pp. 297-301.
Amaldi, “Overview of the world landscape of Hadrontherapy and the projects of the TERA foundation,” Physica Medica, An International journal Devoted to the Applications of Physics to Medicine and Biology, Jul. 1998, vol. XIV, Supplement 1, 6th Workshop on Heavy Charged Particles in Biology and Medicine, Instituto Scientific Europeo (ISE), Sep. 29-Oct. 1, 1977, Baveno, pp. 76-85.
Anferov et al., “Status of the Midwest Proton Radiotherapy Institute,” Proceedings of the 2003 Particle Accelerator Conference, 2003, pp. 699-701.
Anferov et al., “The Indiana University Midwest Proton Radiation Institute,” Proceedings of the 2001 Particle Accelerator Conference, 2001, Chicago, pp. 645-647.
Appun, “Various problems of magnet fabrication for high-energy accelerators,” Journal for All Engineers Interested in the Nuclear Field, 1967, pp. 10-16 (1967) [Lang.: German], English bibliographic information (http://www.osti.gov/energycitations/product.biblio.jsp?osti_id=4442292).
Arduini et al. “Physical specifications of clinical proton beams from a synchrotron,” Med. Phys, Jun. 1996, 23 (6): 939-951.
Badano et al., “Proton-Ion Medical Machine Study (PIMMS) Part I,” PIMMS, Jan. 1999, 238 pages.
Beeckman et al., “Preliminary design of a reduced cost proton therapy facility using a compact, high field isochronous cyclotron,” Nuclear Instruments and Methods in Physics Research B56/57, 1991, pp. 1201-1204.
Bellomo et al., “The Superconducting Cyclotron Program at Michigan State University,” Bulletin of the American Physical Society, Sep. 1980, 25(7):767.
Benedikt and Carli, “Matching to Gantries for Medical Synchrotrons” IEEE Proceedings of the 1997 Particle Accelerator Conference, 1997, pp. 1379-1381.
Bieth et al., “A Very Compact Protontherapy Facility Based on an Extensive Use of High Temperature Superconductors (HTS)” Cyclotrons and their Applications 1998, Proceedings of the Fifteenth International Conference on Cyclotrons and their Applications, Caen, Jun. 14-19, 1998, pp. 669-672.
Bigham, “Magnetic Trim Rods for Superconducting Cyclotrons,” Nuclear Instruments and Methods (North-Holland Publishing Co.), 1975, 141:223-228.
Bimbot, “First Studies of the External Beam from the Orsay S.C. 200 MeV,” Institut de Physique Nucleaire, BP 1, Orsay, France, IEEE, 1979, pp. 1923-1926.
Blackmore et al., “Operation of the Triumf Proton Therapy Facility,” IEEE Proceedings of the 1997 Particle Accelerator Conference, May 12-16, 19973:3831-3833.
Bloch, “The Midwest Proton Therapy Center,” Application of Accelerators in Research and Industry, Proceedings of the Fourteenth Int'l. Conf., Part Two, Nov. 1996, pp. 1253-1255.
Blosser et al., “Problems and Accomplishments of Superconducting Cyclotrons,” Proceedings of the 14th International Conference, Cyclotrons and Their Applications, Oct. 1995, pp. 674-684.
Blosser et al., “Superconducting Cyclotrons”, Seventh International Conference on Cyclotrons and their Applications, Aug. 19-22, 1975, pp. 584-594.
Blosser et al., “A Compact Superconducting Cyclotron for the Production of High Intensity Protons,” Proceedings of the 1997 Particle Accelerator Conference, May 12-16, 1997, 1:1054-1056.
Blosser et al., “Advances in Superconducting Cyclotrons at Michigan State University,” Proceedings of the 11th International Conference on Cyclotrons and their Applications, Oct. 1986, pp. 157-167, Tokyo.
Blosser et al., “Characteristics of a 400 (Q2/A) MeV Super-Conducting Heavy-Ion Cyclotron,” Bulletin of the American Physical Society, Oct. 1974, p. 1026.
Blosser et al., “Medical Accelerator Projects at Michigan State Univ.” IEEE Proceedings of the 1989 Particle Accelerator Conference, Mar. 20-23, 1989, 2:742-746.
Blosser et al., “Superconducting Cyclotron for Medical Application”, IEEE Transactions on Magnetics, Mar. 1989, 25(2): 1746-1754.
Blosser, “Application of Superconductivity in Cyclotron Construction,” Ninth International Conference on Cyclotrons and their Applications, Sep. 1981, pp. 147-157.
Blosser, “Applications of Superconducting Cyclotrons,” Twelfth International Conference on Cyclotrons and Their Applications, May 8-12, 1989, pp. 137-144.
Blosser, “Future Cyclotrons,” AIP, The Sixth International Cyclotron Conference, 1972, pp. 16-32.
Blosser, “Medical Cyclotrons,” Physics Today, Special Issue Physical Review Centenary, Oct. 1993, pp. 70-73.
Blosser, “Preliminary Design Study Exploring Building Features Required for a Proton Therapy Facility for the Ontario Cancer Institute”, Mar. 1991, MSUCL-760a, 53 pages.
Blosser, “Progress on the Coupled Superconducting Cyclotron Project,” Bulletin of the American Physical Society, Apr. 1981, 26(4):558.
Blosser, “Synchrocyclotron Improvement Programs,” IEEE Transactions on Nuclear Science USA, Jun. 1969, 16(3):Part I, pp. 405-414.
Blosser, “The Michigan State University Superconducting Cyclotron Program,” Nuclear Science, Apr. 1979, NS-26(2):2040-2047.
Blosser, H., Present and Future Superconducting Cyclotrons, Bulletin of the American Physical Society, Feb. 1987, 32(2):171 Particle Accelerator Conference, Washington, D.C.
Blosser, H.G., “Superconducting Cyclotrons at Michigan State University”, Nuclear Instruments & Methods in Physics Research, 1987,vol. B 24/25, part II, pp. 752-756.
Botha et al., “A New Multidisciplinary Separated-Sector Cyclotron Facility,” IEEE Transactions on Nuclear Science, 1977, NS-24(3):1118-1120.
Chichili et al., “Fabrication of Nb3Sn Shell-Type Coils with Pre-Preg Ceramic Insulation,” American Institute of Physics Conference Proceedings, AIP USA, No. 711, (XP-002436709, ISSN: 0094-243X), 2004, pp. 450-457.
Chong et al., Radiology Clinic North American 7, 3319, 1969, 27 pages.
Chu et al., “Performance Specifications for Proton Medical Facility,” Lawrence Berkeley Laboratory, University of California, Mar. 1993, 128 pages.
Chu et al., “Instrumentation for Treatment of Cancer Using Proton and Light-ion Beams,” Review of Scientific Instruments, Aug. 1993, 64 (8):2055-2122.
Chu, “Instrumentation in Medical Systems,” Accelerator and Fusion Research Division, Lawrence Berkeley Laboratory, University of California, Berkeley, CA, May 1995, 9 pages.
Cole et al., “Design and Application of a Proton Therapy Accelerator,” Fermi National Accelerator Laboratory, IEEE, 1985, 5 pages.
Collins, et al., “The Indiana University Proton Therapy System,” Proceedings of EPAC 2006, Edinburgh, Scotland, 2006, 3 pages.
Conradi et al., “Proposed New Facilities for Proton Therapy at iThemba Labs,” Proceedings of EPAC, 2002, pp. 560-562.
C/E Source of Ions for Use in Sychro-Cyclotrons Search, Jan. 31, 2005, 9 pages.
Source Search “Cites of U.S. and Foreign Patents/Published applications in the name of Mitsubishi Denki Kabushiki Kaisha and Containing the Keywords (Proton and Synchrocyclotron),” Jan. 2005, 8 pages.
Cosgrove et aI., “Microdosimetric Studies on the Orsay Proton Synchrocyclotron at 73 and 200 MeV,” Radiation Protection Dosimetry, 1997, 70(1-4):493-496.
Coupland, “High-field (5 T) pulsed superconducting dipole magnet,” Proceedings of the Institution of Electrical Engineers, Jul. 1974, 121(7):771-778.
Coutrakon et al. “Proton Synchrotrons for Cancer Therapy,” Application of Accelerators in Research and Industry—Sixteenth International Conf., American Institute of Physics, Nov. 1-5, 2000, vol. 576, pp. 861-864.
Coutrakon et al., “A prototype beam delivery system for the proton medical accelerator at Loma Linda,” Medical Physics, Nov./Dec. 1991, 18(6):1093-1099.
Cuttone, “Applications of a Particle Accelerators in Medical Physics,” Istituto Nazionale di Fisica Nucleare-Laboratori Nazionali del Sud, V.S. Sofia, 44 Cantania, Italy, Jan. 2010, 17 pages.
Dahl P, “Superconducting Magnet System,” American Institute of Physics, AIP Conference Proceedings, 1987-1988, 2: 1329-1376.
Dialog Search, Jan. 31, 2005, 17 pages.
Dugan et al., “Tevatron Status” IEEE, Particle Accelerator Conference, Accelerator Science & Technology, 1989, pp. 426-430.
Eickhoff et al., “The Proposed Accelerator Facility for Light Ion Cancer Therapy in Heidelberg,” Proceedings of the 1999 Particle Accelerator Conference, New York, 1999, pp. 2513-2515.
Enchevich et al., “Minimizing Phase Losses in the 680 MeV Synchrocyclotron by Correcting the Accelerating Voltage Amplitude,” Atomnaya Energiya, 1969, 26:(3):315-316.
Endo et al., “Compact Proton and Carbon Ion Synchrotrons for Radiation Therapy,” Proceedings of EPAC 2002, Paris France, 2002, pp. 2733-2735.
Flanz et al., “Treating Patients with the NPTC Accelerator Based Proton Treatment Facility,” Proceedings of the 2003 Particle Accelerator Conference, 2003, pp. 690-693.
Flanz et al., “Large Medical Gantries,” Particle Accelerator Conference, Massachusetts General Hospital, 1995, pp. 1-5.
Flanz et al., “Operation of a Cyclotron Based Proton Therapy Facility”, Massachusetts General Hospital, Boston, MA 02114, pp. 1-4, retrieved from Internet in 2009.
Flanz et al., “The Northeast Proton Therapy Center at Massachusetts General Hospital,” Fifth Workshop on Heavy Charge Particles in Biology and Medicine, GSI, Darmstadt, Aug. 1995, 11 pages.
Flood and Frazier, “The Wide-Band Driven RF System for the Berkeley 88-Inch Cyclotron,” American Institute of Physics, Conference Proceedings., No. 9, 1972, 459-466.
Foster and Kashikhin, “Superconducting Superferric Dipole Magent with Cold Iron Core for the VLHC,” IEEE Transactions on Applied Superconductivity, Mar. 2002, 12(1):111-115.
Friesel et al., “Design and Construction Progress on the IUCF Midwest Proton Radiation Institute,” Proceedings of EPAC 2002, 2002, pp. 2736-2738.
Fukumoto et al., “A Proton Therapy Facility Plan” Cyclotrons and their Applications, Proceedings of the 13th International Conference, Vancouver, Canada, Jul. 6-10, 1992, pp. 258-261.
Fukumoto, “Cyclotron Versus Synchrotron for Proton Beam Therapy,” KEK Prepr., No. 95-122, Oct. 1995, pp. 533-536.
Goto et al., “Progress on the Sector Magnets for the Riken SRC,” American Institute of Physics, CP600, Cyclotrons and Their Applications 2001, Sixteenth International Conference, 2001, pp. 319-323.
Graffman et al., “Design Studies for a 200 MeV Proton Clinic for Radiotherapy,” AIP Conference Proceedings: Cyclotrons—1972, 1972, No. 9, pp. 603-615.
Graffman et al., Acta Radiol. Therapy Phys. Biol. 1970, 9, 1 (1970).
Graffman, et. al. “Proton radiotherapy with the Uppsala cyclotron. Experience and plans” Strahlentherapie, 1985, 161(12):764-770.
Hede, “Research Groups Promoting Proton Therapy “Lite,”” Journal of the National Cancer Institute, Dec. 6, 2006, 98(23):1682-1684.
Heinz, “Superconducting Pulsed Magnetic Systems for High-Energy Synchrotrons,” Proceedings of the Fourth International Cryogenic Engineering Conference, May 24-26, 1972, pp. 55-63.
Hentschel et al., “Plans for the German National Neutron Therapy Centre with a Hospital-Based 70 MeV Proton Cyclotron at University Hospital Essen/Germany,” Cyclotrons and their Applications, Proceedings of the Fifteenth International Conference on Cyclotrons and their Applications, Caen, Franco, Jun. 14-19, 1998, pp. 21-23.
Hepburn et al., “Superconducting Cyclotron Neutron Source for Therapy,” International Journal of Radiation Oncology Biology Physics, vol. 3 complete, 1977, pp. 387-391.
Hirabayashi, “Development of Superconducting Magnets for Beam Lines and Accelerator at KEK,” IEEE Transaction on Magnetics, Jan. 1981, Mag-17(1):728-731.
Ishibashi and McInturff, “Winding Design Study of Superconducting 10 T Dipoles for a Synchrotron,” IEEE Transactions on Magnetics, May 1983, MAG-19(3):1364-1367.
Ishibashi and McInturff, “Stress Analysis of Superconducting 10T Magnets for Synchrotron,” Proceedings of the Ninth International Cryogenic Engineering Conference, May 11-14, 1982, pp. 513-516.
Jahnke et al., “First Superconducting Prototype Magnets for a Compact Synchrotron Radiation Source in Operation,” IEEE Transactions on Magnetics, Mar. 1988, 24(2):1230-1232.
Jones and Dershem, “Synchrotron Radiation from Proton in a 20 TEV, 10 TESLA Superconducting Super Collider” Proceedings of the 12th International Conference on High-Energy Accelerator, Aug. 11-16, 1983, pp. 138-140.
Jones and Mills, “The South African National Accelerator Centre: Particle Therapy and Isotope Production Programmes,” Radiation Physics and Chemistry, Apr.-Jun. 1998, 51(4-6):571-578.
Jones et al., “Status Report of the NAC Particle Therapy Programme,” Stralentherapie und Onkologie, vol. 175, Suppl. II, Jun. 1999, pp. 30-32.
Jones, “Progress with the 200 MeV Cyclotron Facility at the National Accelerator Centre,” Commission of the European Communities Radiation Protection Proceedings, Fifth Symposium on Neutron Dosimetry, Sep. 17-21, 1984, vol. II, pp. 989-998.
Jones, “Present Status and Future Trends of Heavy Particle Radiotherapy,” Cyclotrons and their Applications 1998, Proceedings of the Fifteenth International Conference on Cyclotrons and their Applications, Jun. 14-19, 1998, pp. 13-20.
Jongen et al., “Development of a Low-cost Compact Cyclotron System for Proton Therapy,” National Institute of Radiol. Sci, 1991, No. 81, pp. 189-200.
Jongen et al., “Progress report on the IBA-SHI small cyclotron for cancer therapy” Nuclear Instruments and Methods in Physics Research, Section B, vol. 79, issue 1-4, 1993, pp. 885-889.
Jongen et al., “The proton therapy system for the NPTC: Equipment Description and progress report,” Nuclear Instruments and methods in physics research, 1996, Section B, 113(1): 522-525.
Jongen et al., “The proton therapy system for MGH's NPTC: equipment description and progress report,” Bulletin du Cancer/Radiotherapie, Proceedings of the meeting of the European Heavy Particle Therapy Group, 1996, 83(Suppl. 1):219-222.
Kanai et al., “Three-dimensional Beam Scanning for Proton Therapy,” Nuclear Instruments and Methods in Physic Research, Sep. 1, 1983, The Netherlands, 214(23):491-496.
Karlin et al., “Medical Radiology” (Moscow), 1983, 28, 13.
Karlin et al., “The State and Prospects in the Development of the Medical Proton Tract on the Synchrocyclotron in Gatchina,” Med. Radiol., Moscow, 28(3):28-32 (Mar. 1983)(German with English Abstract on end of p. 32).
Kats and Druzhinin, “Comparison of Methods for Irradiation Prone Patients,” Atomic Energy, Feb. 2003, 94(2):120-123.
Kats and Onosovskii, “A Simple, Compact, Flat System for the Irradiation of a Lying Patient with a Proton Beam from Different Directions,” Instruments and Experimental Techniques, 1996, 39(1):132-134.
Kats and Onosovskii, “A Planar Magnetooptical System for the Irradiation of a Lying Patient with a Proton Beam from Various Directions,” Instruments and Experimental Techniques, 1996, 39(1):127-131.
Khoroshkov et al.,“Moscow Hospital-Based Proton Therapy Facility Design,” Am. Journal Clinical Oncology: CCT, Apr. 1994, 17(2):109-114.
Kim and Blosser, “Optimized Magnet for a 250 MeV Proton Radiotherapy Cyclotron,” Cyclotrons and Their Applications 2001, May 2001, Sixteenth International Conference, pp. 345-347.
Kim and Yun, “A Light-Ion Superconducting Cyclotron System for Multi-Disciplinary Users,” Journal of the Korean Physical Society, Sep. 2003, 43(3):325-331.
Kim et al., “Construction of 8T Magnet Test Stand for Cyclotron Studies,” IEEE Transactions on Applied Superconductivity, Mar. 1993, 3(1):266-268.
Kim et al., “Design Study of a Superconducting Cyclotron for Heavy Ion Therapy,” Cyclotrons and Their Applications 2001, Sixteenth International Conference, May 13-17, 2001, pp. 324-326.
Kim et al., “Trim Coil System for the Riken Cyclotron Ring Cyclotron,” Proceedings of the 1997 Particle Accelerator Conference, IEEE, Dec. 1981, vol. 3, pp. 214-235 or 3422-3424, 1998.
Kim, “An Eight Tesla Superconducting Magnet for Cyclotron Studies,” Ph.D. Dissertation, Michigan State University, Department of Physics and Astronomy, 1994, 138 pages.
Kimstrand, “Beam Modelling for Treatment Planning of Scanned Proton Beams,” Digital Comprehensive Summaries of Uppsala dissertations from the Faculty of Medicine 330, Uppsala Universitet, 2008, 58 pages.
Kishida and Yano, “Beam Transport System for the RIKEN SSC (II),” Scientific Papers of the Institute of Physical and Chemical Research, Dec. 1981, 75(4):214-235.
Koehler et al., “Range Modulators for Protons and Heavy Ions,” Nuclear Instruments and Methods, 1975, vol. 131, pp. 437-440.
Koto and Tsujii, “Future of Particle Therapy,” Japanese Journal of Cancer Clinics, 2001, 47(1):95-98 [Lang.: Japanese], English abstract (http://sciencelinks.jp/j-east/article/200206/000020020601A0511453.php).
Kraft et al., “Hadrontherapy in Oncology,” U. Amaldi and Larrsson, editors Elsevier Science, 1994, 390 pages.
Krevet et al., “Design of a Strongly Curved Superconducting Bending Magnet for a Compact Synchrotron Light Source,” Advances in Cryogenic Engineering, 1988, vol. 33, pp. 25-32.
Laisne et al., “The Orsay 200 MeV Synchrocyclotron,” IEEE Transactions on Nuclear Science, Apr. 1979, NS-26(2):1919-1922.
Larsson et al., Nature, 1958, 182:1222.
Larsson, “Biomedical Program for the Converted 200-MeV Synchrocyclotron at the Gustaf Werner Institute,” Radiation Research, 1985, 104:S310-S318.
Lawrence et al., “Heavy particles in acromegaly and Cushing's Disease,” in Endocrine and Norendocrine Hormone Producing Tumors (Year Book Medical Chicago, 1973, pp. 29-61.
Lawrence et al., “Successful Treatment of Acromegaly: Metabolic and Clinical Studies in 145 Patients,” The Journal of Clinical Endrocrinology and Metabolism, Aug. 1970, 31(2), 21 pages.
Lawrence et al., “Treatment of Pituitary Tumors,” (Excerpta medica, Amsterdam/American Elsevier, New York, 1973, pp. 253-262.
Lawrence, Cancer, 1957, 10:795.
Lecroy et al., “Viewing Probe for High Voltage Pulses,” Review of Scientific Instruments USA, Dec. 1960, 31(12):1354.
Lin et al., “Principles and 10 Year Experience of the Beam Monitor System at the PSI Scanned Proton Therapy Facility”, Center for Proton Radiation Therapy, Paul Scherrer Institute, CH-5232, Villigen PSI, Switzerland, 2007, 21 pages.
Linfoot et al., “Acromegaly,” in Hormonal Proteins and Peptides, edited by C.H. Li, 1975, pp. 191-246.
Literature Author and Keyword Search, Feb. 14, 2005, 44 pages.
Literature Keyword Search, Jan. 24, 2005, 98 pages.
Literature Search and Keyword Search for Synchrocyclotron, Jan. 25, 2005, 68 pages.
Literature Search by Company Name/Component Source, Jan. 24, 2005, 111 pages.
Literature Search, Jan. 26, 2005, 37 pages.
Livingston et al., “A capillary ion source for the cyclotron,” Review Science Instruments, Feb. 1939, 10:63.
Mandrillon, “High Energy Medical Accelerators,” EPAC 90, 2nd European Particle Accelerator Conference, Jun. 12-16, 1990, 2:54-58.
Marchand et aI., “IBA Proton Pencil Beam Scanning: an Innovative Solution for Cancer Treatment,” Proceedings of EPAC 2000, Vienna, Austria, 3 pages.
Marti et al., “High Intensity Operation of a Superconducting Cyclotron,” Proceedings of the 14the International Conference, Cyclotrons and Their Applications, Oct. 1995, pp. 45-48 (Oct. 1995).
Martin, “Operational Experience with Superconducting Synchrotron Magnets” Proceedings of the 1987 IEEE Particle Accelerator Conference, Mar. 16-19, 1987, vol. 3 of 3:1379-1382.
Meote et al., “ETOILE Hadrontherapy Project, Review of Design Studies” Proceedings of EPAC 2002, 2002, pp. 2745-2747.
Miyamoto et al., “Development of the Proton Therapy System,” The Hitachi Hyoron, 79(10):775-779 (1997) [Lang: Japanese], English abstract (http://www.hitachi.com/rev/1998/revfeb98/rev4706.htm).
Montelius et al., “The Narrow Proton Beam Therapy Unit at the Svedberg Laboratory in Uppsala,” ACTA Oncologica, 1991, 30:739-745.
Moser et al., “Nonlinear Beam Optics with Real Fields in Compact Storage Rings,” Nuclear Instruments & Methods in Physics Research/Section B, B30, Feb. 1988, No. 1, pp. 105-109.
Moyers et al., “A Continuously Variable Thickness Scatterer for Proton Beams Using Self-compensating Dual Linear Wedges” Lorna Linda University Medical Center, Dept. of Radiation Medicine, Lorna Linda, CA, Nov. 2, 1992, 21 pages.
National Cancer Institute Funding (Senate—Sep. 21, 1992) (www.thomas.loc.gov/cgi-bin/query/z?rl02:S21SE2-712 (2 pages).
Nicholson, “Applications of Proton Beam Therapy,” Journal of the American Society of Radiologic Technologists, May/Jun. 1996, 67(5): 439-441.
Nolen et al., “The Integrated Cryogenic—Superconducting Beam Transport System Planned for MSU,” Proceedings of the 12th International Conference on High-Energy Accelerators, Aug. 1983, pp. 549-551.
Norimine et al., “A Design of a Rotating Gantry with Easy Steering for Proton Therapy,” Proceedings of EPAC 2002, 2002, pp. 2751-2753.
Ogino, Takashi, “Heavy Charged Particle Radiotherapy-Proton Beam”, Division of Radiation Oncology, National Cancer Hospital East, Kashiwa, Japan, Dec. 2003, 7 pages.
Okumura et al., “Overview and Future Prospect of Proton Radiotherapy,” Japanese Journal of Cancer Clinics, 1997, 43(2):209-214 [Lang.: Japanese].
Okumura et al., “Proton Radiotherapy” Japanese Journal of Cancer and Chemotherapy, 1993, 10. 20(14):2149-2155[Lang.: Japanese].
Outstanding from Search Reports, “Accelerator of Polarized Portons at Fermilab,” 2005, 20 pages.
Paganetti et al., “Proton Beam Radiotherapy—The State of the Art,” Springer Verlag, Heidelberg, ISBN 3-540-00321-5, Oct. 2005,36 pages.
Palmer and Tollestrup, “Superconducting Magnet Technology for Accelerators,” Annual Review of Nuclear and Particle Science, 1984, vol. 34, pp. 247-284.
Patent Assignee and Keyword Searches for Synchrocyclotron, Jan. 25, 2005, 78 pages.
Pavlovic, “Beam-optics study of the gantry beam delivery system for light-ion cancer therapy,” Nuclear Instruments and Methods in Physics Research, Section A, Nov. 1997, 399(2):439-454(16).
Pedroni and Enge, “Beam optics design of compact gantry for proton therapy” Medical & Biological Engineering & Computing, May 1995, 33(3):271-277.
Pedroni and Jermann, “SGSMP: Bulletin Mar. 2002 Proscan Project, Progress Report on the PROSCAN Project of PSI” [online] retrieved from www.sgsmp.ch/protA23.htm, Mar. 2002, 5 pages.
Pedroni et al., “A Novel Gantry for Proton Therapy at the Paul Scheirer Institute,” Cycloctrons and Their Applications 2001: Sixteenth International Conference. AIP Conference Proceedings, 2001, 600:13-17.
Pedroni et al., “The 200-MeV proton therapy project at the Paul Scherrer Institute: Conceptual design and practical realization,” Medical Physics, Jan. 1995, 22(1):37-53.
Pedroni, “Accelerators for Charged Particle Therapy: Performance Criteria from the User Point of View,” Cyclotrons and their Applications, Proceedings of the 13th International Conference, Jul. 6-10, 1992, pp. 226-233.
Pedroni, “Latest Developments in Proton Therapy” Proceedings of EPAC 2000, pp. 240-244, 2000.
Pedroni, “Status of Proton Therapy: results and future trends,” Paul Scherrer Institute, Division of Radiation Medicine, 1994, 5 pages.
Peggs et al., “A Survey of Hadron Therapy Accelerator Technologies,” Particle Accelerator Conference, Jun. 25-29, 2007, 7 pages.
Potts et al., “MPWP6-Therapy III: Treatment Aids and Techniques” Medical Physics, Sep./Oct. 1988, 15(5):798.
Pourrahimi et al., “Powder Metallurgy Processed Nb3Sn(Ta) Wire for High Field NMR magnets,” IEEE Transactions on Applied Superconductivity, Jun. 1995, 5(2):1603-1606.
Prieels et al., “The IBA State-of-the-Art Proton Therapy System, Performances and Recent Results,” Application of Accelerators in Research and industry—Sixteenth Int'l. Conf., American Institute of Physics, Nov. 1-5, 2000, 576:857-860.
Rabin et al., “Compact Designs for Comprehensive Proton Beam Clinical Facilities,” Nuclear Instruments & Methods in Physics Research, Apr. 1989, Section B, vol. 40-41, Part II, pp. 1335-1339.
Research & Development Magazine, “Proton Therapy Center Nearing Completion.” Aug. 1999, 41(9):2 pages, (www.rdmag.com).
Resmini, “Design Characteristics of the K=800 Superconducting Cyclotron at M.S.U.,” Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, IEEE Transaction on Nuclear Science, vol. NS-26, No. 2, Apr. 1979, 8 pages.
RetroSearch “Berkeley 88-Inch Cyclotron ‘RF’ or ‘Frequency Control’,” Jan. 21, 2005, 36 pages.
RetroSearch “Berkeley 88-Inch Cyclotron,” Jan. 24, 2005, 170 pages.
RetroSearch “Bernard Gottschalk, Cyclotron, Beams, Compensated Upstream Modulator, Compensated Scatter,” Jan. 21, 2005, 20 pages.
RetroSearch “Cyclotron with ‘RF’ or ‘Frequency Control’,” Jan. 21, 2005, 49 pages.
RetroSearch Gottschalk, Bernard, Harvard Cyclotron Wheel, Jan. 21, 2005, 20 pages.
RetroSearch “Loma Linda University Beam Compensation,” Jan. 21, 2005, 60 pages.
RetroSearch “Loma Linda University, Beam Compensation Foil Wedge,” Jan. 21, 2005, 15 pages.
Revised Patent Keyword Search, Jan. 25, 2005, 88 pages.
Rifuggiato et, al., “Status Report of the LNS Superconducting Cyclotron” Nukleonika, 2003, 48: S131-S134, Supplement 2.
Rode, “Tevatron Cryogenic System,” Proceedings of the 12th International Conference on High-energy Accelerators, Fermilab, Aug. 11-16, 1983, pp. 529-535.
Salzburger et al., “Superconducting Synchrotron Magnets Supraleitende Synchrotronmagnete,” Siemens A.G., Erlangen (West Germany). Abteilung Technische Physik, Report No. BMFT-FB-T-75-25, Oct. 1975, p. 147, Journal Announcement: GRAI7619; STAR1415, Subm-Sponsored by Bundesmin. Fuer Forsch. U. Technol. In German; English Summary.
Schillo et al,. “Compact Superconducting 250 MeV Proton Cyclotron for the PSI Proscan Proton Therapy Project,” Cyclotrons and Their Applications 2001, Sixteenth International Conference, 2001, pp. 37-39.
Schneider et al., “Nevis Synchrocyclotron Conversion Program—RF System,” IEEE Transactions on Nuclear Science USA, Jun. 1969, ns 16(3): 430-433.
Schneider et al., “Superconducting Cyclotrons,” IEEE Transactions on Magnetics, vol. MAG-11, No. 2, Mar. 1975, New York, pp. 443-446.
Schreuder et al., “The Non-orthogonal Fixed Beam Arrangement for the Second Proton Therapy Facility at the National Accelerator Centre,” Application of Accelerators in Research and Industry, American Institute of Physics, Proceedings of the Fifteenth International Conference, Nov. 1998, Part Two, pp. 963-966.
Schreuder, “Recent Developments in Superconducting Cyclotrons,” Proceedings of the 1995 Particle Accelerator Conference, May 1-5, 1995, vol. 1, pp. 317-321.
Schubert and Blosser, “Conceptual Design of a High Field Ultra-Compact Cyclotron for Nuclear Physics Research,” Proceedings of the 1997 Particle Accelerator Conference, May 12-16, 1997, vol. 1, 3 pages 1060-1062.
Schubert, “Extending the Feasibility Boundary of the Isochronous Cyclotron,” Dissertation submitted to Michigan State University, 1997, Abstract http://adsabs.harvard.edu/abs/1998PhDT.......147S.
Schubert et al., “Progress toward an experiment to study the effect of RF grounding in an internal ion source on axial oscillations of the beam in a cyclotron,” National Superconducting Cyclotron Laboratory, Michigan State University, Report MSUCL-760, CP600, Cyclotrons and their Applications 2011, Sixteenth International Conference, 2001, pp. 274-276.
Shelaev et al., “Design Features of a Model Superconducting Synchrotron of JINR,” Proceedings of the 12th International Conference on High-energy Accelerators, Aug. 11-16, 1983, pp. 416-418.
Shintomi et. al, “Technology and Materials for the Superconducting Super Collider (SSC) Project,” [Lang.: Japanese], The Iron and Steel Institute of Japan 00211575, 78(8): 1305-1313, 1992, http://ci.nii.ac.jp/naid/110001493249/en/.
Sisterson, “World Wide Proton Therapy Experience in 1997,” The American Insitute of Physics, Applications of Accelerators in Research and Industry, Proceedings of the Fifteenth International Conference, Part Two, Nov. 1998, pp. 959-962.
Sisterson, “Clinical use of proton and ion beams from a world-wide perspective,” Nuclear Instruments and Methods in Physics Research, Section B, 1989, 40-41:1350-1353.
Slater et al., “Developing a Clinical Proton Accelerator Facility: Consortium-Assisted Technology Transfer,” Conference Record of the 1991 IEEE Particle Accelerator Conference: Accelerator Science and Technology, vol. 1, May 6-9, 1991, pp. 532-536.
Slater et al., “Development of a Hospital-Based Proton Beam Treatment Center,” International Journal of Radiation Oncology Biology Physics, Apr. 1988, 14(4):761-775.
Smith et al., “The Northeast Proton Therapy Center at Massachusetts General Hospital” Journal of Brachytherapy International, Jan. 1997, pp. 137-139.
Snyder and Marti, “Central region design studies for a proposed 250 MeV proton cyclotron,” Nuclear Instruments and Methods in Physics Research, Section A, 1995, vol. 355, pp. 618-623.
Soga, “Progress of Particle Therapy in Japan,” Application of Accelerators in Research and Industry, American Institute of Physics, Sixteenth International Conference, Nov. 2000, pp. 869-872.
Spiller et al., “The GSI Synchrotron Facility Proposal for Acceleration of High Intensity Ion and Proton Beams” Proceedings of the 2003 Particle Accelerator Conference, May 12-16, 2003, vol. 1, pp. 589-591.
Stanford et al., “Method of Temperature Control in Microwave Ferroelectric Measurements,” Sperry Microwave Electronics Company, Clearwater, Florida, Sep. 19, 1960, 1 page.
Tadashi et al., “Large superconducting super collider (SSC) in the planning and materials technology,” 78(8):1305-1313, The Iron and Steel Institute of Japan 00211575, Aug. 1992.
Takada, “Conceptual Design of a Proton Rotating Gantry for Cancer Therapy,” Japanese Journal of Medical Physics, 1995, 15(4):270-284.
Takayama et al., “Compact Cyclotron for Proton Therapy,” Proceedings of the 8th Symposium on Accelerator Science and Technology, Japan, Nov. 25-27, 1991, pp. 380-382.
Teng, “The Fermilab Tevatron,” Coral Gables 1981, Proceedings, Gauge Theories, Massive Neutrinos, and Proton Decay, 1981, pp. 43-62.
The Journal of Practical Pharmacy, 1995, 46(1):97-103 [Japanese].
Tilly, et al., “Development and verification of the pulsed scanned proton beam at The Svedberg Laboratory in Uppsala”, Physics in Medicine and Biology, Phys. Med. Biol. 52, pp. 2741-2454, 2007.
Tobias et al., Cancer Research, 1958, 18, 121 (1958).
Tom, “The Use of Compact Cyclotrons for Producing Fast Neutrons for Therapy in a Rotatable Isocentric Gantry,” IEEE Transaction on Nuclear Science, Apr. 1979, 26(2):2294-2298.
Toyoda, “Proton Therapy System”, Sumitomo Heavy Industries, Ltd., 2000, 5 pages.
Trinks et. al., “The Tritron: A Superconducting Separated-Orbit Cyclotron,” Nuclear Instruments and Methods in Physics Research, Section A, 1986, vol. 244, pp. 273-282.
Tsuji, “The Future and Progress of Proton Beam Radiotherapy,” Journal of Japanese Society for Therapeutic Radiology and Oncology, 1994, 6(2):63-76.
UC Davis School of Medicine, “Unlikely Partners Turn Military Defense into Cancer Offense”, Current Issue Summer 2008, Sacramento, California, pp. 1-2.
Umegaki et al., “Development of an Advanced Proton Beam Therapy System for Cancer Treatment” Hitachi Hyoron, 2003, 85(9):605-608 [Lang.: Japanese], English abstract, http://www.hitachi.com/ICSFiles/afieldfile/2004/06/01/r2003_04_104.pdf or http://www.hitachi.com/rev/archive/2003/2005649_12606.html (full text) [Hitachi, 52(4), Dec. 2003].
Umezawa et al., “Beam Commissioning of the new Proton Therapy System for University of Tsukuba,” Proceedings of the 2001 Particle Accelerator Conference, vol. 1, Jun. 18-22, 2001, pp. 648-650.
van Steenbergen, “Superconducting Synchroton Development at BNL,” Proceedings of the 8th International Conference on High-Energy Accelerators CERN 1971, 1971, pp. 196-198.
van Steenbergen, “The CMS, a Cold Magnet Synchrotron to Upgrade the Proton Energy Range of the BNL Facility,” IEEE Transactions on Nuclear Science, Jun. 1971, 18(3):694-698.
Vandeplassche et al., “235 MeV Cyclotron for MGH's Northeast Proton Therapy Center (NPTC): Present Status,” EPAC 96, Fifth European Partical Accelerator Conference, vol. 3, Jun. 10-14, 1996, pp. 2650-2652.
Vorobiev et al., “Concepts of a Compact Achromatic Proton Gantry with a Wide Scanning Field”, Nuclear Instruments and Methods in Physics Research, Section A., 1998, 406(2):307-310.
Vrenken et al., “A Design of a Compact Gantry for Proton Therapy with 2D-Scanning,” Nuclear Instruments and Methods in Physics Research, Section A, 1999, 426(2):618-624.
Wikipedia, “Cyclotron” http://en.wikipedia.org/wiki/Cyclotron (originally visited Oct. 6, 2005, revisited Jan. 28, 2009), 7pages.
Wikipedia, “Synchrotron” http://en.wikipedia.org/wiki/Synchrotron (originally visited Oct. 6, 2005, revisited Jan. 28, 2009), 7 pages.
Worldwide Patent Assignee Search, Jan. 24, 2005, 224 pages.
Worldwide Patent Keyword Search, Jan. 24, 2005, 94 pages.
Wu, “Conceptual Design and Orbit Dynamics in a 250 MeV Superconducting Synchrocyclotron,” Ph.D. Dissertation, Michigan State University, Department of Physics and Astronomy, 1990, 172 pages.
York et al., “Present Status and Future Possibilities at NSCL-MSU,” EPAC 94, Fourth European Particle Accelerator Conference, pp. 554-556, Jun. 1994.
York et al., “The NSCL Coupled Cyclotron Project—Overview and Status,” Proceedings of the Fifteenth International Conference on Cyclotrons and their Applications, Jun. 1998, pp. 687-691.
Yudelev et al., “Hospital Based Superconducting Cyclotron for Neutron Therapy: Medical Physics Perspective,” Cyclotrons and their applications 2001, 16th International Conference. American Institute of Physics Conference Proceedings, vol. 600, May 13-17, 2001, pp. 40-43.
Zherbin et al., “Proton Beam Therapy at the Leningrad Synchrocyclotron (Clinicomethodological Aspects and Therapeutic Results)”, Aug. 1987, 32(8):17-22, (German with English abstract on pp. 21-22).
U.S. Appl. No. 61/676,377, filed Jul. 27, 2012.
U.S. Appl. No. 13/949,459, filed Jul. 24, 2013.
U.S. Appl. No. 13/830,792, filed Mar. 14, 2013.
International Search Report and Written Opinion issued in PCT application PCT/US2014/057750 dated Dec. 3, 2014 (9 pages).
International Preliminary Report on Patentability issued in PCT application PCT/US2014/057750 dated Apr. 7, 2016 (7 pages).
First Office Action (Chinese translation) for CN201480064629.0, 9 pages (dated Jan. 24, 2018).
First Office Action (English translation) for CN201480064629.0, 12 pages (dated Jan. 24, 2018).
Second Office Action (English translation) for JP2016-517466, 5 pages (dated Feb. 19, 2018).
Second Office Action (Japenese translation) for JP2016-517466, 5 pages (dated Feb. 19, 2018).
Communication pursuant to Article 94(3) EPC for EP14781423.0, 30 pages (Jan. 24, 2018).
Office Action for U.S. Appl. No. 15/796,237, 8 pages (dated Sep. 21, 2018).
Second Office Action for CN201480064629.0 (English translation), 4 pages (dated Oct. 26, 2018).
Second Office Action for CN201480064629.0 (Chinese translation), 3 pages (dated Oct. 26, 2018).
Communication pursuant to Article 94(3) EPC for EP14781423.0, 3 pages (dated Nov. 16, 2018).
Decision of Rejection (English translation) for JP2016-517466, 6 pages (dated Jan. 28, 2019).
Decision of Rejection (Japanese translation) for JP2016-517466, 5 pages (dated Jan. 28, 2019).
Related Publications (1)
Number Date Country
20150090894 A1 Apr 2015 US
Provisional Applications (1)
Number Date Country
61883631 Sep 2013 US